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ABSTRACT OF THE DISSERTATION  
 
EXPOSURE TO ENDOCRINE DISRUPTING COMPOUNDS AND REPRODUCTIVE 
TOXICITY IN WOMEN 
by  
 
Marisa Morgan  
 
Florida International University, 2014 
 
Miami, Florida  
 
Professor Deodutta Roy, Major Professor 
 
 The overall objective of the research presented in this dissertation was to assess 
exposure to endocrine disrupting chemicals (EDCs), polychlorinated biphenyls (PCBs), 
phthalates, and bisphenol A (BPA) in the general population and evaluate their 
associations with adverse reproductive health effects, including cancers, in women. 
Given the proven contribution of unopposed estrogens to the risk for endometrial 
neoplasia or breast cancer, renewed health concerns have aroused about estrogen 
mimicking EDCs found in food, personal care products or as environmental 
contaminants. Our meta-analysis showed that exposure to estrogen mimicking PCBs 
increased summary risk of breast cancer and endometriosis. We further evaluated the 
relationship between endometriosis and breast cancer, and EDCs using a bioinformatics 
method. Our bioinformatics approach was able to identify genes with the potential to be 
involved in interaction with PCB, phthalates and BPA that may be important to the 
development of breast cancer and endometriosis.  Therefore, we hypothesized that 
exposure to EDCs such as PCBs, phthalates, and BPA, results in adverse reproductive 
health effects in women. Using subject data and biomarkers available from the Center for 
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Disease Controls National Health and Nutrition Examination Survey database we 
conducted a cross-sectional study of EDCs in relation to self-reported history of 
endometriosis, uterine leiomyomas, breast cancer, cervical cancer, ovarian cancer, and 
uterine cancer.  Significantly higher body burdens of PCBs were found in women 
diagnosed with breast cancer, ovarian cancer, and uterine cancer compared to women 
without cancer.  PCB 138 was significantly associated with breast cancer, cervical 
cancer, and uterine cancer, while PCBs 74 and 118 were significantly associated with 
ovarian cancer.  The sum of dioxin-like PCBs were significantly associated with ovarian 
cancer (OR of 2.02, 95% CI: 1.06-3.85) and the sum of non-dioxin-like PCBs were 
significantly associated with uterine cancer (OR of 1.12, 95%CI: 1.03-1.23). 
Significantly higher body burdens of PCBs were also found in women diagnosed with 
endometriosis and uterine leiomyomas.    Documenting the exposure to EDCs among the 
general U.S. population, and identifying agents associated with reproductive toxicity 
have the potential to fill research gaps and facilitate our understanding of the complex 
role environmental chemicals play in producing toxicity in reproductive organs.  
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INTRODUCTION 
 
There are thousands of chemicals that are manufactured in or imported into the 
United States every year.  These chemicals are released into the environment and pose a 
severe threat to the endocrine systems of wildlife and humans by interfering with normal 
growth and development functions (ATSDR 2000). These chemicals commonly known 
as endocrine disrupting compounds (EDCs) or endocrine disruptors (EDs) are both 
synthetic and natural compounds in the environment that have the ability to disrupt 
metabolic pathways by either mimicking or blocking endogenous hormones, or by 
altering hormone function.  Many EDCs are highly carcinogenic and include a variety of 
chemicals such as pesticides, fungicides, industrial compounds, by-products of industrial 
processes, and chemicals used in the manufacturing of plastics.  Of particular concern are 
the hormonally active agents that are persistent in the environment, highly lipophilic, and 
readily bio-accumulate and magnify within the food chain (Summarized in Meeker et al. 
2009 & Lyche et al. 2009).  
Many of these chemicals are used in a variety of consumer products; therefore 
exposure to EDCs among the general population is widespread. Human exposure to 
EDCs may result from inhalation through the air, absorption through the skin, and most 
commonly through the ingestion of contaminated food and water (Balabanic et al. 2001). 
In addition, transgenerational exposure can result from exposure of the mother to a 
chemical at any time before producing offspring due to the persistence of EDCs in body 
fat.  In the last decade, exposure to multiple EDCs such as polychlorinated biphenyls 
(PCBs), phthalates, and bisphenol A (BPA) have been detected in  90% of blood and 
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urine samples collected from the U.S. general population (Woodruff et al. 2011,Calafat et 
al. 2008, Silva et al. 2004).   
The discovery that chemicals could cause reproductive and endocrine toxicity 
dates back to the 1940’s when the usage of the insecticide dichlorodiphenyl 
trichloroethane (DDT) was at its peak.  DDT was found to induce adverse reproductive 
effects in non-target species including feminized male embryos, weakened eggshells, 
reduced nesting behavior, and diminished birth rates in numerous bird species (Patisaul et 
al. 2009).  DDT was ultimately banned in the United States in 1972, however, the 
widespread use of EDCs continued worldwide.  The first discovery that exposure to 
estrogen could adversely affect reproductive health emerged from the widespread use of 
the synthetic estrogen diethylstilbestrol (DES).  In the 1930’s DES was prescribed to 
pregnant women to prevent miscarriage.  DES was banned in 1971 when researchers 
identified a highly significant association between DES and the development of a very 
rare type of clear-cell-adenocarcinoma (CCA) of the vagina and cervix in female 
offspring born to mothers who took DES (Herbst et al. 1971).  Subsequent studies of 
DES exposure in female offspring have since been associated with breast cancer in older 
women (Troisi et al. 2007), elevated risk of CCA with age (Smith et al. 2012), early 
uterine leiomyomata diagnosis (D’Aloisio et al. 2010), younger age at natural menopause 
(Hatch et al. 2006), and irregular menstrual periods (Titus-Ernstoff et al. 2006).   
 Many EDC’s that persist in the environment today have demonstrated endocrine 
disrupting properties.  PCBs have shown to have both estrogenic and anti-estrogenic 
properties depending on the congener, phthalates have shown the potential to interfere 
with male reproductive development through antiandrogenic mechanisms (Swan 2008), 
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and BPA has shown to have estrogen mimicking properties. PCBs, BPA, and phthalates 
are the most extensively studied EDCs, and therefore, this research focused on analyzing 
the risk of reproductive toxicity in association with exposure to these three selected 
classes of EDCs – PCBs, BPA, and phthalates. 
 Polychlorinated biphenyls. PCBs are a group of synthetic organic chemicals that readily 
accumulate in the environment and have shown to cause a number of adverse health 
effects, including cancer, in humans and animals (ATSDR 2000). PCBs were introduced 
into industry in the 1930’s and used primarily for heat exchange in transformers and 
capacitors, hydraulic and lubricating fluids, plasticizers, inks, paints, adhesives, flame 
retardants, and extenders for pesticides (Letz 1983). The manufacture of PCBs was 
banned in the United States in 1977, however, they are still being released into the 
environment from inadequately maintained hazardous waste sites; illegal dumping of 
PCB wastes; leaks from old transformers; disposal of PCB-containing consumer products 
into municipal landfills, and burning of PCB contaminated waste (ATSDR 2000).  
 PCBs are ubiquitous in the environment and have been found to contaminate air, 
land, and aquatic environments thousands of miles away from the disposal site (Letz 
1983).  Once in the environment, PCBs adsorb strongly to soil and sediment and 
continuously cycle between air, water, and soil (ATSDR 2000). Due to their persistence 
in the environment, PCBs bioaccumulate in the food chain primarily in fish and marine 
animals, eventually reaching levels that are thousands of times higher than in water 
(ASTDR 2000).  The primary route of human exposure to PCBs is from eating 
contaminated food and breathing contaminated air.  Once PCBs have entered a person’s 
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or animal’s body, they are absorbed into adipose tissue and remain there for very long 
periods of time (Summarized in Johnson et al. 1999).  
Phthalates.  Phthalates are a group of synthetic chemicals that are widely used as 
plasticizers and additives in industrial products (Frederiksen et al. 2007).    High-
molecular weight phthalates such as di(2-ethylhexyl) phthalate (DEHP), di-isononyl 
phthalate (DiNP), and di-isodecyl phthalate (DiDP) are primarily used  to impart 
flexibility and durability in plastics and polyvinyl chloride (PVC) products, such as floor 
and wall coverings, clothing, food packaging, children’s toys, paint, and medical devices 
(Summarized in Meeker et al. 2009 & Lyche et al. 2009).  Low-molecular weight 
phthalates such as diethyl phthalate (DEP), dibutyl phthalate (DBP), and dimethyl 
phthalates (DMP) are primarily used in insecticides, varnishes and coatings, 
pharmaceuticals, and as detergents in personal care products such as perfume, hair gels, 
hair sprays, shampoos, body lotion, deodorant, and nail polish, (Swan 2008, Meeker et al. 
2009, Hauser et al. 2003, ATSDR 2002). Although phthalates are rapidly metabolized 
and excreted, the widespread use of both low and high molecular weight phthalates has 
led to a constant and unavoidable exposure to humans.  Ingestion of contaminated food is 
the most common route of exposure for the general population, however, dermal and 
inhalation exposures are also important routes due to their presence in numerous 
personal-care products and cosmetics (Swan 2008, CDC 2005).  According to the CDC’s 
Third National Report on Human Exposure to Environmental Chemicals the majority of 
people in the United States have detectable levels of several phthalate monoesters or their 
metabolites in their urine with detectable levels of DEHP concentrations highest in 
children (CDC 2005).  
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 Bisphenol A.  Bisphenol A (BPA) is a synthetic chemical that has shown to mimic 
estrogen and potentially impact reproductive and developmental function.  BPA is one of 
the highest production volume chemicals in commerce and has been used extensively for 
the past 40 years to manufacture polycarbonate plastics, epoxy resins to line food and 
beverage cans and polyester-styrene (Summarized in Talsness et al. 2009 , Cantonwine et 
al. 2010, Meeker et al. 2009).  BPA can also be found in dental sealants and fillings, 
carbonless paper, flame retardants, water storage tanks, and supply pipes (Summarized in 
Talsness et al. 2009, Meeker et al. 2009).  The majority of human exposure to BPA is via 
ingestion of contaminated food products (Summarized in Meeker et al. 2009).  This is of 
significant concern because many BPA containers are re-used or marketed as 
microwavable which accelerates the degradation of BPA into its monomeric form and 
leads to an increase in leaching into adjacent materials.  Detectable levels of urinary BPA 
have been found in 93% of samples from the 2003-2004 NHANES survey cycle (CDC 
2005) and in > 92% of Americans tested with higher levels in children and adolescents 
(Calafat et al. 2008).   
NHANES.  Information regarding blood and urine concentrations and adverse health 
effects associated with EDCs is important in understanding how the exposure to EDCs 
affects the overall health of the U.S. general population.  The National Health and 
Nutrition Survey (NHANES), conducted annually since 1999 by the Centers for Disease 
Control (CDC), is designed to measure the health of the U.S. general population in 
subjects  2 months of age (CDC 2012).  The surveys consist of a household interview, 
medical questionnaires, standardized physical examinations, and the collection of 
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biological specimens (blood and urine from participants  1 and  6 years of age, 
respectively) (CDC 2012).   
The overarching goal of this research was to determine if risk of reproductive 
toxicity in the general U.S. population is increased due to exposure to endocrine 
disrupting compounds (polychlorinated biphenyls, phthalates, and BPA) commonly 
found in the environment today. Using the CDC’s continuous NHANES database, 1999-
2010, statistical analysis was performed to analyze the associations between urinary and 
serum biomarkers of EDCs, reproductive health variables, and medical questionnaires 
(cancer).  
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CHAPTER II  
 
LITERATURE REVIEW  
 
Endocrine Disrupting Compounds  
 
 A new recent report by the United Nations Environment Programme (UNEP) and 
World Health Organization (WHO) entitled “State of the Science: Endocrine Disrupting 
Chemicals - 2012” highlighted  that approximately 800 chemicals are suspected to act as 
endocrine disruptors (EDs) or  mimic natural hormones or disrupt hormone regulation 
(UNEP/WHO 2013, EU 2013). Some of these EDs mimic natural or synthetic estrogen. 
This recent UNO report has renewed concern by highlighting that there may be some 
associations between exposure to estrogen-mimicking EDs and an increased risk of 
hormonal cancer in women (UNEP/WHO 2013, EU 2013). EDCs may produce a wide 
range of adverse effects because of the complexity of the endocrine system with its 
multiple signaling pathways, feedback mechanisms and cross-talks. Although a number 
of experimental animal studies have shown many chemicals have potential endocrine 
disrupting activities, the data on their endocrine disrupting effects in humans is limited. 
The role of EDC’s in the etiology of some of the human cancers and reproductive health 
hazards has been implicated, although the linkage between these two processes is highly 
controversial (Burantrevedh and Roy, 2001).  In addition to their endocrine disrupting 
effects, some environmental estrogen-like chemicals produce multiple and multi-types of 
genetic and/or nongenetic hits which may contribute to the induction of genomic 
instability in stem cells (Roy et al. 1998).   
 Estrogens and environmental chemicals play a significant role in the development 
of adverse reproductive health effects in women and endogenous sex hormones are 
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known to contribute to the development of reproductive cancers.  Supporting evidence 
includes the known factors of early menarche, late menopause, and nulliparity associated 
with an increased risk of developing breast cancer. Both endometriosis and breast cancer 
have in common one of the etiological factors, i.e., estrogen (Evans 2008). The estrogen 
is a contributing factor in the development of endometriosis as well as in breast cancer. 
Tamoxifen, a hormonal therapy for breast cancer, stimulates the growth of endometrial 
cells and can cause endometriosis (Lin et al. 2009). The increased risk of endometriosis 
and breast cancer among postmenopausal women may be due to an altered endogenous 
estrogen (Bertelsen et al. 2007, Roy et al. 1997, Roy et al. 1998). There is a general 
agreement that human populations are continually exposed to a wide variety of 
environmental estrogen-like chemicals.  We are beginning to acknowledge endocrine 
disrupting effects of these chemicals in humans through experimental animal data and 
epidemiological studies (Bertelsen et al. 2007 and Roy et al. 1997).  Only a limited 
number of EDCs, such as diethylstilbestrol (DES), bisphenol A, polychlorinated 
biphenyls, phthalates and dichlorodiphenyltrichloroethane (DDT), have been studied 
extensively to assess the endocrine disrupting effects in experimental models and in 
humans. Both human exposure data and epidemiological studies focused on assessing 
potential risk of diseases in association with these chemicals have been reported. 
Polychlorinated Biphenyls 
 PCBs are recognized as endocrine disruptors due to their ability to interfere with 
reproductive function and development in animals and humans by either increasing or 
blocking estrogen activity (Fielden et al. 2001; Ma and Sassoon 2006; McLachlan et al. 
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2006).  Adverse reproductive health effects have been established in numerous animal 
studies and have linked PCB exposure to prolonged estrus and decreased sexual 
receptivity in rats, decreased sperm fertilizing ability in mice (Fielden et al. 2001), 
decreased conception in mice, changes in the uterine myometrium and gland formation in 
mice (Ma and Sassoon 2006), prolonged menstruation, decreased birth weights, and 
decreased conception rates in rhesus monkeys (ASTDR 2000), and a significant dose-
dependent relationship in the prevalence and severity of endometriosis in rhesus monkeys 
(Rier et al. 2001).   Human studies on reproductive end-points are less conclusive; 
however, some studies have linked PCB exposure to menstrual disturbances, early age at 
menarche (Schell and Gallo 2009), late miscarriages, a reduction in lactation time, 
preterm delivery, low birth weight, and endometriosis (Tsukimori et al. 2008, Yang et al. 
2008, Yu et al. 2000, Buck Louis et al. 2005, Mendola et al. 1997, Baibergenova et al. 
2003).   
 In retrospective studies from the Taiwan Yucheng cohort, Yucheng women 
exposed to PCBs reported having abnormal menstrual flow twice as often as controls, 
prolonged time to pregnancy, and reduced fertility (Yu et al. 2000; Yang et al. 2008). 
Japanese women from the Yusho cohort had a 2-fold increase in the proportion of 
spontaneous abortion and pregnancy loss and a 5-fold increase in preterm delivery 
(Tsukimori et al. 2008).  In a New York State Angler cohort PCB exposure level was 
significantly associated with a decrease in menstrual cycle lengths as well as a decrease 
in the number of months of lifetime lactation, however, time to pregnancy was not 
associated unless the duration of fish consumption was three to six years (Mendola et al. 
1997; Buck et al. 2000; Kostyniak et al. 1999).   
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 Studies pertaining to PCBs and breast cancer are controversial. While some 
studies reported no significant associations (Xu et al. 2010; Silver et al. 2009; Gammon et 
al. 2002, Wolff et al. 2000, Hunter et al. 1997), others report slight increased risks among 
parous women who never breastfed (Moysich et al. 1998), or increased risks if genetic 
polymorphisms in the cytochrome P-450 1A1 (CYP 1A1) and menopausal status were 
considered (Zhang et al. 2004, Li et al. 2005; Moysich et al. 1999).  Zhang et al. (2004) 
found that breast cancer risk was significantly increased among women with the CYP1A1 
m2 variant genotype and among postmenopausal women with elevated serum PCB 
levels.  In addition, an increased risk of breast cancer recurrence was found only in 
women who had PCB concentrations in the highest tertiles (Muscat et al. 2003).   
Phthalates  
 Among various phthalates, di (2-ethylhexyl) phthalate (DEHP), di-butyl phthalate 
(DBP) and butylbenzylphthalate (BBP) have been studied for their endocrine disrupting 
effects. In numerous animal studies, phthalates have been shown to produce a variety of 
adverse effects including hepatic and renal damage, hepatocellular carcinoma, 
anovulation, decreased fetal growth, and most significantly anti-androgenic effects by 
suppressing testosterone and estrogen production (CDC 2005, Swan 2008).  Reproductive 
abnormalities reported in rodent females include uterine and ovarian abnormalities 
(increased weights and malformations), advanced onset of puberty (delayed vaginal 
opening), reduced fecundity, decreased serum estradiol levels, prolonged estrus cycles, 
absence of ovulation, and modified morphology of the mammary gland (CDC 2005, 
Moral et al. 2011).   
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 While human studies associating phthalate exposure with adverse reproductive 
effects are less conclusive, many of the findings in male infants are consistent with the 
anti-androgenic action that has been demonstrated for phthalates in animal studies.  In a 
follow-up analysis to the 2000 Study of Phthalates in Pregnant Women and Children , 
significant associations were found between AGD and 3 DEHP metabolites (MEHP, 
MEHHP and MEOHP) with mean metabolite concentrations found to be several times 
greater among males with shorter AGD compared to males with longer AGD (Swan 
2008).  Additional human studies with adverse reproductive endpoints including a 
significantly lower gestational age in newborns considered MEHP-positive (Latini et al. 
2003), a dose-response relationship of MBP and low sperm concentration (Summarized 
in Swan 2008), a relationship between urinary MEP levels and sperm DNA damage, 
decreased sperm motility, and a reduction in serum free testosterone in men with 
occupational exposure to DBP and DEHP (Summarized in Frederiksen et al. 2007, 
summarized in Meeker et al. 2009). Human studies demonstrating the association 
between phthalate exposure and adverse reproductive effects in females are limited to 
only a few. Cobellis et al. (2003) reported higher plasma concentrations of DEHP and 
MEHP in women with endometriosis.  More recently, Huang et al. (2010) reported that 
patients with leiomyomas had significantly higher levels of total urinary MEHP, patients 
with endometriosis had increased levels of urinary MnBP, and subjects who had the 
GSTMI null genotype had a significantly increased risk of adenomyosis.     
Bisphenol A 
  Numerous studies have shown adverse effects of low doses of BPA on the 
development of male and female reproductive organs in experimental animals.  In rodent 
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females, BPA exposure has shown to cause alterations in the mammary gland 
development, changes in gene expression of the mammary gland, cystic ovaries, 
endometrial hyperplasia, adenomyosis,  leiomyomas, atypical hyperplasia, stromal 
polyps, ductal hyperplasias and carcinoma, a decline in fertility and fecundity, decreased 
wet weight of the vagina, decreased volume of the endometrial lamina propria, and an 
increased expression of estrogen receptor- (ER) and progesterone receptors  (Talsness 
et al. 2009, Moral et al. 2008, Munoz-de-toro et al. 2005, Cabaton et al. 2011, Markey et 
al. 2004).  Despite their widespread exposure human epidemiologic studies of BPA 
exposure and adverse reproductive endpoints are severely limited.  In the few available 
studies, BPA levels were reported to be associated with miscarriages, fetuses with 
abnormal karyotype, and polycystic ovarian syndrome (Summarized in Meeker et al 
2009).  In a pilot nested case control study of BPA exposure and prematurity, pregnant 
women who delivered less than or equal to 37 weeks of gestation had higher urinary 
concentrations of BPA in a single spot urine sample collected during the third trimester 
compared to women who delivered after 37 weeks (Cantonwine et al. 2010).   
Bioinformatics:  EDCs, Breast Cancer and Endometriosis 
While there are several studies which link EDCs – PCBs, BPA, and phthalate 
exposure to increased risk of a reproductive toxicity, there are other studies which have 
been inconsistent or showed no association between these EDCs and risk of breast cancer 
or endometriosis.  In this study, we used a combined environmental epidemiologic, 
genomic, and bioinformatics approach to understand the relationship between EDCs and 
risk of developing estrogen-dependent complex chronic diseases – breast cancer and 
endometriosis by examining interactions between genes, diseases and these three selected 
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EDCs. We have also evaluated the possibility that ‘‘estrogen mimicking endocrine 
disruptor responsive genes’’ are potentially associated with systemic changes in breast 
cancer and endometriosis.   To accomplish the objectives identified here, we introduce a 
comprehensive bioinformatics method using genomics, environmental and epidemiologic 
data integration that links with diseases - breast cancer and endometriosis to identify: 1) 
genes that interact with EDCs and link to the development of these diseases, and 2) 
important pathways that may be influenced by EDC exposures.  The first and second 
steps in our method included modeling to assess estrogenicity of environmental 
chemicals to show the potential of endocrine disruption and assessing association 
between EDC exposure and diseases, respectively. The third step in our method included 
identifying genes responsive to EDC exposures using the Comparative Toxicology, 
Environmental Genome Project and KEGG.  These EDC responsive genes were then 
compared to a curated list of genes in breast cancer and endometriosis.  This comparison 
produced a list of genes responsive to the environment and important to breast cancer and 
endometriosis that was then further analyzed using gene networking tools such as 
RSpider, Cytoscape, and DAVID.  Using this bioinformatics method we were able to 
identify environmentally responsive genes with the potential to be involved in interaction 
with EDCs that may be important to the development of breast cancer and endometriosis.  
We meta-analyzed environmental epidemiologic evidence for the risk of breast cancer 
and endometriosis with exposure to EDCs - PCB, phthalates, and BPA from 23 selected 
publications which we categorized by outcome: breast cancer and endometriosis.  Meta-
analysis was performed using the general variance-based method and homogeneity was 
tested by means of the Q statistic. Analysis was completed using Comprehensive Meta 
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Analysis Version 2.2.046 from Biostat, Inc. which can be downloaded at www.Meta-
Analysis.com (Borenstein et al. 2005).  The resources, workflow, meta-analysis and 
bioinformatics tools and integration of environmental epidemiologic, genomic and 
disease databases are shown in Figure 1.  
.
 
Figure 1.  Flow chart showing the steps involved in identifying genes that illustrate link 
between endometriosis and breast cancer based on environmental response on 
epidemiologic , genomics, and bioinformatics databases. 
 
EDCs and Breast Cancer 
 We identified twelve epidemiologic studies related to PCB, phthalate, or BPA 
exposure and breast cancer.  Ten of the twelve studies assessed the relationship between 
PCB exposure and breast cancer (Charlier et al. 2004, Cohn et al 2012, Demers et al. 
2002, Gammon et al. 2002, Gatto et al. 2007, Itoh et. al 2009, Millikan et al. 2013, Pavuk 
et. al 2003, Recio-Vega et al. 2001, Wolff et al. 2009), one study assessed the 
relationship between phthalate exposure and breast cancer (Lopez-Carillo et al. 2010), 
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and one study assessed the relationship between BPA exposure and breast cancer (Yang 
et al. 2009).  All twelve of the identified studies were case-control studies. In all of the 
studies, cases had histologically confirmed breast cancer and controls had no history of 
breast cancer diagnosis.  In the majority of the studies, controls were matched on age and 
residence.   
PCBs and Breast Cancer.  Three of the ten PCB case-control studies failed to find any 
associations between exposure to total PCBs and breast cancer risk (Gammon et al. 2002, 
Gatto et al. 2007, Wolff et al. 2009) while two of the ten PCB studies found an inverse 
association between total PCB levels and breast cancer (Itoh et al. 2009, Pavuk et al. 
2003).  The largest case-control study conducted by Gammon et al. (2002) consisted of 
646 newly diagnosed breast cancer cases and 429 matched controls failed to find any 
association between PCB exposure and breast cancer risk when comparing the highest 
quintile of serum Peak-4 (nos. 118, 153, 138, and 180) PCB levels to the lowest quintile 
(OR=0.83, 95% CI 0.54-1.29).  Gatto et al. (2007) did not find any associations with 
breast cancer when comparing the highest vs. lowest quintiles of mean total PCB levels 
in 355 cases and 327 controls (OR=1.01, 95% CI 0.63-1.63) and Wolff et al. (2009) did 
not find any associations with breast cancer when comparing the highest vs. lowest 
quartiles of serum total PCB levels in 110 cases and 213 controls.  Itoh et al. (2009) 
found a decreased risk of breast cancer when comparing the highest quartile of median 
total PCB levels to the lowest quartile (OR=0.33, 95% CI 0.14-0.78) and Pavuk et al. 
(2003) found higher serum PCB levels to be inversely associated with breast cancer in 
total PCBs (OR=0.42, 95% CI 0.10-1.82) and in 3 sub-groups of PCBS: estrogenic, anti-
estrogenic/dioxin-like, and phenobarbital-type.   
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 Five of the PCB case-control studies found significant associations between breast 
cancer and exposure to individual PCB congeners, total PCBs, or specific sub-groups of 
PCBs (Charlier et al. 2004, Cohn et al. 2012, Demers et al. 2002, Millikan et al. 2013, 
Recio-Vega et al. 2001).  Charlier et al. (2004) measured mean levels of 7 PCB 
congeners in 60 breast cancer cases and 60 healthy controls.  They found total PCBs to be 
significantly different (p = 0.012) between  cases and  controls (7.08 vs. 5.10 ppb) which 
can be attributed to significantly higher serum levels of PCB 153 in breast cancer cases 
when compared to controls (1.63 vs. 0.63 ppb, p < 0.0001).  The OR of breast cancer for 
PCB 153 was 1.8 (95% CI 1.4-2.5).  In a nested, matched case-control study of 112 cases 
and controls, Cohn et al. (2012) did not find any associations for total PCBs or PCB 
groupings, however, a significant association was found for PCB 203 when comparing 
the highest vs. lowest quartiles of exposure (OR=6.3, 95% CI 1.9-21.7).  In a matched 
case-control study of 314 cases and 523 controls, Demers et al. (2002) found breast 
cancer risk significantly associated with the sum of mono-ortho congeners (nos. 105, 118, 
156) (OR=2.02, 95% CI 1.24-3.28), PCB 118 (OR=1.60, 95% CI 1.01-2.53) and PCB 
156 (OR=1.80, 95% CI 1.11-2.94) when comparing the fourth vs. first quartiles.  In a 
population based case-control study with sub-groups of African-American women and 
white women, Millikan et al. (2013) did  not find any associations with total PCBs and 
breast cancer among all participants (OR=1.09, 95% CI 0.79-1.52) or white women 
(OR=1.03, 95% CI 0.68-1.56), but did find a slightly elevated risk for African-American 
women (OR=1.74, 95% CI 1.00-3.01).  Recio-Vega et al. (2001) found the GM of total 
PCBs to be significantly higher in cases than controls (5.26 vs. 3.33 ppb) (OR=1.09, 95% 
CI 1.01-1.14) as well as an increased risk of breast cancer among PCBs grouped by 
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structure-activity relationships and 8 individual PCB congeners (nos. 118, 128, 138, 170, 
180, 195, 206, and 209).   
Since the relationship between PCB exposure and breast cancer in ten 
epidemiologic studies was inconsistent or conflicting, risk estimates of PCBs on breast 
cancer from six case control studies were extracted and summarized using meta-analytic 
methods.   Combining six studies of exposure to PCBs produced a summary risk estimate 
of 1.33 (95% CI: 0.72 – 2.65) (Table 1; Fig. 2).  PCB exposures were found to be 
associated with development of breast cancer as a meta-analysis of six studies produced 
an increased risk of 1.33; however, this was not statistically significant. 
 
 
 
 
 
Table 1. Epidemiological studies of the association between exposure to PCBs and risk of breast cancer.
 Reference, 
location 
Study design Study 
Population 
Measurement of 
Exposure 
Outcomes Results Comments  Confounders 
Charlier et al. 
(2004), 
Belgium 
Case-control 
study  
60 cases, 60 age 
matched healthy 
controls  
7 PCBs from 
serum, Total PCBs.   
Mean Total PCB levels 
(ppb =ng/g) 
Cases:  7.08 
Controls:  5.10 
Logistic Regression (OR-
95% CI).   
Total PCBs significantly 
different in cases than 
controls (p=0.012). High 
concentrations of PCB153 
significantly associated 
with an increased risk of 
BC (OR=1.8, 95% CI-1.4-
2.5).  
Cases diagnosed with 
breast cancer and 
undergoing a surgical 
intervention.  
Controls free of BC at age 
agnosis.  
Adjustments made for age, 
menopausal status, number 
of full-term pregnancies, 
lactation, use of HRT, and 
family history of BC.   
Demers et al. 
(2001), Canada 
Case-control 
study  
314 cases, 523 
controls; matched 
by age and 
residence.  
14 PCB congeners 
measured in 
plasma (ug/kg of 
plasma lipids).  
TEQ/kg of lipids 
for sum of mono-
ortho congeners 
(nos. 105, 118, 156).   
Mean TEQ ng/g of lipids:  
Cases: 6.4 
Controls: 5.8  
Logistic Regression (OR-
95% CI); Quartiles.   
Mean total of mono-
ortho congeners 
significantly higher in 
cases than controls 
(p=0.005).   
Significant associations 
between breast cancer 
risk and PCB 156, 118, & 
mono ortho congeners  
In 4th vs. 1st 
quartiles.(OR=2.02, 95% 
CI: 1.24-3.28).    
Cases: histologically 
confirmed infiltrating 
primary BC. Controls: no 
history of BC diagnosis.  
Adjusted for age, residence, 
BMI, history of benign breas
disease, breastfeeding 
duration.   
Pavuk et al. 
(2003), USA 
Case-control 
study  
24 cases, 88 
controls  
Total PCBs from 
serum (n=15);  
Groups of PCBs:  
(1) estrogenic,  
(2) anti-estrogenic, 
dioxin-like, 
(3) phenobarbital-
type 
GMs Total PCBs (ng/g of 
lipid):  
Cases:  3228.2 
Controls:  2885.8 
Logistic Regression (OR-
95% CI); Tertiles 
Higher serum levels of 
total PCBs (OR=0.42, 
95% CI 0.10-1.82) 
inversely associated with 
BC.  Groups 1, 2, & 3 also 
inversely associated.   
Cases: histologically 
confirmed invasive BC.  
Controls: identified 
through random 
sampling of primary care 
physicians.   
Adjusted for age, age at 
menarche, education, alcoho
consumption, smoking.   
Recio-Vega et 
al. (2011), 
Mexico  
Case-control  
Study 
70 cases, 70 
controls 
Individual and 
total PCBs from 
serum (n=20);  
5 PCB groups by 
structure-activity 
relationships.  
GM Total PCB levels 
(ppb):  
Cases:  5.26 
Controls: 3.33 
Logistic Regression (OR-
95% CI).   
Total PCBs significantly 
higher among cases than 
controls (OR=1.09, 95% 
CI 1.01-1.14). Risk of BC 
positively associated with 
8 PCB congeners: 118, 
128, 138, 170, 180, 195, 
206, and 209.  
Cases: first diagnosis of 
BC by biopsy. 
Controls: negative 
biopsies from same 
hospitals and geographic 
area.    
Adjusted for age, age at 
menarche, lactation, 
menopause status, BMI.   
Wolff et al. 
(2000), US  
Prospective 
case-control 
Study 
148 cases, 295 
individually 
matched controls 
Total PCBs from 
serum.   
GM Total PCBs (ng/g of 
lipids):  
Cases:  683 
Controls: 663 
Logistic Regression (OR-
95% CI); Quartiles 
GM Total PCB levels not 
significantly different.  
No association between 
PCB exposure and BC 
(OR=2.02 95% CI 0.76-
5.37).   
BC cases identified 
through active follow-up 
of the NYU Women’s 
Health Study Cohort.   
Controls selected at 
random from cohort who 
were alive and free of 
disease at the time of 
case diagnosis.  
Adjusted for age at 
menarche, # of full-term 
pregnancies, age at first 
birth, family history of BC, 
lifetime history of lactation, 
BMI, menopausal status at 
time of blood donation.  
Itoh et al. 
(2008), Japan  
Matched case-
control study  
403 pairs; matched 
by age (3 years) 
and residence.  
Total PCBs from 
serum (Sum of 41 
PCB peaks).  
Median Total lipid-
adjusted PCBs (ng/g):  
Cases:  170 
Controls:  180 
Logistic Regression (OR, 
95% CI), Quartiles.   
Total PCBs associated 
with a decreased risk of 
BC.  
(OR=0.33, 95% CI: 0.14-
0.78, p-value 0.008); 
highest vs. lowest 
quartile.   
 
 
Cases: histologically 
confirmed invasive BC.  
Controls:  selected from 
medical checkup 
examinees, no BC 
diagnosis.  
Adjusted for lipids, BMI, 
menopausal status & age, 
smoking, fish & veg   
consumption, family history
parity, age at first childbirth
age at menarche, history of 
BC screening 
    
 
 
 
 
 
Figure 2.  Forest plot of epidemiological studies of the association between exposure to 
PCBs and risk of breast cancer.   
Bisphenol A or phthalate and breast cancer: No meta-analysis was performed on 
exposure to BPA or phthalates, because only one study for each chemical fit the criteria.  
Lopez-Carillo et al. (2010)  found urinary concentrations of monoethyl phthalate (MEP) 
to be significantly higher in cases than controls when comparing the highest vs. lowest 
tertile of exposure (169.58 vs 106.78 ug/g creatinine).  The OR of breast cancer risk in 
the highest tertile of urinary MEP, compared with the lowest tertile, was 2.20 (95% CI 
1.33-3.63) and became higher when estimated for premenopausal women (OR=4.13, 95% 
CI 1.60-10.7).  On the contrary, significant negative associations were found for urinary 
concentrations of monobenzyl phthalate (MBzP) (OR=0.46, 95% CI 0.27-0.79) and 
mono (3-carboxypropyl) phthalate (MCPP) (OR=0.44, 95% CI 0.24-0.80).  In a matched 
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case-control study Yang et al. (2009) measured median blood BPA levels in 70 cases and 
80 controls. Median BPA levels were higher in cases than controls (0.61 vs. 0.03 ug/L), 
however, the differences were not found to be statistically significant (p = 0.42).   
PCBs-Breast Cancer-Gene Association: The CTD search revealed that besides 
polychlorinated biphenyls, the five most common PCB congeners studied for gene 
interaction were 3,4,3',4'-tetrachlorobiphenyl (77), 2',3,3',4',5-pentachloro-4-
hydroxybiphenyl (4'-OH-PCB-86),  3,4,5,3',4'-pentachlorobiphenyl (126),  2,3,3',4,4',5-
hexachlorobiphenyl (153), and 2,2',3,4,4',5,5'-Heptachlorobiphenyl (180) (Table 2).  
There were 5289 genes related to PCBs as a family of chemicals and 386 genes related to 
breast cancer (Fig. 3). The common genes between PCBs and breast cancer were 200. 
The top interacting genes with polychlorinated biphenyls as a chemical class were 
CYP1A1, AHR, CYP1A2, AR, CYP1A, CYP1B1, VCAM1, MAPK1, MAPK3, and 
PTGS2. The top interacting genes with polychlorinated biphenyls in breast neoplasms 
were AR, CYP1A1, CYP1B1, ESR1, ESR2, PTGS2, and RAF1. Out of a total 200 gene 
interactions observed with individual PCBs, the interaction of genes AR, BAX, CYP1A1, 
CYP1B1, KDR, PARP1, PTGS2, and RAF1  was common  with tetrachloride-, 
pentachloride-, and hexachloride biphenyls in breast neoplasms (Table 2). CYP1A1, 
AHR, AR, CYP1A, CYP1B1, and PTGS2 genes are common in both PCB-gene and 
PCB-gene-breast cancer groups. Interactions among these genes are shown in Figure 4. 
Enrichment pathway analysis revealed that these genes are part of: 1) pathways in cancer  
(KEGG:05200); 2) signal transduction  (REACT:111102), 3) mTOR signaling pathway 
(KEGG:04150);  4) focal adhesion  (KEGG:04510);  5) VEGF signaling pathway 
(KEGG:04370); and  6) ErbB signaling pathway (Table 3).     
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BPA, Phthalate and Breast Cancer-Gene Association: There were 6365 genes related 
to BPA as chemicals. There were 385 genes known to be related to breast cancer. There 
were 209 common genes between BPA and breast cancer (Fig. 2). There were 5754 genes 
related to phthalate as a family of chemicals and 385 genes related to breast cancer (Fig. 
2). The common genes between dibutyl phthalate and breast cancer and diethylhexyl 
phthalate and breast cancer were 162, and 89, respectively. Identification of the common 
genes with breast cancer and both dibutyl phthalate and diethylhexyl phthalate further 
revealed that there were 54 common genes between dibutyl phthalate and diethylhexyl 
phthalate  and breast cancer: ABCG2, AHR, AKT1, ALDOA, AR, BCL2, BMP2, BMP4, 
CADM1, CASP7, CCND1, CD40, CTNNB1, CYP17A1, CYP19A1, CYP1A1, CYP1B1, 
CYP3A4, DNMT1, DNMT3A, DNMT3B, EDNRB, EEF2, EGFR, ESR1, ESR2, 
ESRRA, F3, FASN, FOS, GPX1, HADHB, HSP90AA1, IGF1, IGFBP7, JUN, LOXL2, 
MMP2, MMP9, NDRG1, NFKBIA, NOTCH2, OCLN, PER3, PIK3CA, PTPRD, RPL31, 
RPS4X, SOD2, THBS1, TNF, TUBB3, WNT10B, and YBX1 (Table 2). Interactions 
among these genes are shown in Figure 3. Enrichment pathway analysis revealed that 
some of these genes are part of: 1) pathways in cancer (KEGG:05200); 2) signal 
transduction  (REACT:111102), and 3) MAPK signaling pathway ( KEGG:04150) (Table 
3).    
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Table 2. Genes interacting with polychlorinated biphenyls in breast neoplasms. 
IUPAC Name (congener number) Interacting genes
Polychlorinated Biphenyls 65 genes: ACHE | AFP | AGR2 | AHR | AKAP12 | AKT1 | ANGPTL4 | APOBEC3B | 
AR | ARAF | AREG | AURKA | BCHE | BIRC5 | CDKN1B | CENPF | CLDN4 | 
COMT | CXCL12 | CXCL2 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | 
CYP3A4 | DNMT1 | DNMT3A | DNMT3B | ESR1 | ESR2 | FOS | GPI | GPNMB | 
H2AFX | HEY1 | HMOX1 | HP | IFNG | IL6 | JUN | KRAS | MKI67 | MMP3 | NCOA3 
| NQO1 | PPARGC1B | PTGS2 | RAD51 | RAD51C | RAD54L | RAF1 | RPS8 | SOD2 | 
SPP1 | STC2 | STMN1 | TGM2 | THBS1 | THEMIS2 | TNF | TOP2A | TYMS | UBE2C  
2,4,4'-trichlorobiphenyl  (28) 11 genes: AR | CYP1A1 | CYP1B1 | CYP2B1 | ESR1 | ESR2 | HIF1A | KDR | PTGS2 | 
RAF1 | TP53   
2,4',5-trichlorobiphenyl  (31) 3 genes: AR | ESR1 | ESR2   
2,5,2',5'-tetrachlorobiphenyl  (55)  13 genes: ACHE | AHR | AKT2 | APC2 | AR | CYP1A1 | CYP2B1 | EPB41L3 | IGF1R 
| MMP2 | PARP1 | PLA2G4A | ZEB2    
3,4,3',4'-tetrachlorobiphenyl  (77) 27 genes: AHR | AR | BAX | CAV1 | CCNE1 | CYP1A1 | CYP1B1 | ESR1 | ESR2 | 
GPI | GPX1 | HADHB | HIF1A | HNRNPK | IL1B | IL6 | KDR | MRPL19 | NDRG1 | 
NOS3 | NQO1 | PARP1 | PER3 | PTGS2 | RAF1 | RELA | TNF   
2',3,3',4',5-pentachloro-4-
hydroxybiphenyl (4'-OH-PCB-86;4-
hydroxy-2 , 2' , 3' , 4' , 5'-
pentachlorobiphenyl ) 
75 genes: ACVR1 | AFP | APC2 | ARAF | ATM | BIRC5 | BMPR2 | CASP8 | CAV1 | 
CD40 | CHEK2 | CSF1 | CSF3 | CST6 | CXCL12 | CXCL2 | CYP17A1 | CYP1A1 | 
DAP3 | DDIT3 | DNMT3A | DNMT3B | DPYD | EEF2 | EFNA1 | EGF | ERBB2 | F3 | 
FABP7 | FGFR2 | FHL2 | FKBPL | GDF10 | HIF1A | HRG | IL24 | JAG1 | JAG2 | JUN 
| LDHB | LEPR | LPAR1 | MFGE8 | MME | MMP2 | MMP3 | MMP9 | MRPL13 | 
MTDH | MTHFR | MTR | NDRG1 | NOTCH3 | NOTCH4 | NRCAM | NUDT2 | OCLN 
| PARP1 | PDE2A | PDGFA | PHB | PPARGC1B | PTPRD | RGS2 | SLC28A1 | STAT3 
| SYNE1 | SYNJ2 | TFRC | THBS1 | THEMIS2 | TOP2A | VEGFC | VPS39 | ZEB1   
2,2',4,6,6'-pentachlorobiphenyl  (104) 9 genes: AKT1 | AR | CXCL8 | EGFR | FOS | JUN | MMP3 | OCLN | SRC    
2,3,3',4,4'-pentachlorobiphenyl  (105) 4 genes: AHR | AR | CYP1A1 | CYP2B1    
2,3',4,4',5-pentachlorobiphenyl  (107) 10 genes: AHR | AR | CASP7 | CYP1A1 | CYP1B1 | CYP2B1 | HIF1A | KDR | OCLN | 
PTGS2   
2,3,4,4',5-pentachlorobiphenyl  (114) 2 genes: AHR | CYP1A1   
2,3',4,4',5-pentachlorobiphenyl  (118) 10 genes: AHR | AR | CASP7 | CYP1A1 | CYP1B1 | CYP2B1 | HIF1A | KDR | OCLN | 
PTGS2   
3,4,5,3',4'-pentachlorobiphenyl (126) 
 
77 genes: ACVR1 | ADAMTS1 | AFP | AHR | AKAP12 | AKT1 | APRT | AR | AREG | 
BARD1 | BAX | BCL2 | BMP4 | BRCA1 | CADM1 | CAV1 | CCL20 | CCND1 | CD74 | 
CXCL12 | CXCL8 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | EGF | 
ESR1 | F3 | FASN | FGFR2 | FHL2 | FST | GPNMB | HES1 | HIF1A | HMOX1 | 
ICAM5 | IGF1 | IGF1R | IGFBP5 | IGFBP7 | IL1B | IL6 | JUN | KDR | LDHAL6B | 
LPAR1 | MME | MMP9 | NOS2 | NOS3 | NOTCH1 | NQO1 | NRG1 | OCLN | PAK1 | 
PARP1 | PDGFA | PER3 | PHGDH | PLA2G4A | PTGS2 | PTPRD | RAF1 | SERPINB2 
| SLC2A5 | SLC5A5 | SNAI1 | SPP1 | STC2 | SYNJ2 | TBX3 | TGM2 | TNF | TP53 | 
VEGFC 
2,3,4,2',3',4'-hexachlorobiphenyl  
(128) 
2 genes: AHR | AR   
2,3,3',4,4',5-hexachlorobiphenyl  (129) 5 genes: AHR | AR | CYP1A1 | CYP1B1 | ESR1   
2,2',3',4,4',5-hexachlorobiphenyl  27 genes: ACHE | AHR | AKT2 | APC2 | AR | BRCA1 | CCT5 | CENPF | CFL1 | 
 
2,3,6,2',3',6'-hexachlorobiphenyl  (136) 2 genes: AR | CYP2B1    
2,4,5,2',4',5'-hexachlorobiphenyl (153)  51 genes: AHR | AKAP12 | AR | BAX | BCL2 | BRCA1 | CASP8 | CCND1 | CDH1 
| CTNNB1 | CXCL12 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | CYP3A4 | 
EGFR | ESR1 | ESR2 | FASN | FOS | GPX1 | GPX2 | HIF1A | HSPA1B | IFNG | 
IGF1 | IL1B | JUN | KDR | MAP3K1 | MEIS1 | NDRG1 | NOTCH1 | NQO1 | NRG1 
| OCLN | PARP1 | PTGS2 | PTPRD | RAF1 | SPP1 | SRC | STAT5A | STMN1 | 
TFPI2 | TNF | TNFSF10 | TP53 | TUBB3 | XRCC3   
3,4,5,3',4',5'-hexachlorobiphenyl   7 genes: AHR | BAX | CYP1A1 | CYP1B1 | HIF1A | KDR | PTGS2    
2,2',3,4,4',5,5'-Heptachlorobiphenyl (180) 19 genes: ABL1 | AHR | AR | BAX | BCL2 | BRCA1 | CYP1A1 | CYP1B1 | 
CYP2B1 | FOS | HIF1A | IGF1 | KDR | MMP2 | MMP9 | NOTCH1 | PTGS2 | TP53 
| ZEB2   
17 beta Estradiol 255 genes: ABCG2 | ACHE | ADAMTS1 | AFP | AGR2 | AHR | AKAP12 | AKT1 | 
AKT2 | ALDOA | APOBEC3B | AR | ARAF | AREG | ARHGDIA | ARTN | ATM | 
ATP7B | AURKA | BARD1 | BAX | BCAR3 | BCHE | BCL2 | BIRC5 | BMP2 | 
BMP4 | BMPR2 | BRCA1 | BRCA2 | C10ORF10 | CADM1 | CASP7 | CASP8 | 
CAV1 | CCL20 | CCND1 | CCNE1 | CD109 | CD40 | CDA | CDH1 | CDH5 | 
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CDKN1B | CENPF | CFL1 | CHEK2 | CLDN1 | CLDN4 | COL7A1 | COMT | CSF1 
| CSF1R | CSF3 | CST6 | CTNNB1 | CXCL12 | CXCL2 | CXCL3 | CXCL8 | 
CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2B1 | CYP3A4 | DDIT3 | DKK1 | 
DNMT1 | DNMT3A | E2F1 | EDNRB | EFEMP1 | EFNA1 | EGF | EGFR | ELK3 | 
ENO1 | EPHB4 | EPOR | ERBB2 | ESR1 | ESR2 | ESRRA | ETS2 | ETV4 | EVL | 
F3 | FASN | FBL | FGF10 | FGFR1 | FGFR2 | FHL2 | FKBPL | FOS | FOXA1 | 
FOXM1 | FOXP3 | FST | GDF10 | GPNMB | GPX1 | GPX2 | GPX4 | GRB7 | 
H2AFX | HADHB | HES1 | HEY1 | HEY2 | HIF1A | HIST1H1C | HIST1H2BC | 
HIST1H2BK | HMMR | HMOX1 | HP | HPSE | HRAS | HRG | HSP90AA1 | 
HSPA1B | IFNG | IGBP1 | IGF1 | IGF1R | IGFBP5 | IL1B | IL24 | IL6 | JAG1 | JUN 
| KCNH1 | KDR | KIT | KRAS | KRT18 | KRT8 | LDHB | LEP | LEPR | LOXL2 | 
LPAR1 | LSP1 | MAL | MAP3K1 | MDM4 | MIF | MIR10B | MIR146A | MIR200B 
| MIR222 | MKI67 | MME | MMP1 | MMP2 | MMP3 | MMP9 | MTR | NAT2 | 
NCOA1 | NCOA2 | NCOA3 | NCOR1 | NDRG1 | NFKBIA | NOS2 | NOS3 | 
NOTCH1 | NOTCH2 | NQO1 | NQO2 | NR2F1 | NRG1 | NRIP1 | NUDT2 | PAEP | 
PAK1 | PARP1 | PDGFA | PGR | PHB | PHGDH | PIK3CA | PIM1 | PLA2G4A | 
PPARGC1B | PPM1D | PTEN | PTGS1 | PTGS2 | PTHLH | RAD51 | RAD51C | 
RAF1 | RARB | RB1 | RBM3 | RELA | RGS2 | RPL31 | RPS4X | RPS6 | RPS7 | 
RRAD | SERPINB2 | SERPINB5 | SFRP1 | SFRP2 | SLC2A1 | SLC2A2 | SLC2A5 | 
SLC39A6 | SLC5A5 | SNAI1 | SNAI2 | SOD2 | SPP1 | SRC | STAT3 | STAT5A | 
STC2 | STMN1 | SYNE1 | SYNJ2 | TANK | TBX3 | TCL1B | TERT | TFAP2A | 
TFPI2 | TFRC | TGM2 | THBS1 | THEMIS2 | TLE3 | TNF | TNFSF10 | TNIP1 | 
TOP2A | TOX3 | TP53 | TRERF1 | TRP53 | TUBB3 | TYMS | UBE2C | VPS39 | 
WNT10B | WT1 | ZEB1 | ZEB2 | ZNF365 | ZNF366 
Diethyl phthalate  
 
AFP, AHR, AR, CXCL8, CYP17A1, CYP1B1, ESR1, ESR2,  IFNB1   
Dibutyl Phthalate and Diethylhexyl 
Phthalate   
54 Common genes: ABCG2, AHR, AKT1, ALDOA, AR, BCL2, BMP2, BMP4, 
CADM1, CASP7, CCND1, CD40, CTNNB1, CYP17A1, CYP19A1, CYP1A1, 
CYP1B1, CYP3A4, DNMT1, DNMT3A, DNMT3B, EDNRB, EEF2, EGFR, ESR1, 
ESR2, ESRRA, F3, FASN, FOS, GPX1, HADHB, HSP90AA1, IGF1, IGFBP7, 
JUN, LOXL2, MMP2, MMP9, NDRG1, NFKBIA, NOTCH2, OCLN, PER3, 
PIK3CA, PTPRD, RPL31, RPS4X, SOD2, THBS1, TNF, TUBB3, WNT10B, 
YBX1. 
Bisphenol A 209 genes: ABCG2 | ABL1 | ACHE | AFP | AGR2 | AHR | AKAP12 | AKT1| 
ALDOA | APOBEC3B | AR | ARAF | AREG | ARHGDIA | AURKA | BAG1 
|BARD1 | BAX | BCAR3 | BCL2 | BCL2A1 | BIRC5 | BMP4 | BRCA1 | BRCA2 
|CASP7 | CASP8 | CAV1 | CCND1 | CCNE1 | CCT5 | CDH1 | CDH5 | CDKN1B 
|CENPF | CFL1 | CHEK2 | CLDN4 | CMC2 | COTL1 | CSF2 | CTNNB1 | CUL5 
|CXCL12 | CXCL3 | CYP17A1 | CYP19A1 | CYP1A1 | CYP1B1 | CYP2D6 
|CYP3A4 | DAP3 | DDIT3 | DNMT1 | DNMT3A | DNMT3B | DSC3 | E2F1 | EEF2 
|EGF | EGFR | ENO1 | ERBB2 | ESR1 | ESR2 | ESRRA | ETS2 | EVL | EZH2 | 
FASN| FBL | FGFR1 | FGFR2 | FHL2 | FOS | FOXM1 | FST | GDF10 | H2AFX | 
HADHB |HES1 | HEY2 | HIC1 | HMMR | HMOX1 | HNRNPL | HNRNPR | HP | 
HRAS |HSP90AA1 | HSPA1B | IFNB1 | IFNG | IGBP1 | IGF1 | IGF1R | IGFBP5 | 
IL1B |IL6 | JAG1 | JAG2 | JUN | KDR | KIT | KRAS | KRT8 | LEP | LEPR | LLGL1 
|LPAR1 | MAL | MAP3K1 | MDM4 | MEIS1 | MFGE8 | MIF | MIR146A | 
MIR200B |MIR222 | MIR29A | MIR342 | MKI67 | MME | MMP1 | MMP2 | MMP9 
| MRPL13 |MRPL19 | MRPS22 | MTR | NAT2 | NCOA1 | NCOA2 | NCOA3 | 
NCOR1 | NDRG1| NOS2 | NOS3 | NOTCH1 | NOTCH2 | NOTCH3 | NQO1 | 
NRCAM | NRIP1 |NUDT2 | OCLN | PAK1 | PARP1 | PDGFA | PER3 | PGR | PHB 
| PHGDH | PIM1 |PIN1 | PLA2G4A | PTEN | PTGS1 | PTGS2 | RAD51 | RAD51B | 
RAD51C |RAD54L | RB1 | RELA | RGS2 | RIBC2 | RPS6 | RPS6KB2 | RPS7 | 
RXRB |SERPINB5 | SFRP1 | SFRP2 | SHMT1 | SIRT1 | SLC22A18 | SLC2A1 | 
SLC2A2 |SLC5A5 | SNAI2 | SOD2 | SPP1 | SRC | STAT3 | STAT5A | STC2 | 
STMN1 |SYNE1 | TANK | TBX3 | TERT | TFAP2A | TFPI2 | TGM2 | THBS1 | 
TNF | TNFSF10| TNIP1 | TOP2A | TP53 | TYMS | UBE2C | UMPS | WNT10B | 
WT1 | WWOX |XRCC3 | YBX1 
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Figure 3.  Venn diagram of list of genes common between breast neoplasms and PCBs, 
phthalates or bisphenol A.  
 
 
Figure 4.  Gene Set/Pathway enrichment analysis of genes associated with PCBs, 
phthalates, or bisphenol A in breast neoplasms.  
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   Table 3.   KEGG enrichment pathways for common AREG, CYP19A1, EGFR, FOS, IGF1, KRAS, 
    and PGR genes in EDCs, breast cancer and endometriosis. 
 
 
Pathways Pathway ID Gene association 
Number of 
associated genes 
Steroid hormone biosynthesis KEGG:00140 CYP19A1 1 
Metabolic pathways KEGG:01100 CYP19A1 1 
MAPK signaling pathway KEGG:04010 EGFR|FOS|KRAS 3 
ErbB signaling pathway KEGG:04012 AREG|EGFR|KRAS 3 
Chemokine signaling pathway KEGG:04062 KRAS 1 
p53 signaling pathway KEGG:04115 IGF1 1 
mTOR signaling pathway KEGG:04150 IGF1 1 
Dorso-ventral axis formation KEGG:04320 EGFR|KRAS 2 
VEGF signaling pathway KEGG:04370 KRAS 1 
Focal adhesion KEGG:04510 EGFR||IGF1| 2 
Adherens junction KEGG:04520 EGFR 1 
Tight junction KEGG:04530 KRAS 1 
Gap junction KEGG:04540 EGFR|KRAS 2 
Toll-like receptor signaling 
pathway KEGG:04620 FOS 1 
Natural killer cell mediated 
cytotoxicity KEGG:04650 KRAS 1 
T cell receptor signaling 
pathway KEGG:04660 FOS|KRAS 2 
B cell receptor signaling 
pathway KEGG:04662 FOS|KRAS| 2 
Fc epsilon RI signaling pathway KEGG:04664 KRAS 1 
Regulation of actin cytoskeleton KEGG:04810 EGFR|KRAS 2 
Insulin signaling pathway KEGG:04910 KRAS 1 
GnRH signaling pathway KEGG:04912 EGFR|KRAS 2 
Pathways in cancer KEGG:05200 EGFR|FOS|IGF1|KRAS 4 
Pancreatic cancer KEGG:05212 EGFR|KRAS 2 
Endometrial cancer KEGG:05213 EGFR|KRAS 2 
 
 
 
 
 
Association between endometriosis and exposure to PCB, phthalates, or BPA:   We 
identified 11 epidemiologic studies related to PCB, phthalate, or BPA exposure and 
endometriosis.  Seven of the studies assessed the relationship between PCB exposure and 
endometriosis (Buck et al. 2005, Heiler et al. 2005, Niskar et al. 2009, Pauwels et al. 
2001, Porpora et al. 2009, Trabert et al. 2010, Tsukino et al. 2005), two studies assessed 
the relationship between phthalate exposure and endometriosis (Kim et al. 2001 and 
Upson et al. 2013), one study assessed the relationship between BPA exposure and 
endometriosis (Itoh et al. 2007) and one study assessed the relationship between phthalate 
and BPA exposure and endometriosis (Buck et al. 2013).  Of these studies, eight were 
case-control studies, one was a cross-sectional study; and two were cohort studies.  In all 
of the studies, endometriosis cases were confirmed with a laparoscopic examination 
and/or biopsy and in nine of the eleven studies controls were also confirmed to be disease 
free through laparoscopic examination.  Controls in the remaining two studies were 
randomly selected from a list of Group Health Enrollees that were known to not have 
endometriosis.   
PCBs and endometriosis. All seven of the studies that addressed the relationship between 
PCB exposure and endometriosis presented individual congener results as well as a 
measure of total PCBs, the sum of individual congeners. Only three of the eight PCB 
case-control studies found any associations between exposure to total PCBs and risk of 
endometriosis (Buck et al. 2005, Heiler et al. 2005, Porpora et al. 2009).  Buck Louis et 
al. (2005) measured total PCBs (n=62), the sum of estrogenic PCBs (n=12), and the sum 
of anti-estrogenic PCBs (n=4) in a cohort study of 84 women undergoing laparoscopy 
(32endometriosis cases, 52 controls).  They found a significant increased risk of 
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endometriosis for the sum of anti-estrogenic PCBs for women in the third tertile 
(OR=3.77, 95% CI 1.12-12.68), however, the risk remained elevated but not significant 
when adjusted for all listed covariates. In a case-control study of 158 women (80 cases 
and 78 controls), Porpora et al. (2009) found the GM of total PCBs to be significantly 
higher in cases than controls (301.3 vs. 203.0, p < 0.01). The OR of endometriosis risk in 
the highest tertile of total PCBs compared with the lowest tertile, was 5.63 (95% CI 2.25-
14.10).  Significant increased risk of endometriosis was also found for PCB congeners 
118, 138, 153, and 170.   Heiler et al. (2005) conducted a case-control study of 50 cases 
(25 with peritoneal endometriosis (PE) and 25 with deep endometriotic (DE) nodules) 
and 21 controls. Multiple dioxin-like PCBs were measured and expressed as toxic 
equivalent (TEQ) per gram of serum lipids.  Dioxin-like PCB concentrations were higher 
in women with DE compared to controls (12.4 vs. 8.5, p = .026) but did not significantly 
differ for women with PE compared to controls (11.0 vs. 8.5) and for women with DE 
compared to women with PE (12.4 vs. 11.0).   
Four of the PCB case-control studies failed to find significant associations 
between endometriosis and exposure to individual PCB congeners, total PCBs, or 
specific sub-groups (Niskar et al. 2009, Trabert et al. 2010, Pauwels et al. 2001, Tsukino 
et al. 2005).  Niskar et al. (2009) conducted a case-control study with 60 confirmed 
endometriosis cases staged as I (minimal), II (mild), III (moderate), and IV (severe) and 
30 controls.  Mean lipid-adjusted PCB concentrations were not significantly different 
(179.98 vs. 217.33 vs. 194.76 vs. 193.37) between stage I-II cases, stage III cases, stage 
IV cases, and controls, respectively. In the largest case-control study, conducted by 
Trabert et al. (2010), total PCBs (n=20), estrogenic PCBs (n=6), and individual PCB 
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congeners were measured in the serum from 251 cases and 538 controls, matched for age 
and reference year.  Adjusted total and estrogenic PCBs in the highest quartiles were not 
associated with an increased risk of endometriosis (Total:  OR=1.2, 95% CI: 0.6-2.3, 
Estrogenic: OR=0.9, 95% CI: 0.5-1.4).  In two case-control studies measuring median 
TEQ values (pg TEQ/g lipid) Pauwels et al. (2001) found no association between 
endometriosis and the median TEQ values (pg TEQ/g lipid) in cases and controls (29 vs. 
27) and Tsukino et al. (2005) found no difference in median TEQ values for 
endometriosis cases (stage II-IV) and controls (stage 0-I) (cPCBs: 3.40 vs. 3.59, PCBs: 
4.61 vs. 5.14), respectively.  The OR of endometriosis risk in the highest quartile of total 
PCBs compared with the lowest quartile was 0.41 (95% CI: 0.14-1.27). 
 Like breast cancer, results of the association between PCB exposure and 
endometriosis in eight epidemiologic studies were inconsistent or conflicting, therefore, 
we extracted and summarized risk estimates of PCBs on endometriosis from four case 
control studies using meta-analytic methods.   Combining four studies of exposure to 
PCBs produced a summary risk estimate of 1.91 (95% CI: 1.05 – 5.54) (Table 4; Fig. 5).  
PCB exposures were found to be significantly associated with development of 
endometriosis as a meta-analysis of four studies produced an increased risk of 1.91. 
However, there is not much confidence in the combined risk estimate of endometriosis 
with exposure to PCBs because of the lower estimate of CI being barely higher than 1 
(1.05).
 
 
 
 
Table 4.  Epidemiological studies of the association between exposure to PCBs and risk of endometriosis.
Reference, 
location 
Study design Study Population Measurement of 
Exposure 
Outcomes Results Comments  Confounders 
Heiler et al. 
(2005), 
Belgium 
Case-control  
Study  
50 cases:  (25 with 
PE, 25 with DE), 21 
controls.  
Multiple PCBs from 
serum - 12 dioxin-
like PCBs (pg 
TEQ/g lipids).   
Mean serum PCB 
Range (pg TEQ/g 
lipids):   
Controls: 6.9-10.5  
PE Cases: 9.1-13.3  
DE Cases: 0.3-14.9;  
Logistic Regression 
(OR-95% CI).   
Significant risk with 
DE nodules (OR=6.7; 
95% CI, 1.4-31.2).   
Controls did not 
present for infertility; 
normal pelvic exam. 
Cases confirmed with 
histological exam of 
lesions. 
 
Adjusted for age, BMI, 
tobacco consumption, 
age at menarche, 
duration of OC use, 
family history, 
menstrual cycle 
regularity, # of 
children, breast-
feeding duration. 
Niskar et al. 
(2009), USA 
Case-control 
study  
60 cases,  
30 controls/ 
64 controls.   
Serum total PCBs 
(ng/g) (n=36).  
GM Total PCBs (ng/g 
lipid):   
Cases stage I-II 
(179.98),  
stage III (217.33), 
stage IV (194.76),  
Controls (193.37).   
Logistic Regression 
(OR-95% CI).   
No significant 
differences in GMs 
(p=.97).  
No significant 
associations (OR= 
1.00, 95% CI 0.99-
1.01).  
Cases confirmed with 
laparoscopic 
examination and/or 
biopsy.  
30 controls confirmed 
with laparoscopy, 27 
with infertile partner 
and 7 with ovulation 
problems. 
Adjusted for age, 
gravidity, education, 
income.   
Pauwels et al. 
(2001), Belgium 
Prospective 
case-control 
study 
42 cases, 27 controls  Multiple PCBs from 
serum; Total PCBs, 
TEQ (pg TEQ/g 
lipid).   
Median TEQ (pg 
TEQ/g lipid):  
Cases (29), Controls 
(27).   
Logistic Regression 
(OR, 95% CI).  
No significant 
associations found 
(OR=4.33, 95% CI 
0.49-38.19).   
Cases and controls 
infertile. 
Endometriosis 
confirmed with 
laparoscopic 
examination.   
Age, BMI, alcohol 
consumption.  
Porpora et al. 
(2009), Italy 
Case-control 
study  
80 cases, 78 
controls  
Multiple PCBs from 
serum, Total PCBs.    
GM of Total PCBs 
(ng/g of fat):  
Cases: 301.3  
Controls: 203.0;  
Logistic Regression 
(OR-95% CI). 
 
  
Total PCB 
concentrations 
significantly higher in 
cases (OR=5.63, 95% 
CI 2.25-14.10); 
Significant increased 
risk for PCBs 118, 138, 
153, and 170 for 2nd 
and 3rd tertiles when 
compared to the 
lowest tertile.   
Cases and controls 
confirmed with 
laparoscopic 
examination.  
Adjusted for age, BMI, 
smoking habits, 
weight modification.   
Trabert et al. 
(2010), USA 
Case-control 
study 
251 cases, 538 
controls; matched 
for age (5 year) and 
reference year.  
Multiple PCB 
congeners in serum 
(n=20); Total PCBs, 
Estrogenic PCBs.  
Logistic Regression 
(OR-95% CI); 
Quartiles.   
 
 
No significant 
associations found.  
Cases:  Group Health 
(GH) enrollees with 
endometriosis 
diagnosis,  
Controls: randomly 
selected from list of 
GH enrollees.   
Adjusted for matching 
factors, serum lipids, 
income, alcohol 
consumption, DDE 
exposure.  
Tsukino et al. 
(2005), Japan  
Case-control 
study  
139 women: 
Controls: Stage 0 & 
I,  
Cases: Stage II-IV;   
Stage 0=59 
Stage I=22 
Stage II=10 
Stage III=23 
Stage IV=25 
Multiple PCBs in 
serum; Total TEQ 
values of cPCBs and 
PCBs.   
Median TEQ values 
(pg TEQ/g lipid);  
Logistic Regression 
(OR-95% CI); 
Quartiles.  
No significant 
associations found 
(OR=1.2, 95% CI 0.6-
2.3).   
Cases and controls 
confirmed with 
laparoscopic 
examination. 
Adjusted for 
menstrual regularity 
and average cycle 
days.   
 
 
 
 
 
Figure 5.  Forest plot of epidemiological studies of the association between exposure to 
PCBs and risk of endometriosis.  
Bisphenol A or phthalate and breast cancer. Table 5 lists epidemiological studies of the 
association between EDCs - phthalate or BPA and endometriosis. No meta-analysis was 
performed on exposure to BPA or phthalates and endometriosis, because only two studies 
that met our criteria of selection examined the association between endometriosis and 
phthalates (Kim et al. 2011 and Upson et al. 2013), one study addressed the association 
between endometriosis and BPA (Itoh et al. 2007) and one study addressed the 
association between both BPA and phthalates and endometriosis (Buck et al. 2013). 
Besides these two studies, there are several other epidemiological studies that have 
examined the association between phthalate or BPA exposure and endometriosis (Table 
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5).  Kim et al. (2011) measured plasma levels of mono (2-ethylhexyl) phthalate (MEHP) 
and di-(2-ethylhexyl) phthalate (DEHP) in 97 women with advanced-stage endometriosis 
and 169 control women.  Mean plasma levels of MEHP and DEHP were found to be 
significantly higher in cases than controls (MEHP:  17.4 vs. 12.4, p < .001, DEHP: 179.7 
vs. 92.5, p = .010).  In a population-based case-control study conducted by Upson et al. 
(2013) 8 urinary phthalate metabolites were measured in 92 surgically-confirmed 
endometriosis cases and 195 controls.  A significant inverse association was found 
between urinary MEHP and risk of endometriosis (OR=0.3, 95% CI 0.1-0.7).  The 
ENDO study was designed to assess the relationship between exposure to environmental 
chemicals and endometriosis.  Buck Louis et al. (2013) analyzed 14 phthalate metabolites 
and total BPA in urine from 495 women who underwent laparoscopy (operative cohort) 
and 131 women (population cohort) who underwent pelvic magnetic resonance imaging 
(MRI) for the assessment of endometriosis. In the operative cohort, GMs of phthalate 
metabolites were not found to be significantly higher in women with endometriosis, 
whereas, in the population cohort, GMs of six phthalate metabolites were found to be 
significantly higher for women with endometriosis and a twofold or higher increase in 
ORs was observed for mono-n-butyl phthalate (mBP), mono- (2-ethyl-5-carboxyphentyl) 
phthalate (mECPP), mono-[(2-carboxymethyl) hexyl] phthalate (mCMHP), mono (2-
ethyl-5-hydroxyhexyl) phthalate (mEHHP), mono (2-ethyl-5-oxohexyl) phthalate 
(mEOHP), and  mono (2-ethylhexyl) phthalate (mEHP).  No significant associations were 
found for urinary BPA concentrations in either the operative cohort or the population 
cohort. In a hospital based cross-sectional study, conducted by Itoh et al. (2007), urinary 
BPA concentrations were analyzed in 140 women who underwent laparoscopy.  The 
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severity of endometriosis was classified into 5 stages: 0 (n=60), I (n=21), II (n=10), III 
(n=24), and IV (n=25).  Median creatinine adjusted urinary BPA concentrations did not 
significantly differ by endometriosis stage (0.74 vs. 0.93, p = 0.24) for stage 0-I and stage 
II-IV, respectively.  
 
 
 
 
      Table 5: Epidemiological studies of the association between EDCs - Phthalate or BPA and endometriosis. 
EDCs      Biological samples  Study Population               Outcomes                          References 
 
Bisphenol A  Serum  69 fertile women 
undergoing laparoscopy, 
Naples, Italy  
Detected in cases  Cobellis et al. 2009  
Bisphenol B  Serum  69 fertile women 
undergoing laparoscopy, 
Naples, Italy  
Detected in cases  Cobellis et al. 2009  
Phthalate esters   Plasma  220 South Indian women 
undergoing laparoscopy  
Increased risk  Reddy et al. 2006b  
 Serum 108 South Indian women 
undergoing laparoscopy 
Increased risk Reddy et al. 2006a 
Diethylphthalate  Blood/perit-
oneal fluid  
59 fertile women 
undergoing laparoscopy  
Higher in cases  Cobellis et al. 2003  
Monoethylphthalate  Blood/peri-
toneal fluid  
59 fertile women 
Undergoing laparoscopy        
No association  Cobellis et al. 2003  
 
Monobutylphthalate Urine 1,227 women from the 
NHANES study, United 
States 
No association Weuve et al. 2010  
 
 Urine 109 women undergoing 
laparotomy, Taiwan  
 
Increased in cases Huang et al. 2010  
 
Monobutylphthalate  Urine  1,227 women from  
the NHANES study, USA 
No association      Weuve et al. 2010  
Urine  109 women undergoing 
laparotomy, Taiwan  
Increased in cases  Huang et al. 2010  
 Urine               137 infertile                     
Japanese women 
undergoing 
laparoscopy  
          No association  Itoh et al. 2009  
 
 
 
 
 
Several hundred genes are altered by exposure to PCBs, phthalate or bisphenol A 
(Fig. 6). The genes related to polychlorinated biphenyls and PCB congeners - 3,4,3',4'-
tetrachlorobiphenyl  (77), 3,4,5,3',4'-pentachlorobiphenyl (126), and 2,4,5,2',4',5'-
hexachlorobiphenyl (153) in endometriosis were 19, 11, 36 and 18, respectively (Table 
6). All these PCBs or their congener-related endometriosis genes were also associated 
with 17 beta estradiol. The top interacting genes with polychlorinated biphenyls and 
endometriosis were ESR2, NR3C1, CYP19A1, EGFR, FKBP5, ITGB8, MAOB, PGR, 
PRLR, SLC16A6, SST, and TXNIP. There were 80 common genes between BPA and 
endometriosis (Fig. 6).  The two phthalates with most gene interactions were: dibutyl 
phthalate and diethylhexyl phthalate. The genes related to dibutyl phthalate and 
diethylhexyl phthalate were 4692 and 1646, respectively. There were 71 common genes 
between dibutyl phthalate and endometriosis and 29 common genes between diethylhexyl 
phthalate and endometriosis (Fig. 6). The common genes between both phthalates - 
dibutyl phthalate and diethylhexyl phthalate, and endometriosis were 22: CNR1, 
CYP19A1, CYP26A1, DUSP1, EGFR, ESR2, FKBP5, FOS, GPX3, IGF1, ITGB1, 
MAOA, MED1, NR3C1, NR4A1, NR5A1, PRLR, PTGER2, PTGER4, SRD5A1, 
TGFB2, and TXNIP (Table 6).  Interactions among these genes are shown in Figure 7. 
Enrichment pathway analysis revealed that some of these genes are part of: 1) pathways 
in cancer (KEGG:05200); 2) signal transduction  (REACT:111102), and 3) MAPK 
signaling pathway ( KEGG:04150) (Table 3).    
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Figure 6.  Venn diagram of list of genes common between endometriosis and PCBs, 
phthalates, and bisphenol A.  
 
 
 
Figure 7.  Gene Set/Pathway enrichment analysis of genes associated with PCBs, 
phthalates, and bisphenol A in endometriosis.    
 
 
 
 
 
 
 Table 6.  Genes interacting with PCBs and endometriosis.   
IUPAC Name (congener number) Interacting genes 
Polychlorinated Biphenyls 19 genes: AKR1C3 | ANKRD1 | AREG | ARNT | CYP19A1 | DUSP1 | ESR2 | FBN1 | FOS | GREB1 | 
IGFBP1 | KRAS | NR2C2 | NR3C1 | PAPPA | PTGER4 | STC2 | TGFB2 | THRA 
2,4,4'-trichlorobiphenyl  (28) 2 genes: ESR2 | NR3C1    
3,4,3',4'-tetrachlorobiphenyl  (77) 11 genes: ARNT | DDX5 | ESR2 | FKBP5 | ITGB8 | KLF13 | MAOB | NR1D2 | PRLR | SULF2 | TXNIP
2',3,3',4',5-pentachloro-4-hydroxybiphenyl 
(4'-OH-PCB-86;4-hydroxy-2 , 2' , 3' , 4' , 
5'-pentachlorobiphenyl ) 
25 genes: ABCC9 | BRD8 | CD55 | CNR1 | ELAVL1 | ERRFI1 | FKBP5 | IFNGR1 | IGFBP1 | MED1 | 
MED4 | MTA1 | NCOA6 | NR2C1 | NR3C1 | NR3C2 | NR4A1 | NRP1 | PRLR | SLC16A6 | SPARCL1 | 
SST | TAGLN | THRA | TNC 
2,2',4,6,6'-pentachlorobiphenyl  (104) 2 genes: EGFR | FOS 
3,4,5,3',4'-pentachlorobiphenyl (126) 
 
36 genes: AREG | CD55 | CXCL14 | CYP19A1 | DUSP1 | ENPP1 | FBN1 | GPX3 | HBEGF | HSD17B1 | 
HSD17B2 | IGF1 | IGFBP1 | IGFBP6 | IL1R1 | IMPA2 | MAOA | MAOB | MED1 | NEDD4L | NR3C1 | 
OSR2 | PRLR | RASL11A | SEPP1 | SLC20A1 | SLC40A1 | SLC7A8 | SPARCL1 | SRD5A1 | SRD5A2 | 
SST | STC2 | TAGLN | TGFB2 | TXNIP 
2,2',3',4,4',5-hexachlorobiphenyl  (137) 10 genes: FBLN1 | FOS | HBEGF | IGF1 | NEFM | PRL | SLC16A6 | SRD5A1 | SRD5A2 | SST
2,3,6,2',3',6'-hexachlorobiphenyl  (136) 2 genes: AR | CYP2B1    
2,4,5,2',4',5'-hexachlorobiphenyl (153)  18 genes: CYP19A1 | DCSTAMP | EGFR | ESR2 | FOS | HSD17B1 | HSD17B2 | IFIT1 | IGF1 | ITGB8 | 
MAOB | NR3C1 | SEPP1 | SLC16A6 | SRD5A1 | SRD5A2 | SST | TXNIP 
17 β Estradiol 114 genes: ABCC9 | ABI3BP | ACTA2 | AKR1C1 | AKR1C2 | AKR1C3 | ANKH | ANKRD1 | AREG | 
ARHGAP28 | ARNT | BMP7 | C10ORF10 | C1R | CCNE2 | CD55 | CFD | CLDN1 | CNIH3 | CNR1 | CPM | 
CXCL14 | CYB5A | CYP19A1 | CYP26A1 | DDX5 | DICER1 | DIO2 | DKK1 | DUSP1 | EGFR | ELAVL1 | 
ERRFI1 | ESR2 | FBLN1 | FBN1 | FKBP5 | FOS | GPX3 | GREB1 | HDAC1 | HDAC2 | HERC5 | 
HS3ST3B1 | HSD17B1 | HSD17B2 | IDO1 | IFIT1 | IGF1 | IGFBP1 | IGFBP6 | IHH | IL15 | IL1R1 | IL7R | 
ITGA2 | ITGB1 | ITGB8 | KLF13 | KLF9 | KRAS | LMOD1 | LTF | MAOA | MAOB | MED1 | MED14 | 
METTL7A | MIR21 | MYLIP | NCOA1 | NCOA6 | NCOR1 | NEDD4L | NR2F2 | NR3C1 | NR3C2 | NR4A1 
| NR5A1 | NRP1 | NTRK3 | OLFM4 | OSR2 | PAPPA | PGR | PRL | PRLR | PTGER2 | PTGER4 | RARB | 
RASGRP1 | RGS4 | RORB | RXFP1 | SEPP1 | SLC16A6 | SLC1A1 | SLC20A1 | SLC40A1 | SLC7A8 | 
SMPDL3A | SPARCL1 | SRD5A2 | STC2 | SULF2 | TACSTD2 | TAGLN | TGFB2 | THRA | TNC | TOB1 | 
TRH | TXNIP | VCAN ZEB2   
Dibutyl Phthalate  71 genes: ABI3BP | ACTA2 | AKR1C1 | ANKRD1 | AREG | ARNT | BMP7 | BRD8 | C1R | CCNE2 | CD55 
| CLDN1| CNR1 | COPS2 | CYB5A | CYP19A1 | CYP26A1 | DDX5 | DICER1 | DUSP1 | EGFR | ELAVL1 | 
ENPP1 | ERRFI1 | ESR2 |FKBP5 | FOS | GPX3 | HDAC1 | HSD17B1 | IGF1 | IL1R1 | ITGB1 | ITGB8 | 
KLF9 | LMOD1 | MAOA | MAOB | MED1 |MED14 | MED17 | NR1D2 | NR2F2 | NR2F6 | NR3C1 | 
NR4A1 | NR5A1 | NRP1 | OSR2 | PAPPA | PGR | PRLR | PTGER2 |PTGER4 | RASL11A | SEPP1 | 
SLC16A6 | SLC20A1 | SLC40A1 | SLC7A8 | SMPDL3A | SRD5A1 | STC2 | SUCLG2 |SULF2 | TAGLN | 
TGFB2 | THRA | TOB1 | TXNIP | VCAN. 
Diethylhexyl Phthalate   29 genes: CNR1 | CYP19A1 | CYP26A1 | EGFR | ESR2 | FKBP5 | FOS | HERC5 | IGF1 | IGFBP1 | ITGB1 | 
MAOA | NCOA1 | NR3C1 | NR4A1 | NR5A1 | PAX2 | PRL | PRLR | PTGER2 | PTGER4 | SRD5A1 | 
TGFB2 | DUSP1 | FMO2 | GPX3 | MED1 | NCOR1 | TXNIP 
Dibutyl Phthalate and Diethyl-hexyl 
Phthalate 
22 genes: CNR1, CYP19A1, CYP26A1, DUSP1, EGFR, ESR2, FKBP5, FOS, GPX3, IGF1, ITGB1, 
MAOA, MED1, NR3C1, NR4A1, NR5A1, PRLR, PTGER2, PTGER4, SRD5A1, TGFB2, TXNIP 
Bisphenol A 80 genes: ABCC9 | ACTA2 | AREG | ARHGAP28 | ARNT | BMP7 | BRD8 | CCNE2 | COPS2 | CYB5A | 
CYP19A1 | CYP26A1 | DDX5 | DICER1 | DIO2 | DUSP1 | EGFR | ELAVL1 | ENPP1 | ERRFI1 | ESR2 | 
 
 
 
 
 
Integration of genes overlapped among EDCs, Breast Cancer and Endometriosis: 
Integration of genes associated with exposure to PCBs, and breast cancer and 
endometriosis based enriched disease analysis showed that there were 16 endometriosis 
genes overlapped with breast neoplasms – AREG, C10ORF10, CLDN1, CYP19A1, 
DKK1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, RARB, and  
STC2 (Tables 2 and 6). All of these genes were also associated with estrogen in breast 
neoplasms. Out of these 16 genes, there were 14 genes - AREG, CLDN, CYP19A1, 
DKK1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, RARB, and 
STC2  common among 17 beta estradiol, breast cancer, and endometriosis (Tables 2, 6 
and 7).  PCBs associated  AREG,  CYP19A1,  ESR2,  FOS, KRAS  and STC2 genes; PCB 
126 associated  AREG, CYP19A1,  and STC2  genes and PCB 15 associated 
CYP19A1,EGFR,ESR2,FOS and IGF1 genes overlapped with 17 beta estradiol, breast 
cancer, and endometriosis (Tables 2, 6 and 7).  Similarly, we identified dibutyl phthalate 
and diethyl-hexyl phthalate associated overlapping genes with 17 beta estradiol, breast 
cancer, and endometriosis: AREG, CLDN1, CYP19A1, EGFR, ESR2, FOS, IGF1, 
NR2F6, PGR and STC2; and CYP19A1,EGFR,ESR2,FOS,IGF1 and  NCOA1.    There 
were 5 common overlapped genes between these two phthalates, 17 beta estradiol, breast 
cancer and endometriosis: CYP19A1, EGFR, ESR2, FOS, and IGF1. We also identified 
another 11 EDC -BPA  associated  genes that were common among 17 beta estradiol,  
breast cancer and endometriosis: AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, 
NCOA1, NCOR1, PGR, and STC2.  Five genes - CYP19A1, EGFR, ESR2, FOS, and 
IGF1 were common among all three EDCs -PCBs, phthalates and BPA, 17 beta estradiol, 
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breast cancer, and endometriosis. For the gene ontology terms associated with each gene, 
please see Table 8. 
Since both of these diseases are dependent on unopposed estrogen for their 
growth, we examined whether estrogen receptor signaling pathway genes are common 
among estrogen, EDCs, breast cancer and endometriosis.  PCBs and congeners 
3,4,5,3',4'-pentachlorobiphenyl (126) and 2,4,5,2',4',5'-hexachlorobiphenyl (153) were 
associated with some of the same estrogen receptor signaling pathway genes – AR, 
ESR1, ESR2, NCOA3, and PPARGC1B;  AR, BRCA1, ESR1, IGF1, and  PAK1; and 
AR, BRCA1, CTNNB1, ESR1, ESR2, IGF1,  and SRC, respectively (Table 7). The 
following were also observed with 17 beta estradiol - AR, BRCA1, CCNE1, CTNNB1, 
ESR1, ESR2, FHL2, FOXA1, IGF1, NCOA1, NCOA2, NCOA3, NRIP1, PAK1, PGR, 
PHB, PPARGC1B, RB1, SFRP1, SRC, and ZNF366. Similarly, common genes of 
estrogen receptor signaling pathways were also observed with another three EDCs. 
Dibutyl phthalate associated AR, BRCA1, CCNE1, CTNNB1, ESR1, ESR2, 
FHL2,,HEYL, IGF1,PGR, RB1 and SRC genes; diethylhexyl phthalate associated -  AR, 
CTNNB1, ESR1, ESR2, IGF1, NCOA1, and PPARGC1B,  and BPA associated AR, 
BRCA1, CCNE1, CTNNB1, ESR1, ESR2, FHL2, IGF1, NCOA1, NCOA2, NCOA3, 
NRIP1, PAK1, PGR, PHB, RB1, SFRP1, SIRT1, and SRC genes which are also 
associated  with 17 beta-estradiol in breast neoplasms (Table 7). Another factor that 
appears to be common in both diseases is inflammation. Therefore, we also examined 
whether inflammation associated genes are common among estrogen, EDCs and breast 
cancer. PCBs and congeners 3,4,5,3',4'-pentachlorobiphenyl (126) and 2,4,5,2',4',5'-
hexachlorobiphenyl (153) were associated with the following inflammation related genes 
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– AHR, CXCL2, HMOX1, IFNG, IL6, PTGS2, SOD2, and TNF; AHR, CXCL8, 
HMOX1, IL1B, IL6, MMP9, NOS2, NOS3, PARP1, PTGS2, and TNF; and AHR, IFNG, 
IL1B, PARP1, PTGS2, and TNF, respectively (Table 7). Dibutyl phthalate, diethyl-hexyl 
phthalate and BPA-associated set of inflammation-related genes were AHR, CXCL8, 
HMOX1, IL1B, IL6, MIF, MMP9, PARP1, SOD2, TFRC and TNF; AHR, CSF2, 
CXCL8, IFNG, LEP, MMP9, SOD2 and TNF; and AHR, CSF2, HMOX1, IFNG, IL1B, 
IL6, LEP, MIF, MMP9,NOS2, NOS3, PARP1, PTGS2,SOD2, and TNF, respectively.  
All of these genes were also associated with 17 beta estradiol in breast neoplasms. In 
summary, EDC associated inflammation set of genes in breast neoplasms are estrogen 
responsive. 
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Table 7. EDC-interacting endometriosis, environmental response and inflammation 
associated estrogen responsive genes in breast neoplasms. 
EDC interacting 
with genes in 
breast 
neoplasms 
Steroid hormone receptor 
signaling pathway 
Endometriosis Inflammation 
17 beta 
Estradiol 
 
21 genes AR, BRCA1, CCNE1, 
CTNNB1, ESR1, ESR2, FHL2, 
FOXA1, IGF1, NCOA1, NCOA2, 
NCOA3, NRIP1, PAK1, PGR, 
PHB, PPARGC1B, RB1, SFRP1, 
SRC, ZNF366   
AREG, CLDN1, 
CYP19A1, DKK1, 
EGFR, ESR2, FOS, 
IGF1, KRAS, 
NCOA1, NCOR1, 
PGR, RARB, STC2   
AHR,CSF3,CXCL2,
CXCL8,HMOX1,   
IFNG,IL1B,IL6   
LEP,MIF,MMP9   
NOS2,NOS3,PARP1  
PTGS2,SOD2,TFRC  
TNF 
PCBs  AR,ESR1,ESR2,NCOA3,   
PPARGC1B   
AREG,CYP19A1,   
ESR2,FOS,KRAS   
STC2   
AHR,CXCL2,HMO
X1, IFNG,IL6   
PTGS2,SOD2,TNF   
3,4,5,3',4'-
pentachlorobiph
enyl (126) 
AR, BRCA1, ESR1, IGF1, PAK1 AREG, CYP19A1, 
STC2  
AHR,CXCL8,HMO
X1,IL1B,IL6,MMP9,
NOS2,NOS3,   
PARP1,PTGS2,TNF 
2,4,5,2',4',5'-
hexachlorobiph
enyl (153) 
AR,BRCA1,CTNNB1,ESR1,ESR
2,IGF1,SRC   
CYP19A1,EGFR,   
ESR2,FOS,IGF1   
AHR,IFNG,IL1B, 
PARP1,PTGS2,TNF   
Dibutyl 
Phthalate 
AR,BRCA1,CCNE1,CTNNB1,E
SR1,ESR2,FHL2,HEYL,IGF1,PG
R,RB1,SRC 
AREG,CLDN1,   
CYP19A1,EGFR   
ESR2,FOS,IGF1   
NR2F6,PGR,STC2   
AHR,CXCL8,HMO
X1, IL1B, IL6, MIF   
 MMP9, PARP1,   
 SOD2, TFRC,TNF   
Diethylhexyl 
Phthalate 
 AR,CTNNB1,ESR1   
ESR2,IGF1,NCOA1   
PPARGC1B   
CYP19A1,EGFR   
ESR2,FOS,IGF1   
NCOA1   
AHR,CSF2,CXCL8   
IFNG,LEP,MMP9   
SOD2,TNF   
Bisphenol A AR,BRCA1,CCNE1,CTNNB1,E
SR1,ESR2,FHL2,IGF1   
NCOA1,NCOA2,NCOA3   
NRIP1,PAK1,PGR,PHB   
 RB1,SFRP1,SIRT1,SRC   
AREG,CYP19A1, 
EGFR, ESR2, FOS, 
IGF1, KRAS, 
NCOA1,  NCOR1, 
PGR, STC2 
AHR, CSF2, 
HMOX1, IFNG, 
IL1B, IL6, LEP, 
MIF, MMP9, NOS2, 
NOS3, PARP1, 
PTGS2,SOD2, TNF   
 
 
 
 
 
Table 8. Integration of changes in the expression of genes showing common genes modified in EDCs, breast cancer and 
endometriosis.  
Gene name Gene ID Location Database* Gene function 
AREG 374 4q13–q21 E Amphiregulin  
CYP19A1 1588 15q21.1 E cytochrome P450, family 19, subfamily A, polypeptide 1 
EGFR 1956 7p12 E epidermal growth factor receptor  
ESR2 3468 14q23.2 H estrogen receptor 2 (ER beta)  
FOS 2353 14q24.3 E v-fos FBJ murine osteosarcoma viral oncogene homolog 
IGF1 3479 12q22-q23 E insulin-like growth factor 1 (somatomedin C) 
KRAS 6407 12p12.1 H Kirsten rat sarcoma viral oncogene homolog  
NCOA1 7668 2p23 H nuclear receptor coactivator 1 
NCOR1 7672 17p11.2 H nuclear receptor corepressor 1 
PGR 5241 11q22-q23 E progesterone receptor 
STC2 11374 5q35.1 H stanniocalcin 2 
Underline shows 5 genes that were common among all three EDCs -PCBs, phthalate and bisphenol A, breast cancer and 
endometriosis. Environmentally responsive genes are indicated in database column. 
*(E): Environmental responsive gene based on Environmental Genome Project; (H): HGNC database. 
 
 
 
 
Literature based validation of genes showing links between endometriosis and 
breast cancer: The set of estrogen responsive genes from EDCs, environmental, 
inflammation, and toxicogenomics showing a link between endometriosis and breast 
cancer is shown in Table 7. Research supporting the potential involvement and 
importance of all EDC responsive common genes in breast cancer and endometriotic 
lesions was found in the literature and human genome databases. The search of the 
environmental genome project databases showed that six genes out of 12 PCBs 
associated genes - AREG, CYP19A1, EGFR, FOS, IGF1, and PGR were environmentally 
responsive genes (Table 8). These common genes were then compared to a curated list of 
genes in PCB exposed human cell lines.  PCB congeners 77 and 153 increased the 
expression of the following estrogen responsive genes AREG, CYP19A1, EGFR, ESR2, 
FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR,STC2 (De et al. 2010). The 
expression of estrogen responsive genes common to breast cancer: AREG, CYP19A1, 
EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR,STC2 genes was 
upregulated in human endometriotic lesions (Burney et al. 2007, Hever et al. 2007, Sha et 
al. 2007).   
 We also analyzed the interaction among AREG, CYP19A1, EGFR, ESR2, FOS, 
IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, and STC2 genes using enrichment 
pathway analysis (Fig. 8). In order to investigate connections between PCBs responsive 
gene lists in breast cancer and endometriosis, we performed Bayesian network analysis.  
The Bayesian network analysis on the Cancer Genome Atlas (TCGA) Research Network 
data available through cbioportal.org identified the maximum likelihood structure of 
PCBs associated genes in breast neoplasm (Fig. 9). Figure 9 shows plausible interactions 
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among genes. Parents of a variable in Bayesian networks are defined as variables that 
arcs are originated to that variable. For example, in Figure 9, parents of BCHE are 
PTGS2 and HMOX1. Ancestors of a variable are all the parents of the variable, all 
parents of parents, and so on. Arcs in Figure 9 indicate correlations and they indicate 
Markov conditions. In Figure 9, from the arcs, the relationships between PTGS2 and 
BCHE was the strongest among all pairwise relationships, but also they formed a special 
Y structure (Spirtes et al. 2000) that indicates plausible causality, i.e., PTGS2 regulating 
BCHE. Similarly we have analyzed mRNA expression endometriosis data (Fig.10). 
These genes were more sparsely connected.  
 Some of the common estrogen responsive interacting  genes are part of  steroid 
hormone biosynthesis; metabolic pathways; MAPK signaling pathway; ErbB signaling 
pathway; chemokine signaling pathway; p53 signaling pathway; mTOR signaling 
pathway; VEGF signaling pathway; focal adhesion; adherens junction; tight junction; gap 
junction; toll-like receptor signaling pathway; natural killer cell mediated cytotoxicity; T 
cell receptor signaling pathway; B cell receptor signaling pathway; Fc epsilon RI 
signaling pathway; regulation of actin cytoskeleton; insulin signaling pathway; GnRH 
signaling pathway; and pathways in cancer (Table 3). We also compared these common 
genes to a curated list of genes in breast cancer, endometriosis as well as EDC exposed 
populations.  The search of the environmental databases showed that some of these 
common genes were environmentally responsive. All these EDC associated set of genes 
are estrogen responsive (Table 8). All these PCB, Phthalate and BPA associated common 
genes are altered in human breast tumor, uterine tumor tissues and endometriosis lesions 
(Table 8). 
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Figure 8. Interaction of common genes between estrogen, PCBs and breast neoplasms: 
AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, NR2F6, PGR, 
and STC2.  
  
Figure 9.  Identification of the maximum likelihood structure of PCBs associated genes 
in breast neoplasm. 
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Discussion  
 In the present study, we determined whether estrogen mimicking EDCs-
associated gene expression contributed to the risk of breast cancer among women with 
endometriosis with the aim of elucidating the role of environmental endocrine disrupting 
chemicals- PCBs, phthalates and BPA while focused on identifying environmental 
epidemiologic evidence and molecular signatures. Women with endometriosis have been 
implicated to develop certain types of cancer, including breast and ovarian cancers 
(Melin et al 2007). Although several molecular and environmental risk factors are 
common to endometriosis and breast cancer, the results of epidemiologic studies have 
been inconsistent on whether endometriosis is linked to particularly breast cancer.  Both 
of these diseases are dependent on unopposed estrogen for their growth. Endometrial 
tissue shows elevated activity of aromatase, and this enzyme is a key for the biosynthesis 
of estrogens (Irahara et al. 2006). Our meta-analysis showed that exposure to estrogen 
mimicking EDC - PCBs increased summary risk of both breast cancer and endometriosis.   
We further evaluated the relationship between endometriosis and breast cancer, and 
EDCs using a bioinformatics method. Our bioinformatics approach was able to identify 
genes with the potential to be involved in interaction with PCBs and other EDCs – 
phthalates and BPA that may be important to the development of breast cancer and 
endometriosis.  We identified six PCBs associated genes - AREG, CYP19A1, EGFR, 
FOS, IGF1, and PGR that are environmentally responsive. Similarly, we also observed 
dibutyl phthalate and diethyl-hexyl phthalate associated 5 common genes - CYP19A1, 
EGFR, ESR2, FOS, and IGF1 in breast cancer and endometriosis; and BPA  associated 
11 genes - AREG, CYP19A1, EGFR, ESR2, FOS, IGF1, KRAS, NCOA1, NCOR1, 
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PGR, and STC2 that were common in both breast cancer and endometriosis.  Five genes - 
CYP19A1, EGFR, ESR2, FOS, and IGF1 were common among all three EDCs –PCB 
153, phthalates and BPA, breast cancer, and endometriosis. All five common genes are 
modified in human breast tumor, uterine tumor tissues and endometriosis lesions. All of 
these genes are estrogen responsive. These findings suggest that the increased risk 
associated with endometriosis may be due to common environmental and molecular risk 
factors between endometriosis and breast cancer.  
Human and wild life populations are continually exposed to a wide variety of 
EDCs.  Experimental animal and human studies have indicated that EDCs have the 
ability to cause endocrine toxicity. For example, exposure to PCBs has been reported to 
show a significant delay in puberty in boys. De-feminization, early secondary breast 
development, or thelarche have been reported in girls exposed to phthalates (Roy et al. 
2009). Despite existing debates over the form and amount of BPA to which developing 
and adult humans are exposed, there is considerable data indicating  that exposure of 
humans to BPA is associated with increased risk for breast cancer and  reproductive 
dysfunctions (Bertelsen et al. 2007 and Roy et al. 1997). Postmenopausal women with 
high serum levels of BPA and mono-ethyl phthalate have been reported to have elevated 
breast density, one of the risk factors for breast cancer (Buck Louis et al. 2005).  These 
findings are consistent with parallel research in experimental models (Colerangle et al. 
1997, Munoz-de-Toro et al. 2005, Newbold et al. 2007, Murray et al. 2007).  For 
example, fetal bisphenol A exposure induces the development of preneoplastic and 
neoplastic lesions in the mammary gland in rats (Newbold et al. 2007). Fetal exposure of 
BPA significantly increases susceptibility to DMBA to produce mammary tumors in 
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mice (Murray et al. 2007).  BPA has also been reported to promote tumor growth of 
human breast cancer cells -MCF-7 in ovariectomized NCR nu/nu female mice. Excess 
exposures to polychlorinated dioxins and certain PCBs in women who lack detoxifying 
enzymes are risk factors in breast cancer. A landmark UN report assessing effects of 
human exposure to hormone-disrupting chemicals acknowledges that approximately 800 
chemicals are suspected to act as endocrine disruptors or mimic natural hormones or 
disrupt hormone regulation (UNEP, 2013).  This report highlights that there is some 
associations between exposure to many of the endocrine disruptors, particularly, 
estrogen-mimicking chemicals and an increased risk of breast cancer in women. 
Exposure to EDCs, such as, PCBs and BPA during early development of the breast, 
endometrium, and prostate can alter their development, and possibly contribute to the 
susceptibility to diseases through effects on stem cells.  
Breast cancer and endometriosis are complex chronic diseases and they are not 
caused by one agent or one environmental factor. The majority of the epidemiologic 
studies have largely focused on a single EDC and have ignored the possibility that 
multiple environmental agents may act in concert. It is important to consider that during 
the development of an individual from the single cell to prenatal stages to adolescent to 
adulthood and through the complete life span, humans are exposed to countless 
environmental EDCs. Like genes, environmental factors also interact among themselves. 
A single exposure to an EDC alone cannot explain the development of a complex chronic 
disease – like breast cancer, rather it appears that exposure to multiple EDCs across the 
lifespan and their interactions influence the development of breast cancer in an 
individual. A recent study from Spain lends support to the above concept. They have 
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shown that the body burden of lipophilic estrogenic organ halogen chemicals through 
cumulative exposure is associated with breast cancer risks (Ibarluzea et al. 2000). The 
temporal and spatial environmental modulations of the normal genetic and phenotypic 
changes in a cell lead to the development of a particular type of disease phenotype. 
However, the majority of epidemiologic studies measured EDC exposures later in a 
woman’s life, when the breast or endometrium tissue is less vulnerable. In-utero exposure 
to the estrogenic anti-miscarriage compound-  diethylstilbestrol (DES) underlines the 
importance of early life EDC exposure in breast cancer development and is apparent from 
the recent report showing elevated breast cancer risks in the daughters of exposed women  
(Palmer et al. 2006). Given the proven contribution of unopposed estrogens in the 
development of breast cancer and endometriosis, it is biologically plausible that less 
potent EDCs may also contribute to risks of chronic diseases, such as breast cancer and 
endometriosis (Bertelsen et al. 2007 and Roy et al. 1997).  
To date, most research on the endometriosis connection to breast cancer biology has 
focused on a few mechanisms and pathways in their development.  Genes involved in 
estrogen biosynthesis, metabolism, estrogen signaling pathway and signal transduction 
have been suggested to affect susceptibility of breast cancer and endometriosis. ESR is an 
important molecular risk factor in the pathogenesis of breast cancer (Treek et al. 2009). 
We examined the association of estrogen receptor ESR2 and estrogen biosynthesis 
enzyme, aromatase, CYP19A1 with endometriosis and breast cancer. Both mRNA and 
protein levels of estrogen receptor 2 (ESR2) were found higher in endometriotic tissue 
(Xue et al 2007). Increased expression of aromatase has been found in breast tumors 
(Irahara et al. 2006). In women with endometriosis, elevated tissue levels of estradiol due 
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to increased aromatase activity are found (Bulun et al. 2009). In this we found that five 
common estrogen responsive genes, including CYP19A1 and ESR2 were associated with 
all three EDCs -PCBs, phthalates and BPA, breast cancer, and endometriosis. We also 
observed association of EGFR, FOS and IGF1 genes with EDCs, endometriosis and 
breast cancer.   Increased circulating IGF1 level is associated with and increased risk of 
breast cancer (Al Zahrani et al. 2006). Another common gene identified in both 
endometriosis and breast cancer in this study was stanniocalcin 2 (STC2). This is a 
downstream target of estrogen signaling pathways (Raulic et al. 2008). The expression of 
STC2 is induced in MCF-7 cells and the endometrial gland of women by 17 beta 
estradiol and in breast tumors (Wood et al. 2010 and Gruvberger et al. 2001).  Modified 
expression of these genes is known to be involved in pathway of cancer, including breast 
cancer, mTOR signaling pathway, focal adhesion, VEGF signaling pathway and ErbB 
signaling pathway. However, the link of these common genes between the 2 diseases and 
EDCs does not prove that one causes the other. Furthermore, our study also revealed that  
PCBs and  congeners 3,4,5,3',4'-pentachlorobiphenyl (126) and 2,4,5,2',4',5'-
hexachlorobiphenyl (153) are associated with some of the same estrogen receptor 
signaling pathway genes in breast neoplasm that are also observed with 17 beta estradiol. 
Similarly, common genes of estrogen receptor signaling pathways were also observed 
with EDCs -dibutyl phthalate; diethylhexyl phthalate; and BPA and breast neoplasms that 
are also observed with 17 beta-estradiol.  These finding support genes involved in 
estrogen biosynthesis and estrogen signaling pathway may contribute to the susceptibility 
of breast cancer and endometriosis.    
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Another factor that appears to be common in both diseases is inflammation. The 
role of estrogen in inflammation is complex. On one hand, studies have observed 
suppression of inflammation with increased estrogen in several animal models of chronic 
inflammatory diseases. On the other hand, there is evidence of proinflammatory effects in 
some chronic autoimmune diseases in humans. Estrogen induces proinflammatory 
cytokines, such as interleukin-1 beta (IL-1beta) and tumor necrosis factor alpha (TNF-
alpha), and a number of other inflammation associated genes.  Inflammation-mediated 
oxidative stress is involved in the development of both of these diseases (Roy et al. 
2007). Prostaglandin E2 is up regulated in endometriosis as a result of inflammation, 
which increases estrogen synthesis by up regulating aromatase. A proinflammatory 
milieu can also directly increase estrogen production. Hence, inflammation may work in 
conjunction with or in addition to estrogen exposure in the development of breast cancer 
in women with endometriosis (Modungo et al. 2005).   
There are several strengths of the meta-analysis of EDCs associated with breast 
cancer or endometriosis.  The use of the general variance based method gave more 
weight to larger studies, considered confounding, and limited the number of studies 
excluded because of missing data.  Most studies used interview data to assess exposure, 
providing a more direct accounting of exposure.  Finally, the combining of similar 
exposure time periods and splitting of occupational and household agricultural/non-
agricultural exposures allowed for assessment of the range of possible external etiological 
factors involved in breast cancer or endometriosis development. Limitations of the study 
include those typical of the epidemiological studies combined in meta-analyses such as 
publication bias, recall bias and exposure misclassification.  Also, EDCs and breast 
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cancer type, along with individual practices of participants, were not distinguished in 
most studies. There are also obvious limitations to this type of bioinformatics analyses.  
While this analysis provides numerous hypotheses for potential gene-EDC interactions, it 
can only suggest possibilities, and therefore further research in a lab setting is necessary 
to validate their involvement in breast cancer and endometriosis.    While we did choose 
studies and databases we felt would provide a comprehensive set of modified genes, we 
did not assess the entire set of literature on breast cancer and endometriosis-related genes, 
and therefore may have missed some potential modified genes in our analysis.  
Furthermore, we have not included epigenetic genes in our analysis and therefore may 
have missed other potential gene-EDC interaction pathways to breast cancer and 
endometriosis through these mechanisms.  While these are shortcomings of this type of 
research, the clear benefit of this study in particular, is the identification of genes with 
potential to contribute to breast cancer and endometriosis.  Furthermore, generation of 
gene-EDCs interaction data relevant to breast cancer and endometriosis through this 
bioinformatics method provides highly useful information for a more comprehensive 
understanding of gene-EDCs interaction in the development breast cancer and 
endometriosis. Further research with an integrated bioinformatic, biostatistic and 
molecular epidemiologic approach is needed to study  
CONCLUSION 
In summary, the major novel findings emerged from the meta-analyses that PCBs 
exposure may increase risk of breast cancer and endometriosis. A single exposure to an 
internal or external environmental factor alone cannot explain the development of a 
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complex chronic disease, such as breast cancer and endometriosis, rather it appears that 
exposure to multiple environmental and molecular factors across the lifespan and their 
interactions influence the development of these chronic diseases in an individual. There 
may be common molecular risk factors between endometriosis and breast cancer and it is 
biologically plausible that an altered endogenous estrogen levels presumably from 
exposure to estrogen mimicking EDCs may contribute to the risk of these diseases. Our 
bioinformatics approach helps to identify genes associated with EDCs, and to generate a 
new hypothesis to evaluate the relationship between endometriosis and breast cancer. 
Endocrine disruptor responsiveness and systems impacts consistent with system-wide 
findings in breast cancer and endometriosis are thus supported as important 
considerations in identifying the numerous and complex modes of gene-EDCs interaction 
in these diseases. Given the proven contribution of unopposed estrogens to the risk for 
endometriosis or endometrial neoplasia or breast cancer, renewed health concerns have 
aroused about estrogen mimicking EDCs found in food, personal care products or as 
environmental contaminants. Although limited and inconsistent evidence exists for an 
association between some EDC’s and adverse human reproductive outcomes, the 
widespread human exposure to EDC’s and the increasing concern for their potential to 
induce reproductive toxicity, especially in susceptible populations with sensitive gene 
polymorphisms, demonstrates a clear need for more research.   
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HYPOTHESIS 
Exposure to EDCs through altering hormone levels results in an increased risk of 
reproductive toxicity in females.   
SPECIFIC AIMS 
 This research was designed in response to the recent resurgence of findings 
related to the potential reproductive and endocrine toxicity of endocrine disrupting 
compounds (EDCs).  Using the CDC’s NHANES database, statistical analysis was 
performed to analyze the associations between urinary and blood biomarkers of EDCs, 
reproductive health variables, and medical questionnaires (cancer).  The objective of this 
research was to assess exposure to endocrine disrupting compounds in the general U.S. 
population through the CDC’s National Health and Nutrition Examination Survey and 
determine if risk of reproductive dysfunction is increased due to exposure to endocrine 
disrupting compounds (polychlorinated biphenyls, phthalates, and bisphenol A) 
commonly found in the environment today. 
Specific Aim 1: To assess exposure to PCBs in the general U.S. population using blood 
serum PCB biomarkers available in the CDC’s 1999-2004 NHANES database and 
conduct secondary statistical analysis to determine if there is an association between 
higher body burdens of PCBs and breast cancer in women.   
 Sub Aim 1a:  Female participants in the 1999-2004 NHANES cycles, 20 years of 
 age and older who have higher body burdens of PCBs will have an increased risk 
 of breast cancer.   
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Specific Aim 2: To assess exposure to PCBs in the general U.S. population using blood 
serum PCB biomarkers available in the CDC’s 1999-2004 NHANES database and 
conduct secondary statistical analysis to determine if there is an association between 
higher body burdens of PCBs and adverse reproductive health effects  in women.   
 Sub Aim 2a:  Female participants in the 1999-2004 NHANES cycles, 20-54 years 
 of age who have higher body burdens of PCBs will have an increased risk  of 
 endometriosis.   
 Sum Aim 2b:  Female participants in the 1999-2004 NHANES cycles, 20-54 
 years of age who have higher body burdens of PCBs will have an increased risk 
 of uterine leiomyomas.   
Specific Aim 3: To assess exposure to EDCs in the general U.S. population using blood 
serum and urinary biomarkers available in the CDC’s 1999-2010 NHANES database and 
conduct secondary statistical analysis to determine if there is an association between 
higher body burdens of EDCs and reproductive cancers (breast cancer, cervical cancer, 
ovarian cancer, and uterine cancer) in women.   
 Sub Aim 3a:  Female participants in the 1999-2004 NHANES cycles, 20 years of 
 age and older who have higher body burdens of PCBs will have an increased risk 
 of cervical cancer, ovarian cancer, or uterine cancer.    
 Sum Aim 3b:  Female participants in the 2003-2010 NHANES cycles, 20 years 
 of  age  and older who have higher body burdens of phthalates will have an 
 increased risk of breast cancer, cervical cancer, ovarian cancer, or uterine cancer.    
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 Sum Aim 3c:  Female participants in the 2005-2010 NHANES cycles, 20 years of  
 age and older who have higher body burdens of bisphenol A will have an 
 increased risk of breast cancer, cervical cancer, ovarian cancer, or uterine cancer.  
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CHAPTER III 
METHODS 
Study Design  
 The primary objective of this study was to assess exposure to EDCs (PCBs, BPA, 
and phthalates) and determine whether exposure to these agents is a contributing factor in 
reproductive dysfunction in the U.S. general population.  To support or refute the 
proposed role of EDCs, secondary statistical analysis was conducted using data from the 
CDCs 1999-2010 National Health and Nutrition Examination Study.  The National 
Center for Health Statistics (NCHS), a branch of the U.S. Public Health Service in the 
U.S. Department of Health and Human Services, developed the National Health and 
Nutrition Examination Survey (NHANES).  NHANES, conducted annually since 1999 by 
the Centers for Disease Control and Prevention (CDC), is an ongoing cross-sectional 
survey designed to be nationally representative of the non-institutionalized, U.S. civilian 
population.  The survey design is a complex multistage probability sample, with 
oversampling of adolescents 12-19 years of age, adults greater than or equal to 60 years 
of age, low-income persons, Mexican Americans, and non-Hispanic blacks. 
Oversampling of subgroups is done to allow for more precise and valid estimates to be 
derived than a simple random sampling would allow. To obtain a representative sample 
of the U.S. population, the country is divided into geographic areas known as primary 
sampling units which are then combined to form strata, each strata is then divided into a 
series of neighborhoods.  From these neighborhoods, households are chosen at random 
and inhabitants are interviewed to determine if they are eligible for participation in the 
study.  Once eligibility is determined participants complete a confidential and voluntary 
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home interview followed by a standardized physical examination in a specially equipped 
mobile evaluation clinic (MEC).  The MEC examination consists of a physical 
examination, dental examination, detailed face-to-face personal interview, and collection 
of biological specimens.  Blood is obtained by venipuncture from a subsample of 
participants aged 1 year and older and urine specimens were collected from a subsample 
of participants aged 6 years and older.  Each survey includes a nationally representative 
sample of approximately 5,000 participants. The study protocol was reviewed and 
approved by the CDC institutional review board and informed consent was obtained from 
all subjects prior to participating in the NHANES.  All data collected is held in the 
strictest confidence and cannot be given out without consent. Code numbers are assigned 
in place of names or other identifying factors to maintain confidentiality.   All 
participants received a cash payment for time and effort, as well as, reimbursement for 
transportation and baby/elder care (CDC, 2012)  
Laboratory Methods 
  In each 2-year survey period, environmental chemicals or their metabolites were 
measured in blood serum or urine specimens from random subsamples of approximately 
2,500 participants.  The measurement of environmental chemicals in blood, serum, and 
urine reflect the amount of the chemical that enters the body through ingestion, 
inhalation, or dermal exposure routes. Environmental exposure measurements were made 
by the CDC’s Environmental Health Laboratory (Division of Laboratory Sciences, 
National Center for Environmental Health) by isotope dilution mass spectrometry, 
inductively coupled plasma mass spectrometry, or graphite furnace atomic absorption 
spectrometry.  For chemicals measured in urine, levels are expressed per volume of urine 
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or per gram of creatinine.  For lipophilic compounds such as dioxins, furans, PCBs, and 
organochlorine pesticides, serum levels are expressed per gram of total lipid and per 
whole weight of serum reflecting the amount of compounds that are stored in body fat.  
Blood serum and urinary samples collected during the MEC exam were stored at 4 
degrees Celsius or frozen at -20 degrees Celsius and then shipped to the CDC’s National 
Center for Environmental Health, Division of Environmental Health Laboratory Sciences 
for analysis.  (CDC, 2013b).  
Serum PCB, urinary BPA, and urinary phthalate metabolites. PCB levels were 
measured in serum from a random one-third subsample of people aged 12 years and older 
in the 1999-2000 and 2003-2004 survey cycles and people aged 20 years and older in the 
2001-2002 survey cycle. Analytical results for PCBs are reported on a whole weight 
(ng/g or ppb) and a lipid-adjusted basis (ng/g or ppb). Urinary Bisphenol A (BPA) was 
measured in a random one-third subsample of participants aged 6 years and older in the 
2003-2004, 2005-2006, 2007-2008, and 2009-2010 survey cycles.  Urinary phthalate 
monoesters were measured in a random one-third subsample of participants aged 6 years 
and older in the 1999-2000, 2001-2002, 2003-2004, 2005-2006, and 2007-2008 survey 
cycles (CDC, 2012).  
Questionnaire Methods 
 Demographic data was collected during the household interview in persons 16 
years of age and older and emancipated minors.  Reproductive health data was obtained 
during the Mobile Examination Center (MEC) private face-to-face interview in female 
participants aged 12 years and older. Medical health data was also obtained during the 
MEC interview from male and female participants, however, questions vary by age and 
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gender.  All interviewers completed a comprehensive two-week training program which 
included role-playing exercises and practice interviews, monitored by NCHS and 
contractor staff.  In addition, MEC interviewers received extensive training on personal 
and audio-computer-assisted interview administration.  Prior to implementing 
questionnaires a full pilot test was conducted as well as several types of quality control 
monitoring methods (CDC, 2012).  
Selection of Participants 
   
 Inclusion criteria for the study included women, 20 years of age and older who 
completed a private face to face interview and provided a blood and/or urine sample in 
the mobile examination center. All subjects had to have available PCB, BPA, or phthalate 
measurements to be included in the study populations.  In addition to available biological 
data, subjects in the 1999-2010 survey cycles had to complete the reproductive health and 
medical conditions questionnaires. To be included in the data for manuscript 1 and/or 3, 
female participants had to provide a response to the medical question “Have you ever 
been told by a doctor or other health professional that you had cancer or a malignancy of 
any kind?”  Participants with missing values for this question were deleted from the 
dataset.   For manuscript 2, female participants had to provide a response to the 
reproductive health question “Has a doctor or other health professional ever told you that 
had endometriosis?” and/or “Has a doctor or other health professional ever told you that 
you had uterine fibroids?” Survey participants with missing values for these questions 
were deleted from the dataset (CDC, 2012). 
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Sample Weights and Limits of Detection 
 Due to the complex survey design of NHANES, sample weights must be used to 
adjust for unequal probability of selection and possible bias resulting from non-response. 
Environmental chemicals are measured in subsamples of the study population and 
therefore must be weighted accordingly.  PCBs, phthalates, and BPA were measured in a 
randomly selected 1/3 subsample for each survey cycle.  When merging data from 
multiple survey cycles, appropriate sampling weights must be created according to 
NHANES analytic guidelines (CDC, 2013b ) 
  A detection limit variable is provided for all PCBs, phthalates, and BPA in the 
data sets.   The variable LBD_LC has two values:  the value “0” indicates that the result 
was below the limit of detection and the value “1” indicates that the result was at or 
above the limit of detection.  Any participant with a serum PCB concentration below the 
limit of detection was assigned a serum level of the LOD divided by the square root of 
two.  Limits of detection vary by individual PCB congener and survey cycle and can be 
found in the CDC’s Fourth National Report on Human Exposure to Environmental 
Chemicals (CDC, 2013).  LOD values may vary by survey year due to improvements in 
analytical methods.  While most LODs are constant for each individual specimen 
analyzed, individual PCB samples have their own LODs because the sample volume used 
for analysis differed for each sample.  For chemicals measured in urine, LOD 
calculations were performed using the chemical concentration expressed per volume of 
urine and for chemicals measured in serum, LOD calculations were performed using the 
chemical concentration expressed per amount of lipid because these concentrations 
determine the analytical sensitivity (CDC, 2013b).   
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EDC Exposure Assessment 
PCB Variables.  NHANES sampled for 22 PCB congeners in the 1999-2000 survey 
cycle, 34 PCB congeners in the 2001-2002 survey cycle, and 38 PCB congeners in the 
2003-2004 survey cycle.  To avoid bias among those below the LOD, we selected 6 
individual PCB congeners that were available in the 1999-2000, 2001-2002, and 2003-
2004 survey cycles and had concentrations above the LOD in at least 60% of the study 
subjects. The data analysis explored the relationship between reproductive health 
variables in women using the following six individual PCB congeners:  2,4,4’,5-
tetrachlorobiphenly (74), 2,2’4,4’,5-pentachlorobiphenyl (99),  2,3’,4,4’,5-
pentachlorobiphenyl (118), 2,2’,3,4,4’,5-hexachlorobiphenyl  (138), 2,2’,4,4’,5,5’-
hexachlorobiphenyl (153), and 2,2’,3,4,4,5,5’-heptachlorobiphenyl (180). Analysis was 
also conducted on the sum of non-dioxin-like PCBs (99, 138, 153, 180) and the sum of 
dioxin-like PCBs (74 and 118).  We conducted analysis of PCBs and breast cancer and 
PCBs and other reproductive cancers (cervical, ovarian, and uterine) using 1999-2004 
survey cycles with female participants 20 to 85 years of age.  We conducted analysis of 
PCBs and endometriosis and uterine leiomyomata using the 1999-2004 survey cycles and 
women 20-54 years of age (CDC, 2012).   
Phthalate Variables. NHANES sampled for 13 urinary phthalate metabolites in the 
2003-2004 survey cycle, and 15 urinary phthalate metabolites in the 2005-2006, 2007-
2008, and 2009-2010 survey cycles.  We selected the following seven urinary phthalate 
metabolites for our analysis:    mono-n-butyl phthalate (MnBP),  mono-isobutyl phthalate 
(MiBP), mono-ethyl phthalate (MEP), mono-(3-caroxypropyl) phthalate (MCPP), mono-
benzyl phthalate (MZP),  and three metabolites of  di (2-ehtylhexyl) phthalate (DEHP):  
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[mono-2-ethylhexyl phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate 
(MEHHP),and  mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP).  These metabolites were 
chosen because they were consistently measured in the 2003-2010 survey cycles and their 
concentrations were above the LOD in 98% of the study subjects, with the exception of 
MEHP which was present in concentrations above the LOD for 68% of the study 
subjects.  Data analysis was conducted using the 2003-2004, 2005-2006, 2007-2008 and 
2009-2010 survey cycles and female participants, 20 years of age and older (CDC, 2012).   
BPA Variables.  Urinary BPA measurements are available from the 2003-2004, 2005-
2006, 2007-2008, and 2009-2010 survey cycles in survey participants aged 6 years and 
older.  We conducted analysis of BPA and reproductive cancers using the  2005-2006, 
2007-2008, and 2009-2010 survey cycles and female participants, 20 years of age and 
older.  We did not include the 2003-2004 survey participants because BPA samples were 
taken from a different subsample of participants (subsample A vs. subsample B) and the 
CDC does not recommend combining different subsamples across survey cycles (CDC, 
2012).   
Reproductive and Medical Health Variables 
 Data analysis explored the relationship between serum PCB, urinary BPA and 
urinary phthalate levels and self-reported health outcomes obtained from the reproductive 
and medical health questionnaires of female participants 20 years of age and older.  
Medical Health Questionnaire.  Self-reported cancer status was obtained through the 
medical questionnaires in participants’ 20 years of age and older who provided a 
response for “Have you ever been told by a doctor or other health professional that you 
had cancer or a malignancy of any kind?” Women who answered “yes” were 
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subsequently asked “What kind of cancer was it?” and “What was your age at 
diagnosis?” Only women who reported no cancer diagnosis or a breast cancer diagnosis 
were included in our study population for manuscript 1. Participants who reported no 
cancer diagnosis and breast cancer, ovarian cancer, uterine cancer, or cervical cancer 
diagnosis were included in the analyses for manuscript 3.  Cancer diagnosis (yes/no) was 
modeled as a categorical dependent variable for all analyses (CDC, 2012). 
Reproductive Health Questionnaire. NHANES data was used to examine the 
relationship between serum PCB levels and endometriosis and uterine leiomyomata in 
manuscript 2. Self-reported endometriosis diagnosis was obtained through the 
reproductive health questionnaire in participants 20 to 54 years of age, who provided a 
response for “Have you ever been told by a doctor or other health professional that you 
have endometriosis?” Women who answered “yes” were subsequently asked “What was 
your age at diagnosis?” Self-reported uterine fibroid diagnosis was obtained through the 
reproductive health questionnaire in participants 20 to 54 years of age, who provided a 
response for “Have you ever been told by a doctor or other health professional that you 
have uterine fibroids?” Women who answered “yes” were subsequently asked “What was 
your age at diagnosis?” Endometriosis (yes/no) and uterine leiomyomas (yes/no) were 
modeled as categorical dependent variables in our analysis.  Additionally, the following 
outcomes from the reproductive health questionnaire were evaluated using categorical 
data: having undergone a medical procedure (hysterectomy, oophorectomy, or both: 
yes/no), age at menarche (< 12 years, 12-14 years, ≥15 years), number of pregnancies 
resulting in live births (0, 1, ≥2), oral contraceptive use (yes/no) and history of lactation 
(yes/no) (CDC, 2012).  
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Statistical Analysis 
  Females, 20 years and older with PCB, BPA, and/or phthalate levels and available 
reproductive or medical health data were used in our analyses.  Reproductive health 
outcomes are normally distributed and were modeled untransformed, while all PCBs, 
BPA, and phthalate metabolites are not normally distributed and were log transformed 
prior to statistical analyses.  In addition, all urinary BPA and phthalate metabolites were 
creatinine corrected prior to analyses. All estimates were weighted according to the 
National Center for Health Statistics guidelines to produce accurate national estimates, 
adjusting for the oversampling of minority subgroups (CDC, 2013b).  Variance 
estimation was conducted using the required stratum and PSU variables from the 
demographics data files.  Geometric means (GM), geometric standard errors (GSE), and 
proportions of EDCs were calculated for demographic and reproductive health variables. 
GMs of EDCs were compared among reproductive health variables by means of 
Student’s t-test or chi-square tests, depending on the type of variable. We used logistic 
regression models to calculate ORs and their 95% CIs to investigate the risk between 
blood and urinary levels of EDCs and breast cancer, ovarian cancer, uterine cancer, and 
cervical cancer as well as PCBs and endometriosis and uterine leiomyomas.  All 
statistical analyses were performed using SAS for windows (release 9.2; SAS Institute 
Inc. Cary, N.C.). These analyses used a 5% significance level (p≤0.05).   
Potential Confounding Variables 
 Potential confounding variables from the demographics file include age, 
race/ethnicity, education and income.  All potential confounding variables from the 
demographics file were inputted as categorical variables. For analysis of EDCs and 
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reproductive cancers (manuscripts 1 and 3), age was categorized into three groups (20-59 
years, 60-74 years and ≥ 75 years) due to a small number of reproductive cancer cases in 
the lower age range and race was categorized into two groups (non-Hispanic White and 
Other) due to a small number of reproductive cancer cases from races other than non-
Hispanic white.  Women classified as ‘Other’ included non-Hispanic Blacks, Mexican 
Americans, Other Hispanic, and Other Races including Multi-Racial. For analysis of 
PCBs and endometriosis and uterine leiomyomas (manuscript 2), age was categorized 
into four groups (20-29 years, 30-39 years, 40-49 years, and 50-54 years) and race was 
categorized into three groups (non-Hispanic White, non-Hispanic Black, and Other). 
Women classified as ‘Other’ included Mexican Americans, Other Hispanic, and Other 
Races including Multi-Racial. Data on BMI was obtained through the examination 
component of the MEC exam and smoking status, alcohol consumption, education 
completed, and annual family income were obtained in the household interview. For all 
of our analyses, body mass index (BMI, kg/m2) (> 25, 25-30 and ≥ 30), smoking status 
[“Have you smoked at least 100 cigarettes in your entire life?” (yes/no)], alcohol 
consumption [In any one year, have you had at least 12 drinks of any type of alcoholic 
beverage?” (yes/no)], education completed (< 12th grade, 12th grade and > 12th grade) and 
annual family income (0-$24,999, $25,000-$54,999, $55,000-$74,999 and ≥ $75,000) 
were evaluated as potential confounding variables, however smoking status, alcohol 
consumption,  education completed, and annual family income were not retained in the 
final logistic regression models for manuscripts 1 and 3 because they were not found to 
be significant predictors of risk; manuscript 2 did not retain education and income in the 
final models.    From the reproductive health questionnaire, additional covariates of age at 
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menarche (< 12, 12-14, ≥ 15) , parity, history of breastfeeding (yes/no), oral 
contraceptive use (yes/no) were evaluated for use in logistic regression models. Parity 
and oral contraceptive use were not retained in the final logistic regression models for 
manuscript 1, breast feeding was not retained in the final logistic regression models for 
manuscript 2, and parity, breastfeeding, and oral contraceptive use were not retained in 
the final logistic regression models for manuscript 3 because of they contained a large 
number of missing values that significantly decreased the number of cancer cases in the 
model.   
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CHAPTER IV 
MANUSCRIPT 1  
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND BREAST CANCER 
AMONG U.S. WOMEN: ANALYSES OF NHANES DATA 1999-2004 
ABSTRACT 
Background:  Breast cancer is the most commonly diagnosed cancer among women 
worldwide.  A number of chemicals are suspected to act as endocrine disruptors (EDs) by 
mimicking natural or synthetic estrogen resulting in an increased risk of breast cancer in 
women.  Polychlorinated biphenyls (PCBs) have been recognized as endocrine disrupters 
due to their ability to interfere with reproductive function and development in animals 
and humans by either increasing estrogen activity or blocking estrogens from acting.   
Objectives: The purpose of this study was to examine the cross-sectional relationship 
between exposure to PCBs and breast cancer among U.S. women.   
Methods:  We analyzed data from female participants (20 years of age and older) who 
provided blood  samples for the Centers for Disease Control and Prevention’s National 
Health and Nutrition Examination Survey (NHANES) between 1999 and 2004. Exposure 
was based on lipid adjusted serum levels of 6 individual PCB congeners (PCB 074, 099, 
118, 138, 153, and 180), the sum of dioxin-like PCBs (074 + 118), and the sum of non-
dioxin-like PCBs (099 + 138 + 153+187) in conjunction with data obtained from the 
medical and reproductive health questionnaires.  We calculated geometric means to 
compare PCB concentrations in women who self-reported a breast cancer diagnosis vs. 
women who self-reported never being diagnosed with cancer. We used logistic regression 
models to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the 
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association between PCB measurements and breast cancer.  We evaluated age, 
race/ethnicity, age at menarche, body mass index (BMI; kg/m2), and lactation as potential 
confounders in our final models.   
Results: Separate analyses showed weighted geometric mean levels of all 6 PCB 
congeners to be significantly higher among women with breast cancer when compared to 
the rest of the study population. After adjusting for age, race, and BMI we found breast 
cancer risk to be significantly associated with PCB 138 in the 50-75th and ≥75th percentile 
groups, [odds ratios of  2.93, 95%  confidence interval (CI): 1.04-8.26 and 3.43,  95% CI: 
1.12-10.4], respectively.  After adjusting for age, race, BMI, lactation, and age at 
menarche we found that PCB 138 and 180 were  significantly associated with breast 
cancer [ORs of 2.88; 95% CI: 1.14-7.30 and 4.54, 95% CI: 1.11-18.6, respectively] in 
women with higher body burdens of individual PCB congeners (> 50th percentile).  After 
adjusting for age and race, we also found the sum of non-dioxin-like PCBs to be weakly 
associated with breast cancer [OR of 1.14; 95% CI: 1.00-1.29].   
Conclusions: Our results suggest a link between environmental exposures to PCBs and 
increased risk of breast cancer among U.S. women. Despite the ban on PCB production, 
environmental exposures appear to continue posing significant threats on the health of the 
general population.  
Keywords:  PCBs, NHANES, breast cancer 
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MANUSCRIPT 1  
 
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND BREAST CANCER 
AMONG U.S. WOMEN: ANALYSES OF NHANES DATA 1999-2004 
INTRODUCTION 
Breast cancer is the most commonly diagnosed cancer among women in both 
developing and developed nations, representing 11.9% of all cancers diagnosed 
worldwide (SEER 2013, IARC 2012).   Incidence rates of breast cancer vary greatly, with 
age standardized rates reaching 43.3 per 100,000 worldwide and 92.9 per 100,000 in 
North America (IARC 2012). The latest estimates released by the World Health 
Organization’s (WHO) International Agency for Research on Cancer (IARC) 
GLOBOCAN 2012 database indicate that breast cancer incidence has increased 20% 
while mortality has increased 14% since 2008 (IARC 2012).  While estimates vary, 
breast cancer cases cannot be solely attributed to risk factors such as family history, 
parity, prolonged exposure to endogenous estrogens (Bodicoat et al. 2014), physical 
inactivity, alcohol use, and obesity (Madigan et al 1995).  A new recent report by the 
United Nations Environment Programme (UNEP) and WHO entitled “State of the 
Science: Endocrine Disrupting Chemicals - 2012” highlighted  that approximately 800 
chemicals are suspected to act as endocrine disruptors (EDs) or  mimic natural hormones 
or disrupt hormone regulation  (UNEP/WHO 2013, EU 2013).  Some of these EDs mimic 
natural or synthetic estrogen. This recent UNEP/WHO report has renewed the concern by 
highlighting that there may be some associations between exposure to estrogen-
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mimicking EDs and an increased risk of breast cancer in women (UNEP/WHO 2013, EU 
2013).   
Polychlorinated biphenyls (PCBs) are a group of synthetic organic chemicals that 
were introduced into industry in the late 1920’s and used primarily for heat exchange in 
transformers and capacitors, hydraulic and lubricating fluids, plasticizers, inks, paints, 
adhesives, flame retardants, and extenders for pesticides (ATSDR 2000).  Despite the ban 
of PCBs in the late 1970’s due to serious health concerns, environmental exposures are 
still possible due to a release from hazardous waste sites; illegal dumping; leaks from old 
transformers; and burning of PCB contaminated waste (Carpenter 2006, Johnson et al. 
1999).  Furthermore, PCBs bioaccumulate in the fatty tissues of fish and mammals, 
increasing the likelihood of dietary exposures.  Elimination half-lives of PCBs vary 
substantially in humans for each PCB congener and range from a few months to a few 
decades depending on PCB chlorination, age, body fat, and breast feeding (Anderson et 
al. 1998, Phillips et al. 1989, Paris-Pombo et al. 2003, Tee et al. 2003, Milbrath et al. 
2008).   
PCBs have been recognized as endocrine disrupters due to their ability to interfere 
with reproductive function and development in animals and humans by either increasing 
estrogen activity or blocking estrogens from acting (Fielden et al. 2001, Aoki et al. 2001, 
Ma and Sassoon 2006, McLachlan et al. 2006).  Estrogen is a contributing factor in the 
development of breast cancer (Lin et al. 2009). The increased risk of breast cancer among 
postmenopausal women may be due to an altered endogenous estrogen (Bertelsen et al. 
2007, Roy et al. 1997, Roy et al. 1998).  Furthermore, animal and limited human data 
suggest that exposure to PCBs may lead to a number of adverse reproductive effects such 
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as decreased conception rates, prolonged time to pregnancy, irregular menstrual cycles, 
spontaneous abortion, preterm delivery, abnormal sperm morphology, decreased sperm 
motility, preterm delivery, low birth weight, reduced lactation time, and late miscarriages 
(Arisawa et al. 2005, Baibergenova et al. 2003, Buck et al. 2000, Kostyniak et al. 1999, 
Mendola et al. 1997, Rylander et al. 1998, Tsukimori et al. 2000, Yu et al. 2000, Yang et 
al. 2008). 
Studies pertaining to PCBs and breast cancer are controversial. While some 
studies reported no significant associations (Gammon et al. 2002, Gatto et al. 2007, Wolff 
et al. 2000), or inverse associations (Pavuk et al. 2003, Itoh et al. 2009) other studies have 
found an increased breast cancer risk when analyzing total PCB exposure or specific 
individual PCB congeners (Charlier et al. 2004, Cohn et al. 2012, Demers et al. 2002, 
Millikan et al. 2013, Recio-Vega et al. 2001, Muscat et al. 2003).  Charlier et al. (2004) 
found concentrations of PCB 138 (1.25 vs. 0.94 ppb; p = 0.0068), PCB 153 (1.63 vs. 
0.63; p < 0.0001), and total PCBs (7.08 vs. 5.10 ppb; p = 0.012) to be significantly higher 
in cases when compared to controls. After adjusting for confounding risk factors, PCB 
153 was found to be significantly associated with an increased risk of breast cancer 
(OR=1.8; 95% CI, 1.4-2.5) (Charlier et al. 2004).  Cohn et al. (2012) did not find any 
associations between breast cancer risk and the sum of total PCBs or PCB groupings, 
however, a significant association was found for PCB 203 when comparing the highest 
vs. lowest quartiles of exposure (OR=6.3; 95% CI, 1.9-21.7). Demers et al. (2002) found 
mean plasma lipid concentrations of individual PCB congeners 99, 118, and 156 and 
mean total concentrations of mono-ortho PCB congeners (nos. 105, 118, and 156) to be 
significantly higher in breast cancer cases than controls.   Breast cancer risk was found to 
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be significantly associated with the sum of mono-ortho congeners (nos. 105, 118, 156) 
(OR=2.02; 95% CI, 1.24-3.28), PCB 118 (OR=1.60; 95% CI, 1.01-2.53) and PCB 156 
(OR=1.80, 95% CI 1.11-2.94) when comparing the fourth vs. first quartiles (Demers et al. 
2002).  Millikan et al. (2013) did not find any associations with total PCBs and breast 
cancer among all participants (OR=1.09; 95% CI, 0.79-1.52) or white women (OR=1.03; 
95% CI, 0.68-1.56), but did find a slightly elevated risk for African-American women 
(OR=1.74; 95% CI, 1.00-3.01). Recio-Vega et al. (2001) found the GM of total PCBs to 
be significantly higher in cases than controls (5.26 vs. 3.33 ppb) (OR=1.09; 95% CI, 
1.01-1.14) as well as an increased risk of breast cancer among PCBs grouped by 
structure-activity relationships and 8 individual PCB congeners (nos. 118, 128, 138, 170, 
180, 195, 206, and 209) and Muscat et al. (2003) found that PCB concentrations in the 
highest tertile for PCB congener 118 (RR=4.0; 95%, CI 1.32-4.9) and total PCBs 
(RR=2.9; 95% CI, 1.02-8.2) were related to an increased risk of breast cancer recurrence 
in women with nonmetastatic breast cancer.  Stronger associations were reported between 
PCB exposure and breast cancer risk in studies that considered genetic polymorphism of 
the CYP 1A1 enzyme and menopausal status (Zhang et al. 2004, Li et al. 2005, Moysich 
et al. 1998, Moysich et al. 1999). CYP1A1-M2 genetic variants were found to modify the 
association between PCB exposure and breast cancer in postmenopausal Caucasian 
women, while CYP1A1-M3 genotypes were found to modify this association in African 
American women (Zhang et al. 2004, Li et al. 2005).  
In this study, we examined the relationship between 6 individual PCB congeners, 
the sum of dioxin-like PCBs and the sum of non-dioxin-like PCBs with self-reported 
breast cancer in female subjects participating in the National Health and Nutrition 
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Examination Survey (NHANES) between the years 1999-2004.  The objectives of this 
study were to: 1) describe the mean PCB levels in women (≥ 20 years of age) diagnosed 
with breast cancer compared to women not diagnosed with cancer; and 2) assess the 
association between higher body burdens of PCBs and increased risk of breast cancer.   
METHODS 
Study design and population. NHANES is an ongoing cross-sectional survey designed to 
be nationally representative of the non-institutionalized U.S. civilian population.  
Conducted annually since 1999 by the National Center for Health Statistics of the Centers 
for Disease Control and Prevention (CDC), NHANES uses a complex multi-stage 
sampling design where approximately 5,000 survey participants a year complete in-home 
interviews and physical examinations in mobile examination units (CDC 2012). All 
participants provided written informed consent and all procedures were approved by the 
National Center for Health Statistics (NCHS) Institutional Review Board  (CDC 2012).  
We merged data from the 1999-2000, 20012-2002, and 2003-2004 survey cycles. We 
limited our analysis to women 20 to 85 years of age who completed the reproductive and 
medical health questionnaires in a face-to-face interview at a mobile examination center.  
PCB measurements.  Blood serum concentrations of individual PCB congeners were 
measured in a representative, random one-third subsample of people 12 years of age and 
older in the 1999-2000, 2001-2002, and 2003-2004 survey cycles. PCB congeners were 
measured in serum by high-resolution gas chromatography/isotope-dilution high-
resolution mass spectrometry (HRGS/ID-HRMS).   NHANES provides both wet-weight 
and lipid adjusted values for each sample, corrected for sample weight and analyte 
recovery; we used lipid adjusted values in our analyses.  Detailed laboratory methods 
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were consistent among survey cycles and are available online (CDC 2013b).   A detection 
limit variable is provided for all PCB congeners in the data set.  The variable LBD_LC 
has two values:  the value “0” indicates that the result was below the limit of detection 
and the value “1” indicates that the result was at or above the limit of detection.  Any 
participant with a serum PCB concentration below the limit of detection was assigned a 
serum level of the LOD divided by the square root of two.  Limits of detection vary by 
individual PCB congener and survey cycle and can be found in the CDC’s Fourth 
National Report on Human Exposure to Environmental Chemicals (CDC 2013).  Lipid-
adjusted serum concentrations (ng/g) for 6 individual PCB congeners as well as the sum 
of the dioxin-like PCBs (74 + 118) and the sum of non-dioxin-like PCBs (118 + 138 
+153 + 170) were used in this study.  PCB congeners 74, 99, 118, 138, 153, and 180 were 
selected because they were available in all three survey cycles and concentrations were 
above the LOD in > 60% of the survey participants.   
Breast cancer diagnosis.  We included female 1999-2004 NHANES participants 20 to 85 
years of age who completed the self-reported medical health questionnaire and provided a 
response for “Have you ever been told by a doctor or other health professional that you 
had cancer or a malignancy of any kind?” Women who answered “yes” were 
subsequently asked “What kind of cancer was it?”  8,315 women 20 to 85 years of age 
provided a response in the 1999-2004 survey cycles.  After deleting observations that 
were missing PCB data and 25 additional observations that were missing values for 
PCB99, our study population consisted of 2,007 participants:  43 who reported a breast 
cancer diagnosis and 1,964 who reported no cancer diagnosis. There were 43 breast 
cancer cases for all six PCB congeners and 1959 non cancer cases for PCBs 74, 99, 118, 
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and 138; 1960 non cases in PCB153; and 1954 noncases in PCB 180.  The sum of dioxin-
like PCBs and non-dioxin-like PCBs were available in 1,996 and 1,984 subjects, 
respectively (CDC 2012).  
Statistical analysis.  All statistical analyses were performed using SAS system software 
(release 9.2; SAS Institute Inc. Cary, N.C.).  A six year subsample weight was calculated 
according to the National Center for Health Statistics guidelines to adjust for 
oversampling of minority groups in the merged 1999-2004 NHANES data cycles (CDC 
2013b).  Nonmissing values for serum concentrations below the LOD were assigned a 
serum level of the LOD divided by the square root of two.  In our analysis, all lipid-
adjusted serum PCB concentrations were log transformed to satisfy normality 
assumptions.   Due to a small number of breast cancer cases, participants were 
categorized the following ways depending on data analysis: < LOD vs. ≥ LOD;   < LOD 
to 50th percentile vs. ≥ 50th percentile; and < LOD to 50th percentile vs. 50th percentile to 
75th percentile vs. ≥ 75th percentile.  We also conducted separate analyses on all females 
with serum PCB levels > LOD where breast cancer cases were compared with non-cancer 
cases.   Significance was set at p < 0.05 for all analyses.   
We used PROC SURVEYMEANS to account for the complex sampling design of 
NHANES and to obtain weighted means, 95% confidence intervals, and standard errors 
of individual PCB congeners, the sum of dioxin-like PCBs, and the sum of non-dioxin-
like PCBs. We used the Taylor Series (linearization) method to estimate standard errors.   
A two-sided student t-test was calculated using PROC SURVEYREG to test whether the 
mean PCB levels between women who reported a breast cancer diagnosis and women 
who reported no cancer diagnosis were significantly different. Geometric mean (GM) 
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PCB levels and geometric standard errors (GSE) were reported for breast cancer status, 
age at interview, and race/ethnicity for all participants with individual serum PCB levels 
above the LOD.  Arithmetic mean serum levels of dioxin-like and non-dioxin-like PCBs 
and 95% CIs were reported for breast cancer status and select confounding variables (age, 
race, BMI, lactation, age at menarche, lactation, oral contraceptive use, smoking status, 
alcohol consumption, education completed and annual family income).  Age was divided 
into three groups (20-59 years, 60-74 years, and ≥ 75 years) that were selected based on 
the age distribution of breast cancer cases and noncases in our data set. Race/ethnicity 
was divided into two groups (non-Hispanic White and ‘Other’) due to a very small 
number of breast cancer cases from races/ethnicities other than non-Hispanic White.  The 
category of ‘Other’ includes Mexican American, Non-Hispanic Black, Other Hispanic 
and Other Race – Including Multi-Racial. To account for the different age structures 
among non-Hispanic whites and ‘Other’ ethnicities in our study population, we presented 
age standardized GM PCB levels for individual PCB congeners and age standardized 
arithmetic mean dioxin-like and non-dioxin-like PCB levels for race/ethnicity.  We also 
calculated both crude and age standardized GMs for breast cancer cases and noncases in 
women with PCB levels above the LOD. We used the direct method for age 
standardization provided by the CDC (CDC 2014).   
Using PROC SURVEYLOGISTIC, we derived unadjusted and adjusted ORs and 
their 95% CIs to evaluate the association between exposure to PCBs and breast cancer.  
We conducted separate analyses for the sum of dioxin-like and non-dioxin-like PCBs and 
individual PCB congeners and breast cancer. Due to a small number of breast cancer 
cases, ORs and 95% CIs were calculated using the following groups: < LOD to 50th 
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percentile vs. ≥ 50th percentile; and < LOD to 50th percentile vs.  50th percentile to 75th 
percentile vs. ≥ 75th percentile.     The reference group for each PCB congener is defined 
as those participants whose serum concentrations were < LOD to 50th percentile.  We 
conducted further analyses which included participants (breast cancer cases vs. noncases) 
with only PCB levels > LOD.  ORs and 95% CIs were reported for each group in the 
model.   
Covariates.  We considered a number of potential confounders based on previous 
literature and well-established risk factors for breast cancer. The following potential 
confounders were either self-reported in the questionnaire interviews or taken as a 
laboratory measurement.  The demographic variables of age at interview (20-59 years, 
60-74 years, and ≥ 75 years), race (white vs. other), education completed (< 12th grade, 
12th grade, > 12th grade) and income (0-$24,999, $25,000-$54,999, $55,000-$74,999) 
were obtained during the NHANES home interview (CDC 2012).  Reproductive variables 
including age at menarche (<12 years, 12-14 years, ≥15 years), history of regular periods 
(yes/no), parity (0, 1, ≥ 2), oral contraceptive use (yes/no) and breast-feeding (yes/no) as 
well as lifestyle variables including smoking (yes/no) and alcohol use (yes/no) were 
obtained from health questionnaires completed in the mobile examination center. Body 
mass index (< 25 kg/m2, 25 to < 30 kg/m2, and ≥ 30 kg/m2) was obtained through the 
body measurement component in the mobile examination center (CDC 2013b).  For 
individual PCB congeners, ORs and 95% CIs are reported for three models: unadjusted; 
age, race/ethnicity and BMI adjusted; and age, race/ethnicity, BMI, lactation, and age at 
menarche adjusted. For the sum of dioxin-like and non-dioxin-like PCBs, ORs and 95% 
CIs are reported for four models:  unadjusted;  race/ethnicity adjusted; age and 
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race/ethnicity adjusted; and age, race/ethnicity,  BMI, lactation, and age at menarche 
adjusted.   Parity and oral contraceptive use were not included in the models because of 
the extent of missing data.  Smoking history, alcohol use, education, and income were not 
significant predictors of breast cancer risk and therefore were also not presented in the 
final logistic regression models.   
RESULTS 
Descriptive Statistics. The study population included 2,007 female participants 20 years 
of age and older with available PCB data and who completed the medical conditions 
questionnaire and provided a response for “Have you ever been told by a doctor or other 
health professional that you had cancer or a malignancy of any kind?” Women who 
answered “yes” were subsequently asked, “What kind of cancer was it?” Among the 
2,007 participants, 1,964 (97.9%) reported never being diagnosed with cancer and 43 
(2.14%) reported being diagnosed with breast cancer (Table 1.1). Participants were fairly 
evenly distributed over the two races: 48.6% were of non-Hispanic white ethnicity and 
51.4% were classified as ‘Other’, however the majority of breast cancer cases were in 
non-Hispanic white women (81.5%).   The majority of participants were 20-59 years of 
age at the time of interview (68.6%) (Table 1.1).  The mean age at time of interview was 
45.5 years for women who reported never being diagnosed with cancer and 65.2 years for 
women who reported being diagnosed with cancer with a mean age at breast cancer 
diagnosis of 55.3 years (Table 1.1).  BMI was normal (< 25 kg/m2) for 39.6%, 
overweight (25to < 30 kg/m2) for 30.6%, and obese (≥ 30 kg/m2) for 35.1% of study 
participants.  Age of menarche was < 12 years of age for 19.4%, 12-14 years for 66.2%, 
and ≥ 15 years for 14.3% of study participants.  The majority of study participants 
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reported ≥ 2 live births (73.9%), responded yes to breastfeeding (59.4%),  responded yes 
to oral contraceptive use (60.8%) ,  responded no to a history of smoking (69.3%), yes to 
alcohol consumption (56.4%), completed more than 12th grade (45.2%), and reported a 
yearly family income of 0-$24,999 (37.1%) (Table 1.1).   
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Table 1.1.  Descriptive statistics for breast cancer status and selected covariates among women ≥ 20 years
of age, NHANES 1999-2004.   
                                 Breast Cancer               No Breast Cancer 
Variable                                                 n(%)                        n (%)   
Total Population (n,%)                    43(2.14%)                  1964(97.9%)   
Age at interview (years; mean ± se)                 65.2 ± 2.10                  45.5 ± .43  
Age at diagnosis (years; mean ±se)              55.3 ± 3.11 
Race/Ethnicity           
 Non-Hispanic white                     35 (1.74%)                 940 (46.8%) 
Other                           8 (0.40%)                  1024(51.0%) 
Age at time of interview (years) 
 20-59                            7 (0.35%)                    1368(68.2%)  
 60-74                             26 (1.30%)                 384 (19.1%)  
 ≥ 75                                10 (0.50%)                   212 (10.6%) 
Age at menarche (years)  
 < 12 years                      6 (0.33%)                  344 (19.1%) 
 12-14 years                       30 (1.67%)                 1160 (64.5%) 
 ≥ 15 years                      4 (0.22%)                      254 (14.1%) 
Parity (no. of live births)  
 0                                                                     0 (0.00%)                                             82 (5.27%) 
 1                                                                    5 (0.32%)                                             319 (20.5%) 
 > 2                                                               29 (1.86%)                                           1120 (72.0%) 
BMI (kg/m2)  
 Normal weight (18.5 to <25)                  12(0.62%)                 655 (33.7%) 
 Overweight (25 to <30)                         18 (0.93%)                   578 (29.7%)  
 Obese (≥30)                            12 (0.62%)                                  670 (34.5%) 
Breastfed  
 Yes                                 19(1.33%)                                         835 (58.1%) 
 No                                                                15 (1.05%)                                          558 (39.1%) 
Oral Contraceptive Use  
 Yes                                 19 (1.03%)                                         1103(59.8%) 
 No                                                                21 (1.14%)                                           701 (38.0%) 
Ever Smoked   
 Yes                                                                23 (1.15%)                                           773 (38.5%)   
No                               20 (1.00%)                 1190 (59.3%) 
Alcohol Use   
 Yes                                  24 (1.30%)                        1018 (55.1%)  
 No                                 16 (0.87%)                   790 (42.8%) 
Education   
 < 12th grade                              15 (0.75%)                 445 (22.2%) 
 12th grade                                 15 (0.75%)                 626 (31.2%) 
> 12th grade                             13 (0.65%)                 893(44.5%)  
Income  (yearly family income)     
 0-$24,999                              17 (0.96%)                  642 (36.1%)  
 $25,000-$54,999                        13 (0.73%)                                         566 (31.8%) 
 $55,000-$74,999                                              1 (0.06%)                                              208 (11.7%)  
 ≥ $75,000                                                         7 (0.39%)                                             326(18.3%)   
Estimated percent distribution after applying NHANES sampling weights.   
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Table 1.2 presents GMs and GSEs of lipid adjusted PCBs by breast cancer status in 
participants with individual PCB concentrations above the LOD. Crude GM PCB levels 
were significantly higher for all 6 PCB congeners in women who reported a breast cancer 
diagnosis compared to women who reported no cancer diagnosis (Table 1.2). Overall GM 
levels of individual blood PCBs ranged from 7.24 ng/g lipid to 31.8 ng/g lipid in women 
who reported never being diagnosed with cancer and from 9.87 ng/g lipid to 55.1 ng/g 
lipid in women who reported being diagnosed with breast cancer, with the lowest levels 
observed for PCB congener 99 and the highest levels observed for PCB 153 (Table 1. 2; 
Figure 1.1).  After adjusting for age, GM PCB levels in women with breast cancer 
remained significantly higher in breast cancer cases for PCB congeners 99, 138, 153, and 
180. Age standardized GM PCB levels ranged from 7.03 ng/g lipid to 31.5 ng/g lipid in 
women who reported never being diagnosed with cancer and from 10.4 ng/g lipid to 47.5 
ng/g lipid in women who reported being diagnosed with breast cancer. These results are 
consistent with crude GM PCB levels with the lowest and highest blood levels being 
observed for PCB congeners 99 and 153, respectively.  
 
Table 1.2.  Geometric Mean PCB levels (ng/g) by breast cancer status among women ≥ 20 years of age 
with PCB concentrations above the LOD, NHANES 1999-2004. 
 Geometric mean2(ng/g) (GSE) 
             Noncases/        No            Breast             No         Breast  
Analyte1      Cases       Cancer        Cancer         Cancer3     Cancer3 
PCB 074           1483/43       9.87 (1.07)      16.0 (1.07) b       9.58 (1.03)    10.8 (1.23) 
PCB 099     1334/41       7.24 (1.09)       9.87 (1.03) b      7.03 (1.04)    10.4 (1.11)b 
PCB 118          1533/43       11.7 (1.06)      17.5 (1.16) b         11.4 (1.03)    10.9 (1.23) 
PCB 138           1594/43       23.6 (1.06)         39.6 (1.07) a          23.1 (1.03)    33.8 (1.19)b 
PCB 153           1651/43       31.8 (1.06)        56.3 (1.08) a          31.5 (1.03)    47.5 (1.16)b 
PCB 180           1599/43       23.3 (1.63)        44.3 (1.05) a          22.9 (1.02)    36.2 (1.12)a 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights.  
3Age Standardized: 20-59 years, 60-74 years, ≥75 years. 
PCB levels significantly higher in women with breast cancer vs. women without cancer; 
 ap < 0.0001, bp < 0.05  
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Figure 1.1.  Geometric mean PCB levels (ng/g) by cancer status for women ≥ 20 years of age with PCB  
concentrations above the LOD, NHANES 1999-2004.   
 
GM PCB levels were also examined by age group in women with individual PCB 
concentrations above the LOD (Table 1.3). The overall GM levels of PCBs in blood 
significantly increased with age for each individual PCB congener measured with the 
exception of PCB 99, which decreased slightly for women diagnosed with breast cancer 
in the 60-74 year old age group.  In the first age group (20-59 years), women diagnosed 
with breast cancer had significantly higher GM PCB levels of congeners 99, 138, 153, 
and 180 when compared to women never diagnosed with cancer (Table 1.3).  Significant 
differences in GM PCB levels were not found in the other two age groups between 
women who reported being diagnosed with breast cancer and women who reported never 
being diagnosed with cancer (Table1. 3).  
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Table 1.3   Geometric Mean PCB levels (ng/g) by age group and breast cancer status among women with 
PCB concentrations above the LOD, NHANES 1999-2004. 
                             Geometric mean2 (ng/g) (GSE, n)   
             Age:  20-59 years                        Age: 60-74 years               Age: ≥ 75 years 
            No      Breast                    No                   Breast             No            Breast   
Analyte        Cancer              Cancer               Cancer               Cancer         Cancer          Cancer  
PCB 074   7.54 (1.04, 902)      8.85 (1.30, 7)    18.0 (1.04, 372)     18.2 (1.11, 28)     28.2 (1.05, 209) 25.8 (1.09, 10)
PCB 099   5.99 (1.04, 796)   10.6 (1.13, 6)b   10.5 (1.04, 341)     9.49 (1.14, 25)     14.6 (1.07, 197)  10.5 (1.21, 10)
PCB 118      9.03 (1.04, 952)   8.76 (1.30, 7)    21.8 (1.04, 371)       20.9 (1.17, 27)   32.1 (1.06, 210)   27.4 (1.15, 10)
PCB 138      18.9 (1.03, 1019)   31.2 (1.23, 7)b   40.9 (1.04, 370)       42.1 (1.11, 28)    58.0 (1.04, 205) 48.4 (1.11, 10)
PCB 153      25.0 (1.03, 1072)  43.4 (1.21, 7)b   59.1 (1.03, 371)       58.6 (1.11, 28)    83.1 (1.04, 208) 74.4 (1.09, 10)
PCB 180      18.0 (1.03, 1016)    32.8 (1.15, 7)a    44.3 (1.03, 375)    45.6 (1.09, 28)   61.6 (1.03, 208)   61.6 (1.12, 10)
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
GM PCB levels significantly higher in women with breast cancer vs. women without cancer; 
 ap < 0.0001, bp < 0.05. 
 
 Table 1.4 presents age standardized GMs and GSEs of lipid adjusted PCBs by 
race/ethnicity in participants with individual PCB concentrations above the LOD.  For 
women who reported being diagnosed with breast cancer, women classified as ‘Other’ 
had significantly higher GM PCB levels for PCB congeners 74, 99, 118, 138, 153, and 
180 compared to non-Hispanic white women (Table 1.4).  In women who reported never 
being diagnosed with cancer, only PCBs 74, 153, and 180 were found to be significantly 
higher in non-Hispanic white women compared to classified as ‘Other’ (Table 1.4).   
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Table 1.4.  Age standardized geometric mean PCB levels (ng/g) by race/ethnicity amongwomen ≥ 20 years 
of age with PCB concentrations above the LOD, NHANES 1999-2004. 
                                     Geometric mean2(ng/g) (GSE, n) 
                       No Cancer                             Breast Cancer  
              Non-Hispanic         Non-Hispanic  
Analyte1      White             Other                        White               Other  
PCB 074      10.4 (1.08, 772)e       8.67 (1.07, 711)        15.3 (1.07, 35)d        27.4 (1.05, 8)b,c
PCB 099     7.17 (1.11, 679)     7.39 (1.08, 655)       9.12 (1.08, 34)d             23.1 (1.00, 7)a ,c
PCB 118         12.2 (1.06, 779)     11.8 (1.07, 754)          16.4 (1.21, 35)               32.8 (1.01, 8)b,c
PCB 138        24.0 (1.06, 800)     22.6 (1.07, 794)          37.7 (1.11, 35)d              69.4 (1.12, 8)b ,c
PCB 153         33.1 (1.06, 826)e      29.1 (1.06, 825)          54.1 (1.09, 35)c              90.9 (1.12, 8)b,c
PCB 180        24.8 (1.05, 809)e        20.3 (1.04, 790)           43.4 (1.05, 35)c            52.5 (1.17, 8)c 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
PCB levels significantly higher in ‘Other’ women with breast cancer vs. non-Hispanic white women with 
breast cancer;  ap < 0.0001, bp < 0.05   
PCB levels significantly higher in women with breast cancer vs. women without breast cancer;  
 cp < 0.0001, dp < 0.05   
PCB levels significantly higher in non-Hispanic white women without cancer vs. ‘Other’ women without 
cancer,  ep < 0.0001. 
  
 Table 1.5 shows the arithmetic means and 95% CIs of serum levels of dioxin-like 
PCBs for breast cancer status and selected variables in the study population.  Arithmetic 
means of dioxin-like PCBs were significantly higher  in women who reported being 
diagnosed with breast cancer (5.64 ng/g) compared to women who reported never being 
diagnosed with cancer (4.33 ng/g), however mean dioxin-like PCBs did not remain 
significant after adjusting for age (Table 1.5).   Mean dioxin-like PCBs increased with 
age, however there were no significant differences in the three age groups for women 
who reported being diagnosed with breast cancer compared to women who reported 
never being diagnosed with cancer.  Age standardized dioxin-like PCBs were found to be 
significantly higher for breast cancer cases in both races (non-Hispanic white and 
‘Other’)  but were not found to significantly different from each other. With the 
exception of age at menarche (< 12 years) and education (<12th grade completed) , 
dioxin-like PCBs were found to be significantly higher in women who reported a breast 
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cancer diagnosis compared to women who reported no cancer diagnosis (Table 1.5) for 
all covariates in the study population (Table 1.5).  Table 1.6 shows the arithmetic means 
and 95% CIs of serum levels of non-dioxin-like PCBs for breast cancer status and 
selected variables in the study population.  Crude arithmetic means of non-dioxin-like 
PCBs were significantly higher  in women who reported being diagnosed with breast 
cancer (13.7 ng/g) compared to women who reported never being diagnosed with cancer 
(11.1 ng/g), and remained significant after adjusting for age (13.2 ng/g vs 11.2 ng/g)  
(Table 1.6).  Mean non-dioxin-like PCBs increased with age, however  only the women 
diagnosed with breast cancer in the first age group  (20-59 years)  had significantly 
higher non-dioxin-like PCBs compared to women never diagnosed with cancer.  Age 
standardized non-dioxin-like PCBs were found to be significantly higher for breast 
cancer cases in both races (non-Hispanic white and ‘Other’) but were not found to 
significantly different from each other.  With the exception of age at menarche, non-
dioxin-like PCBs were found to be significantly higher in women who reported a breast 
cancer diagnosis compared to women who reported no cancer diagnosis for all covariates 
in the study population (Table 1.6).   
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Table 1.5.  Serum Levels of dioxin-like PCBs (ng/g) in the study population, women ≥ 20 years of age, 
NHANES 1999-2004.  
             Mean1 (ng/g) (95% CI) 
Variable                        Noncase s/Cases       No Cancer          Breast Cancer   
Dioxin-like PCBs2                                  1953/43                        4.33 (4.21-4.54)        5.64 (5.09-6.18)a
Dioxin-like PCBs3                                           1752/45                         4.38 (4.28-4.48)        4.77 (3.97-5.57)
Dioxin-like PCBs_504                                   
    <LOD to 50%                                      973/4                             2.96 (2.89-3.03)        3.27 (3.02-3.51) 
    ≥ 50%                                                  979/39                          5.76 (5.67-5.84)        6.11 (5.80-6.44)b
Age                                    
20-59 years                    1362/7            3.82 (3.71-3.95)       4.35 (3.29-5.41) 
      
60-74 years                       379/26          5.92 (5.76-6.08)       5.94 (5.45-6.43) 
≥ 75 years                 212/1 0           6.73 (6.48-6.98)       6.56 (6.11-7.00)   
Race/Ethnicity3                                  
 Non-Hispanic White            933/35            4.43 (3.98-4.26)        5.53 (4.94-6.12)b
Other                      1020/8             4.12 (4.28-4.58)       6.80 (6.60-7.00)a 
Age at Menarche (years) 
 < 12 years                342/6             4.35 (4.06-4.63)       5.77 (3.45-8.09) 
 12-14 years               1154/30            4.34 (4.19-4.50)       5.65 (5.12-6.19)a 
 ≥ 15 years                  252/4              4.34 (4.12-4.57)       6.11 (5.44-6.78)a
BMI (kg/m2)  
 Normal weight ( <25)             651/12               4.14 (3.98-4.31)      5.34 (4.40-6.28)b
 Overweight (25 to <30)              573/18                4.45 (4.25-4.65)      5.76 (4.91-6.60)b 
 Obese (≥30)                     668/12              4.41 (4.27-4.55)      5.70 (4.73-6.67)b 
Breastfed 
 No                                                554/15          4.71 (4.54-4.88)      6.03 (5.36-6.70)b 
 Yes                       831/19          4.43 (4.27-4.58)      5.34 (4.58-6.10)b 
Oral Contraceptive Use  
 No                             698/21                         4.87 (4.68-5.05)      5.98 (5.38-6.58)b 
 Yes                      1095/19          4.12 (3.99-4.26)      5.49 (4.65-6.33)b  
Ever Smoked   
 No                    1184/20         4.37 (4.24-4.51)      5.78 (5.20-6.35)a   
 Yes                      768/23          4.28 (4.10-4.46)      5.52 (4.77-6.26)b 
Alcohol Use   
 No                        784/16          4.47 (4.28-4.66)      6.16 (5.73-6.60)a 
 Yes                      1013/24         4.28 (4.15-4.42)      5.49 (4.69-6.29)b 
Education   
 < 12th grade                441/15         4.46 (4.26-4.67)      5.31 (4.38-6.25)   
 12th grade                    624/15          4.67 (4.42-4.91)      5.95 (5.52-6.39)a  
       
> 12th grade                888/13          4.16 (4.02-4.29)      5.72 (4.51-6.92)b  
Income  (yearly family income)     
 0-$24,999                     639/17          4.60 (4.41-4.80)      6.31 (5.80-6.82)a 
 $25,000-$74,999            772/14          4.19 (4.05-4.33)      5.14 (4.33-5.94)b 
 ≥ $75,000                                        323/7          4.23 (3.99-4.46)      5.30 (4.11-6.50)  
1Means calculated after applying NHANES sampling weights.   
2Sum of Dioxin-like PCBs = (074 +118);  Lipid adjusted and log transformed PCBs.   
3Age Standardized Dioxin-like- PCBs 
4Serum Dioxin-like Levels: < 50th percentile vs ≥ 50th percentile 
PCB levels significantly higher in women with breast cancer vs. women without breast cancer; ap < 0.0001, 
bp < 0.05 
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Table 1.6.  Serum Levels of non-dioxin-like PCBs (ng/g) in the study population, women ≥ 20 years of age, 
NHANES 1999-2004.   
              Mean1 (ng/g) (95% CI) 
Variable                           Noncase s/Cases           No Cancer      Breast Cancer     
Non-Dioxin-like PCBs2                               1941/43                        11.1 (11.0-11.3)   13.7 (13.0-14.5)a 
Non-Dioxin-like PCBs3                                        1941/43      11.2 (11.0-11.4)   13.2 (12.0-14.3)b 
Non-Dioxin-like PCBs_504                                    
    <LOD to 50%                                               967/2    8.56 (8.41-8.71)     9.62 (8.86-10.4)b  
    ≥ 50%                                                          974/41                        13.8 (13.7-13.9)     14.1 (13.6-14.6) 
Age                                    
20-59 years                        1354/7            10.3 (10.1-10.5)     12.9 (11.4-14.3)b  
60-74 years                          380/26          13.8 (13.5-14.1)    13.9 (13.1-14.6) 
≥ 75 years                    207/1 0           15.1 (14.6-15.5)    14.7 (13.9-15.4)     
Race/Ethnicity3                                  
 Non-Hispanic White              926/35          11.3 (11.1-11.5)     13.5 (12.8-14.3)a  
Other                          1015/8          10.8 (10.5-11.1)    15.8 (14.8-16.8)a  
Age at Menarche (years) 
 < 12 years                      340/6            11.0 (10.5-11.5)    13.4 (9.50-17.3) 
 12-14 years                 1145/30            11.1 (10.9-11.4)    13.8 (13.1-14.4)a  
 ≥ 15 years                        252/4           11.5 (11.1-11.9)    14.0 (12.0-16.0)b 
BMI (kg/m2)  
 Normal weight ( <25)              649/12            11.1(10.8-11.3)    13.8 (12.7-14.9)a 
 Overweight (25 to <30)               570/18               11.3 (11.0-11.6)    13.9 (13.0-14.8)a 
 Obese (≥30)                      664/12            10.9 (10.7-11.2)    13.4 (11.8-15.0)b 
Breastfed 
 No                                                       551/15          12.1 (11.8-12.4)    14.1 (13.2-14.9)a 
 Yes                         824/19          11.3 (11.1-11.6)    13.2 (12.1-14.3)b 
Oral Contraceptive Use  
 No                                     693/21                         11.9 (11.6-12.3)    14.1(13.4-14.8)a 
 Yes                         1090/19         10.8 (10.6-11.0)    13.4 12.1-14.7)b     
Ever Smoked   
 No                        1176/20          11.0 (10.7-11.2)    13.5 (12.4-14.5)a    
 Yes                            764/23          11.4 (11.1-11.7)    14.0 (13.2-14.8)a 
Alcohol Use   
 No                              781/16          11.3 (11.0-11.6)    14.3 (13.4-15.1)a  
  Yes                        1006/24          11.1 (10.8-11.3)    13.5 (12.3-14.6)b 
Education   
 < 12th grade                     435/15        11.4 (13.3-14.5)    13.9 (13.3-14.5)a   
 12th grade                         621/15        11.8 (11.3-12.2)    14.2 (13.2-15.2)a   
> 12th grade                     885/13        10.8 (10.6-11.0)    13.1 (11.0-15.2)b   
Income  (yearly family income)     
 0-$24,999                          635/17        11.5 (11.2-11.8)    14.5 (13.5-15.4)a  
   $25,000-$74,999                765/14         10.9 (10.6-11.1)    12.4 (11.0-13.9)a 
 ≥ $75,000                                                 323/7         11.1 (10.7-11.5)    14.5 (13.8-15.1)b  
1Means calculated after applying NHANES sampling weights.   
2Sum of non-Dioxin-like PCBs = (099 + 138 + 153 + 180); Lipid adjusted and log transformed PCBs.   
3Age Standardized Non-Dioxin-like PCBs. 
4Serum Non-Dioxin-like Levels: < 50th percentile vs ≥ 50th percentile. 
PCB levels significantly higher in women with breast cancer vs. women without breast cancer; ap < 0.0001, 
bp < 0.05. 
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GM and 95% CI’s of lipid-adjusted PCB levels are reported in table 1.7 for 
women with PCB levels < LOD and ≥ LOD. PCB congeners 74, 118, 138, 153, and 180 
did not have any breast cancer cases with PCB levels < LOD.  Women with PCB 
concentrations ≥ LOD who reported being diagnosed with breast cancer had significantly 
higher GM levels of PCB74 (16.0 ng/g vs 9.87 ng/g), PCB 99 (9.87 ng/g vs. 7.24 ng/g), 
PCB118 (17.5 ng/g vs 11.7 ng/g), PCB138 (39.6 ng/g vs. 23.6 ng/g), PCB153 (56.2 ng/g 
vs. 31.8 ng/g), and PCB180 (44.3 ng/g vs. 23.3 ng/g), compared to women who reported 
never being diagnosed with cancer (Table1.7).   
Table 1.7.  Geometric Mean PCB levels (ng/g) by cancer status among women ≥ 20 years of age, NHANES 
1999-2004 
        Geometric mean2(ng/g) (95% CI) 
                        No.      No.                           
 Analyte1                Noncases   Cases      No Cancer     Breast Cancer   
PCB 074 
 < LOD                    476     0       4.01 (3.90-4.13)              
  ≥ LOD                  1483     43      9.87  (7.24-13.5)   16.0 (12.1-21.3)b  
PCB 099 
 < LOD                  625     2       3.94 (3.82-4.01)   3.13 (3.03-3.25)  
 ≥ LOD                  1334     41      7.24 (4.85-10.8)   9.87 (8.50-11.5)b 
PCB 118   
 < LOD                  426     0       4.01 (3.90-4.14)         
 ≥ LOD                  1533     43       11.7 (9.03-15.3)   17.5 (9.12-33.4)b 
PCB 138       
 < LOD                  365     0       11.9 (11.0-12.8)        
 ≥ LOD                  1594     43       23.6 (18.5-30.3    39.6 (28.8-55.1)a  
PCB 153  
 < LOD                  309     0       16.4 (15.5-17.6)     
 ≥ LOD                  1651     43      31.8 (24.8-40.9)     56.2 (40.9-78.3)a 
PCB 180 
 < LOD                  355     0       7.69 (7.24-8.17)              
 ≥ LOD                  1599     43      23.3 (18.4-29.7)     44.3 (35.9-54.1)a  
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
GM PCB levels significantly higher in women with breast cancer vs. women without cancer; ap < 0.0001, 
bp < 0.05.  
 
 To account for the lack of breast cancer cases in women with low blood PCB 
levels and in women with blood PCB levels below the LOD, we divided lipid-adjusted 
PCB levels into the following two groups:  < LOD to 50th percentile and ≥ 50th percentile 
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(Table 1.8).  Women with PCB concentrations in first group (< LOD to 50th percentile) 
who reported a breast cancer diagnosis had significantly higher GM PCB levels 
compared to women who reported never being diagnosed with cancer for PCB congeners 
74 (5.58 ng/g vs. 4.26 ng/g), 138 (15.0 ng/g vs. 11.4 ng/g), 153 (23.3 ng/g vs. 15.3 ng/g), 
and 180 (21.1 ng/g vs. 10.5 ng/g) (Table 1.8).  GM PCB concentrations did not 
significantly differ between any breast cancer cases and non-cases in the second group (≥ 
50th percentile) (Table 1.8).   
Table 1.8.  Geometric Mean PCB levels (ng/g) by cancer status among women ≥ 20 years of age, NHANES 
1999-2004. 
        Geometric mean2(ng/g) (95% CI) 
                        No.      No.                              
Analyte1                 Noncases   Cases     No Cancer        Breast Cancer 
PCB 074 
 < LOD to 50%               1047        4     4.26 (4.10-4.44)       5.58 (4.39-7.17)b 
  ≥ 50%                    912       39     17.3 (16.6-18.0)     19.9 (17.1-23.1) 
PCB 099 
 < LOD to 50%              1172     12     3.74 (3.60-3.90)     4.48 (3.67-5.42) 
 ≥ 50%                     787     31       13.1 (12.4-13.6)     14.0 (11.7-16.6) 
PCB 118   
 < LOD to 50%                999         6     4.71 (4.53-4.85)     5.26 (4.48-6.23) 
 ≥ 50%                     960     37     21.5 (20.5-22.4)     24.3 (19.9-29.4) 
PCB 138       
 < LOD to 50%              1068       4     11.4 (10.9-11.9)      15.0 (13.2-19.1)b 
 ≥ 50%                     891     39     45.6 (43.8-47.5)      47.5 (41.3-54.1) 
PCB 153  
 < LOD to 50%              1078       4     15.3 (14.7-16.0)      23.3 (18.4-30.0)b 
 ≥ 50%                     882       39     64.1 (61.6-66.0 )        64.1(55.1-74.4) 
PCB 180 
 < LOD to 50%              1148       4     10.5 (9.97-10.9)     21.1 (16.9-26.0)a 
 ≥ 50%                     806     39     48.9 (47.0-50.4)      48.9 (42.1-56.8) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
GM PCB levels significantly higher in women with breast cancer vs. women without cancer; ap < 0.0001,  
bp < 0.05.  
 
We further divided lipid-adjusted GM PCB levels into the following three groups: 
< LOD to 50th percentile, 50th percentile to 75th percentile, and ≥ 75th percentile (Table 1. 
9).    Women in the first group (< LOD to 50th percentile) who reported a breast cancer 
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diagnosis had significantly higher GM levels of PCB 74 (5.58 ng/g vs. 4.26 ng/g),  
PCB138 (16.0 ng/g vs. 11.5 ng/g), PCB153 (23.3 ng/g vs. 15.5 ng/g), PCB170 (8.08 ng/g 
vs. 5.00 ng/g), PCB180 (21.1 ng/g vs. 10.5 ng/g), and PCB187 (6.05 ng/g vs. 3.90 n/g) 
compared to women who reported never being diagnosed with cancer (Table 1.9). GM 
PCB concentrations did not significantly differ between breast cancer cases and non-
cases in the second group (50th percentile to 75th percentile) or third group (≥ 75th 
percentile).   
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Table 1.9.  Geometric Mean PCB levels (ng/g) by cancer status among women ≥ 20 years of age, NHANES 
1999-2004.  
        Geometric mean2(ng/g) (95% CI) 
                        No.      No.                           
 Analyte1                 Noncases   Cases       No Cancer       Breast Cancer 
PCB 074 
 < LOD to 50%               1047     4       4.26 (4.10-4.44)    5.58 (4.39-7.17)b 
  50 – 75%                351     10      11.1 (10.9-11.5)    11.2 (10.1-12.8) 
  ≥ 75%                  561     29      24.5  (23.6-25.5)    25.3 (22.4-28.5) 
PCB 099 
 < LOD to 50%               1172     12      3.74(3.60-3.90)     4.48 (3.67-5.42) 
 50 – 75%                 357     10      8.58 (8.33-8.76)    8.50 (7.85-9.12) 
 ≥ 75%                   430     21      19.3(18.5-20.3)     18.0 (15.5-20.7) 
PCB 118   
 < LOD to 50%               999     6       4.71 (4.53-4.85)    5.26 (4.48-6.23) 
 50 – 75%                 388     9       12.7 (12.4-13.1)    12.8 (10.7-15.3) 
 ≥ 75%                   572     28      33.1 (31.5-34.8)    32.1 (27.4-37.7) 
PCB 138       
 < LOD to 50%              1068     4       11.5 (10.9-11.9)     15.0 (11.7-19.3)b 
 50 – 75%                 394     14      30.0 (29.7-30.6)      31.5 (28.8-34.8) 
 ≥ 75%                   497     25      67.4 (64.7-70.8)    62.8 (54.1-73.7) 
PCB 153  
 < LOD to 50%              1078     4       15.3 (14.9-16.0)     22.9 (16.9-30.6)b 
 50 – 75%                 383     14      43.8 (42.5-44.7)    44.3 (42.1-47.0) 
 ≥ 75%                   499     25      92.8 (89.1-96.5)    86.5 (75.9-98.5) 
PCB 180 
 < LOD to 50%              1148     4       10.5 (9.97-10.9)    21.1 (16.9-26.0)a 
 50 – 75%                 386     19      35.2 (34.5-35.9)    38.1 (34.8-41.3) 
 ≥ 75%                   420     20      72.2 (69.4-75.9)    69.4 (59.7-79.8) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
GM PCB levels significantly higher in women with breast cancer vs. women without cancer; ap < 0.0001,  
bp < 0.05.  
 
 
 Estimated ORs and 95% confidence intervals for the risk of having breast cancer 
and the six individual PCB congeners are shown in table 1.10. Due to the lack of breast 
cancer cases in women with low blood PCB levels and in women with blood PCB levels 
below the LOD, the following two groups were used to estimate breast cancer risk:  < 
LOD to 50th percentile (reference group) and ≥ 50th percentile. Results are presented for 
three logistic regression models: unadjusted; age, race/ethnicity, and BMI adjusted; and 
age, race/ethnicity, BMI, lactation, and age at menarche adjusted. In unadjusted models, 
PCBs were significantly associated with breast cancer risk for subjects in the second 
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group (≥ 50th percentile) when compared to the reference group (< LOD to 50th 
percentile) for PCB congeners 74, 99, 118, 138, 153, and 180 (Table 1.10).  After 
adjusting for age, race/ethnicity and BMI, PCB138 was found to be significantly 
associated with breast cancer [OR of 3.16 (95% CI: 1.14-8.76)  (Table 1.10).   After 
adjusting for age, race/ethnicity, BMI, lactation, and age at menarche, PCB138 and 
PCB180 were found to be significantly associated with breast cancer [OR of 2.88, 95% 
CI: 1.14-7.30 and OR of 4.54, 95% CI: 1.11-18.6], respectively (Table 1.10).  Adjusting 
for lactation and age at menarche decreased the sample size to 34 breast cancer cases and 
1324 and 1320 cancer noncases in PCB138 and PCB180, respectively.     
Table 1.10. Estimated ORs (95% CIs) of breast cancer by concentration of PCB levels among women ≥ 20 
years of age, NHANES 1999-2004. 
                                                                     
              No.     No.    Unadjusted OR        Adjusted OR2    Adjusted OR3 
Analyte1        Cases     Noncases    (95% CI)             (95% CI)     (95% CI) 
PCB 074       
< LOD to 50%       4    1047     1.00           1.00          1.00 
≥ 50%           39   912     5.82 (2.56-13.3)a     1.55 (0.46-5.24)   2.64 (0.59-12.0) 
PCB 099  
< LOD to 50%       12   1172     1.00             1.00          1.00 
 ≥ 50%           31   787     3.09 (1.60-5.98)b     1.39 (0.66-2.92)   1.67 (0.60-3.43) 
PCB 118  
 < LOD to 50%       6    999    1.00           1.00          1.00 
 ≥ 50%           37   960    4.34 (1.95-9.67)b    1.32 (0.38-4.65)   2.01 (0.48-8.44) 
PCB 138 
< LOD to 50%       4    1068    1.00           1.00          1.00 
 ≥ 50%            39   891    7.35 (3.10-17.4)a      3.16 (1.14-8.76)b   2.88 (1.14-7.30)b 
PCB 153 
< LOD to 50%       4    1078    1.00           1.00          1.00 
 ≥ 50%            39   882    9.20 (2.30-36.7)b      3.96 (0.59-26.4)   3.6 (0.73-18.6) 
PCB 180 
< LOD to 50%       4    1148    1.00           1.00          1.00 
 ≥ 50%           39   806    10.6 (3.03-37.1)b      4.61 (0.86-24.7)    4.54 (1.11-18.6)b 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age, race/ethnicity, BMI;  
 Cases/Noncases:  42/1898 in 74, 138, 180; 42/1900 in 099; 42/1899 in 153; 42/1894   in 180.   
3Adjusted for age, race/ethnicity, BMI, lactation, age at menarche;  
 Cases/Noncases:  34/1323 in 74; 34/1326 in 99, 118; 34/1324 in 138; 34/1325 in 153; 34/1320 in 180.   
 Significance ap < 0.0001, bp < 0.05. 
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ORs and 95% confidence intervals for breast cancer were further explored for 
subjects with PCB concentrations divided into the following three groups: < LOD to 50th 
percentile, 50th to 75th percentile, and ≥ 75th percentile (Table 1.11).  Subjects with PCB 
concentrations in the first group (< LOD to 50th percentile) were used as the reference 
group.  In all of the unadjusted models, a significant risk of breast cancer was found for 
subjects with PCB concentrations in the second group (50th to 75th percentile) for all six 
PCB congeners except PCB 99 and in the third group (≥75th percentile) (Table 1.11). In 
unadjusted models, the strongest associations with breast cancer risk among subjects in 
the third group (≥75th percentile) were found for PCB congeners 180, 153, 138, and 74 
[ORs of 10.0 (95% CI: 3.20-31.4), 9.99 (95% CI: 2.59-38.5), 8.49 (95% CI:  3.41-21.1), 
and 7.30 (95% CI: 3.08-17.3), respectively] (Table 1.11).  In age, race/ethnicity and BMI 
adjusted models, we found PCB138 significantly associated with breast cancer for 
subjects in the second (50th to 75th percentile) and third (≥75th percentile) groups:  [ORs 
of 2.93, 95% CI: 1.04-8.26 and 3.43, 95% CI: 1.13-10.4, respectively] (Table 1.11). 
However, this risk did not remain for either group after adjusting for age, race/ethnicity, 
BMI, lactation, and age at menarche.  Race/ethnicity was significantly associated with 
breast cancer in models for all six PCB congeners, however, only BMI category four (≥ 
30 kg/m2) was significantly associated with breast cancer in models for PCB congener 
180.  The association between individual PCBs and breast cancer was also examined in 
multiple variable adjusted models that included the covariates parity, oral contraceptive 
use, smoking status, alcohol use, education, and yearly family income, however these 
variables were not included in the final model because they significantly decreased the 
sample size and were not found to be significant predictors of breast cancer risk.   
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Table 1.11.  Estimated ORs (95% CIs) of breast cancer by concentration of PCB levels among women ≥ 20 
years of age, NHANES 1999-2004.  
                                                            
               No.      No.     Unadjusted OR    Adjusted OR2      Adjusted OR3 
Analyte1         Cases   Noncases    (95% CI)         (95% CI)                 (95% CI) 
PCB 074 
 < LOD to 50%       4    1047    1.00           1.00           1.00 
50% to 75%       10    351    3.96 (1.52-10.3)b    1.51 (0.44-5.17)    1.79 (0.29-10.8)
 ≥ 75%          29    561    7.30 (3.08-17.3)a    1.61 (0.42-6.17)    1.65 (0.24-11.4)
PCB 099 
 < LOD to 50%     12    1172    1.00           1.00           1.00 
 50% to 75%       10    357    2.12 (0.77-5.80)    1.12 (0.39-3.25)    1.26 (0.36-4.49)
≥ 75%          21    430    4.01 (2.16-7.47)a    1.63 (0.77-3.44)    1.64 (0.60-4.49)
PCB 118    
 < LOD to 50%     6     999    1.00           1.00           1.00  
 50% to 75%       9     388    2.98 (1.29-6.85) b    1.19 (0.31-4.58)    1.27 (0.21-7.79)
 ≥ 75%          28    572    5.48 (2.32-12.9) a    1.45 (0.40-5.24)    1.45 (0.26-7.92)
PCB 138      
 < LOD to 50%     4     1068    1.00           1.00           1.00 
 50% to 75%       14    394    6.17 (2.46-15.5)b    2.93 (1.04-8.26)b    1.93 (0.76-4.86)
 ≥ 75%          25    497    8.49 (3.41-21.1)a    3.43 (1.13-10.4)b       2.70 (0.90-8.09) 
PCB 153 
 < LOD to 50%     4     1078    1.00           1.00           1.00 
 50% to 75%       14    383    8.40 (1.75-40.3)b    3.82 (0.47-31.1)    2.57 (0.39-16.8)
 ≥ 75%          25    499    9.99 (2.59-38.5)b    4.14 (0.73-23.4)    3.28 (0.62-17.4)
PCB 180 
 < LOD to 50%     4     1148    1.00           1.00           1.00 
 50% to 75%       19    386    11.1 (2.63-46.6)b    5.00 (0.84-29.9)    3.60 (0.72-17.9)
 ≥ 75%          20    420    10.0 (3.20-31.4)a    3.89 (0.87-17.5)    2.77 (0.61-12.6)
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age, race/ethnicity, BMI; Breast Cancer Cases/Noncases:   
42/1898 in 74, 138, 180; 42/1900 in 99; 42/1899 in 153; 42/1894 in 180.   
3Adjusted for age, race/ethnicity, BMI, lactation, age at menarche; Breast Cancer Cases/Noncases:  
 34/1323 in 74; 34/1326 in 99, 118; 34/1324 in 138; 34/1325 in 153; 34/1320 in 180.   
Significance ap < 0.0001, bp < 0.05.  
 
Estimated ORs and 95% confidence intervals for the risk of having breast cancer 
and dioxin-like and non-dioxin-like PCBs are shown in table 1.12.  In the unadjusted and 
race/ethnicity adjusted models, dioxin-like PCBs were significantly associated with 
breast cancer [ORs of 1.50, 95% CI: 1.27-1.77 and 1.49, 95% CI: 1.24-1.79] as well as 
non-dioxin-like PCBs [ORs of 1.28, 95% CI: 1.18-1.38 and 1.29, 95% CI: 1.18-1.40], 
respectively.  After adjusting for age, race/ethnicity, and BMI, non-dioxin-like PCBs 
remained significantly associated with breast cancer risk [OR of 1.14, 95% CI: 1.00-1.29] 
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(Table 1.12).  Neither dioxin-like or non-dioxin-like PCBs remained significantly 
associated for breast cancer in the models after adjusting for age, race/ethnicity, BMI, 
lactation, and age at menarche (Table 1.12).    We further analyzed breast cancer risk of 
dioxin-like and non-dioxin-like PCBs using the following two groups:  < LOD to 50th 
percentile (reference group) and ≥ 50th percentile.  In subjects with PCB levels ≥ 50th 
percentile, breast cancer was significantly associated with dioxin-like and non-dioxin-like 
PCBs in the unadjusted models [ORs of 4.95, 95%CI: 2.36-10.4 and 11.6, 95% CI: 2.37-
57.2] and in the race/ethnicity adjusted models [ORs of 4.65, 95% CI: 2.00-10.8 and 
11.1, 95% CI: 2.24-55.1], respectively. The risk of breast cancer did not remain 
significant for these dioxin-like and non-dioxin-like PCBs after further adjustment for 
age, lactation, and age at menarche (Table 1.12).   
 
 
 
 
Table 1.12.  Estimated ORs (95% CIs) of breast cancer by concentrations of dioxin-like and non-dioxin-like PCBs among women ≥ 20 years of 
age, NHANES 1999-2004.  
                                                                                  
                                Unadjusted OR      Adjusted OR1        Adjusted OR2        Adjusted OR3 
                  Cases/Noncases          (95% CI)          (95% CI)                  (95% CI)            (95% CI) 
Dioxin-like PCBs4            43/1953     1.50 (1.27-1.77)a     1.49 (1.24-1.79)a     1.08 (0.84-1.40)         1.07 (0.78-1.49)+ 
 
Dioxin-like PCBs_504,6 
 < LOD to 50%             4/973       1.00            1.00            1.00             1.00 
 ≥ 50%                   39/979      4.95 (2.36-10.4)a     4.65 (2.00-10.8)b     1.47 (0.46-4.71)        1.58 (0.29-8.53)+ 
 
Dioxin-like PCBs_754,7 
 < LOD to 75%            12/1404      1.00            1.00            1.00               1.00 
 ≥ 75%                   31/543      5.08 (2.19-11.8)a     4.63 (2.17-9.89)a     1.71 (0.82-3.54)        1.45 (0.57-3.69)+ 
 
Non- Dioxin-like PCBs5       43/1941      1.28 (1.18-1.38)b     1.29 (1.18-1.40)a     1.14 (1.00-1.29)b       1.10 (0.94-1.29)++ 
 
Non-Dioxin-like PCBs_505,6 
 < LOD to 50%             15/1274      1.00            1.00            1.00              1.00 
 ≥ 50%                  45/1315      11.6 (2.37-57.2)a     11.1 (2.24-55.1)b     4.73 (0.92-4.50)       3.97 (0.52-22.3)++ 
 
Non-Dioxin-like PCBs_755,7 
 < LOD to 75%              2/967        1.00            1.00            1.00              1.00 
 ≥ 75%                     41/974       4.56 (2.35-8.83)a     4.43 (2.25-8.72)a     2.04 (0.92-4.50)       2.63 (0.88-7.87)++ 
1Adjusted for race/ethnicity. 
2Adjusted for age and race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, age at menarche, lactation. 
4Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (074 + 118). 
+34 breast cancer cases/1420 noncases. 
5Non-Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (099 + 138 + 153 + 180). 
 ++34 breast cancer cases/1312 noncases. 
6 Serum PCB Levels < 50th percentile vs ≥ 50th percentile.  
7Serum PCB Levels < 75th percentile vs ≥ 75th percentile.  
Significance ap < 0.0001, bp < 0.05.  
 
 
 
 
DISCUSSION 
This cross-sectional assessment of a representative sample of U.S. women 
demonstrated that higher body burdens of PCBs were significantly associated with breast 
cancer in the general population. We evaluated 6 individual PCB congeners, the sum of 
dioxin-like PCBs, and the sum of non-dioxin-like PCBs.  Analysis of GM levels of PCBs 
by breast cancer status, age, and race was done to assess PCB concentrations in 
subpopulations.  All PCB congeners and total PCBs showed an increasing trend with age.  
These results are supported by previously reported associations of PCB body burdens and 
age in women (Axelrad et al. 2009, Thompson et al. 2013).  While this may be a result of 
lower levels of PCBs in the environment today, it may also be due to the persistent nature 
of PCBs and increased accumulations in the human body over time.   In women who 
reported being diagnosed with breast cancer, women classified as ‘Other’ had 
significantly higher age standardized GMs of PCB than non-Hispanic white women.   
Higher PCB and DDE levels have been previously reported among African-American 
women compared with non-Hispanic white women by Millikan et al. (2013) and Zheng et 
al. (1999), respectively.  While race was found to be a protective factor against the odds 
of breast cancer for all non-Hispanic white women, the small number of nonwhite breast 
cancer cases limits the interpretation of the findings in this study.  Differences between 
races could be attributed to differences in diet and geographic locations.  While these 
results do not provide any evidence of causal associations, it is noteworthy that women 
diagnosed with breast cancer have higher levels of dioxin-like, non-dioxin-like, and 
individual PCB congeners compared to women who reported never being diagnosed with 
cancer.   
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A landmark UN report assessing effects of human exposure to hormone-
disrupting chemicals acknowledges that approximately 800 chemicals are suspected to 
act as endocrine disruptors or mimic natural hormones or disrupt hormone regulation 
(UNEP/WHO 2013).  This report highlights that there is some associations between 
exposures to many of the endocrine disruptors, particularly, estrogen-mimicking 
chemicals and an increased risk of breast cancer in women. Exposure to EDCs, such as 
PCBs, during early development of the breast can alter its development, and possibly 
contribute to the susceptibility to diseases through effects on stem cells.  
For women with detectable levels of blood PCBs, age adjusted GMs for PCB 
congeners (99, 138, 153, and 180) were significantly higher among breast cancer cases 
compared to noncases.  These findings are consistent with previously reported studies by 
Charlier et al. (2004) who found higher blood levels of PCB congeners 138 and 153, 
Demers et al. (2002) who found significantly greater concentrations of PCB congeners 
99, 118, and 156, and Recio-Vega et al. (2001) who found significantly higher 
concentrations of 11 PCB congeners (8,105, 118, 126, 128, 138, 170, 180, 195, 206, and 
209) in breast cancer cases compared to controls.  The sum of dioxin-like and non-
dioxin-like PCBs were also found to be significantly higher in breast cancer cases 
compared to noncases which is consistent with findings from Demers et al. (2002)  (sum 
of 105, 118, and 156) and Recio-Vega et al. (2001) (sum of 20 PCB congeners), however 
significance only remained for non-dioxin-like PCBs after we adjusted for age. Our 
results for age adjusted total PCBs are fairly consistent with epidemiological studies by 
Cohn et al. (2012), Gammon et al. (2002),  Gatto et al. (2007) and Wolff et al. (2000), 
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however, these comparisons are limited due to the difference in PCB congeners used in 
the sum of total PCBs and adjustment for confounding variables in each study.   
Breast cancer risk appeared to be highest in women with the highest PCB 
concentrations in unadjusted logistic regression models.  Only PCB 138 was found to be 
significantly associated with increased breast cancer risk after adjusting for age, 
race/ethnicity, BMI, lactation, and age at menarche.  There were no associations between 
the sum of dioxin-like and non-dioxin-like PCBs and breast cancer when models were 
adjusted for age, race/ethnicity, BMI, lactation, and age at menarche.  While these results 
are consistent with previous studies reporting age and multivariate adjusted ORs for 
breast cancer risk and PCBs (Gammon et al. 2002, Gatto et al. 2007, Wolff et al. 2000), a 
few studies have reported significant associations for specific PCB congeners or 
subpopulations  (Cohn et al. 2012, Millikan et al. 2103, Recio-Vega et al. 2001).  Cohn et 
al. (2012) found a significant association with breast cancer in women diagnosed before 
50 years of age for PCB 203 after adjusting for lipids, race, year, lactation, and body 
mass; Millikan et al. (2013) found a slightly elevated risk of breast cancer (OR=1.74, 
95% CI:1.00-3.01) in African American women after adjusting for age, age-squared, 
race, menopausal status, BMI, parity/lactation, HRT use, and income; and Recio-Vego et 
al. (2001) found the risk of breast cancer to be positively associated with eight PCB 
congeners: 118, 128, 138, 170, 180, 195, 206, and 209 and total PCBs (OR=1.09, 95% 
CI: 1.02-1.16) after adjusting for age, age at menarche, lactation, menopausal status, 
BMI, and family history.    
There are a number of limitations to our study, the most important of which is its 
cross-sectional design with self-reported data.  Self-reported data increases the risk of 
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misclassification bias of cases and controls, particularly in analyses of associations 
between PCBs and reproductive outcomes.  We also had a relatively small sample size 
for breast cancer cases resulting in decreased statistical power within subgroup analyses.    
Furthermore, observed associations could be potentially confounded by lack of 
information on geographical location of primary residence and family history of some of 
the variables.  Strengths of this cross-sectional study design include the large sample 
survey size, availability of biological measurements of environmental contaminants, and 
oversampling of minority populations that make it highly representative and 
generalizable to the U.S. population.   
CONCLUSION 
Based on our analysis of serum blood lipid PCB levels in the 1999-2004 
NHANES data cycles, biological levels of PCBs may contribute to breast cancer risk 
among U.S. women.  Despite the ban on PCB production, environmental exposures 
appear to pose significant threats on the reproductive health of the general population.   A 
single exposure to an internal or external environmental factor alone cannot explain the 
development of a complex chronic disease, such as breast cancer, rather it appears that 
exposure to multiple environmental and molecular factors across the lifespan and their 
interactions influence the development of these chronic diseases in an individual. Given 
the proven contribution of unopposed estrogens to the risk for breast cancer, it is 
biologically plausible that altered endogenous estrogen levels presumably from exposure 
to estrogen mimicking EDCs may contribute to the risk of disease.  Findings of this study 
are based on the use of cross-sectional self-reported data.  Thus, further research is 
needed to assess specific biological mechanisms of reproductive health outcomes and 
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cancer development in relation to PCB biomarker levels among women in the general 
population. 
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CHAPTER V 
MANUSCRIPT 2 
 ASSOCIATION OF POLYCHLORINATED BIPHENYLS, ENDOMETRIOSIS 
AND UTERINE LEIOMYOMAS AMONG U.S. WOMEN:  NHANES 1999-2004 
ABSTRACT 
Background:  It is estimated that endometriosis occurs in 10% of women and is the most 
common cause of infertility in the United States.  Uterine leiomyomas are the most 
common benign tumors in women and leading cause of hysterectomies.   There is 
considerable evidence that endometriosis and uterine leiomyomas are estrogen dependent 
diseases.  The estrogenic activity of polychlorinated biphenyls (PCBs) may play a role in 
the development of these diseases.     
Objectives: The purpose of this study was to examine the cross-sectional relationship 
between exposure to PCBs and endometriosis and uterine leiomyomas among U.S. 
women. 
Methods:  We analyzed data from female participants (20-54 years of age) who provided 
blood samples for the Centers for Disease Control and Prevention’s National Health and 
Nutrition Examination Survey (NHANES) between 1999 and 2004. Exposure was based 
on lipid adjusted serum levels of 6 individual PCB congeners (74, 99, 118, 138, 153, and 
180), the sum of dioxin-like PCBs (074 + 118), and the sum of non-dioxin-like PCBs 
(099 + 138 + 153+187) in conjunction with data obtained from the reproductive health 
questionnaire.  We calculated geometric means to compare PCB concentrations in 
women who self-reported an endometriosis or uterine leiomyoma diagnosis vs. women 
who self-reported never being diagnosed with endometriosis or uterine leiomyomas. We 
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used logistic regression models to estimate odds ratios (ORs) and 95% confidence 
intervals (CIs) of endometriosis and uterine leiomyomas by concentration of lipid-
adjusted serum PCBs.  We evaluated age, race/ethnicity, body mass index (BMI; kg/m2), 
age at menarche, oral contraceptive use, parity, smoking status, and alcohol consumption 
as potential confounders.   
Results: Separate analyses showed weighted geometric mean levels of PCB congeners 
138, 153, and 180 to be significantly higher among women diagnosed with endometriosis 
and geometric mean levels of PCB congeners 74, 99, 118, 138, 153, and 180 to be 
significantly higher among women diagnosed with uterine leiomyomas compared to the 
rest of the study population. Dioxin-like PCBs were found to be significantly higher in 
women diagnosed with uterine leiomyomas and non-dioxin-like PCBs were found to be 
significantly higher in women diagnosed with endometriosis and uterine leiomyomas 
compared to women who were not diagnosed.  After adjusting for age, race, BMI, parity, 
age at menarche, oral contraceptive use, alcohol, and smoking status we found that PCB 
74 and 118 were significantly associated with uterine leiomyomas [ORs of 1.91; 95% CI: 
1.10-3.29 and 1.91, 95% CI:1.13-3.22] in women with higher body burdens of individual 
PCB congeners (< LOD vs. ≥ LOD), respectively.  PCB 180 was also found to be 
significantly associated with uterine leiomyomas for women in the second tertile (33rd to 
66th %ile)  [OR of 1.87, 95% CI: 1.15-3.02].  We did not find endometriosis to be 
significantly associated with any PCBs in the adjusted logistic regression models.  
Conclusions: Our results suggest a link between environmental exposures to PCBs and 
increased risk of uterine leiomyomas among women in the general U.S. population.   
Keywords:  PCBs, NHANES, endometriosis, uterine leiomyomas.  
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MANUSCRIPT 2 
ASSOCIATION OF POLYCHLORINATED BIPHENYLS, ENDOMETRIOSIS, 
AND UTERINE LEIOMYOMAS AMONG U.S. WOMEN:  
NHANES DATA 1999-2004 
INTRODUCTION 
 Endometriosis and uterine leiomyomas are estrogen dependent disorders 
associated with pelvic pain, significant morbidity, and infertility (Borah et al. 2013, 
Parker et al. 2007, Buttram and Reiter 1981).  They are both common disorders among 
reproductive women with prevalence estimates in premenopausal women of 10% and 
30% for endometriosis and uterine leiomyomas, respectively (Baird et al. 2003, Ezkenazi 
and Warner 2008, Diamanti-Kandarakis et al. 2009).  Endometriosis is characterized by 
growth of tissue outside the uterus and uterine leiomyomas, also known as uterine 
fibroids, are benign tumors of the smooth muscle cells found in the human uterus.  Both 
are the leading indication of hysterectomy in the United States (Farquhar and Steiner 
2002).  Through research on hormone contraception, postmenopausal hormonal therapies 
and estrogen-receptor (ER)-based endocrine therapies, we know estrogens are a major 
risk factor for endometriosis and uterine leiomyomas (Evans et al. 2008, Lin et al. 2009, 
Bertelsen et al. 2007, Hodges et al. 2006).  
 There is a renewed concern that exposure to environmental chemicals that act as 
endocrine disruptors (EDs) and  mimic natural hormones or disrupt hormone regulation   
are associated with an increased risk of endometriosis and reproductive dysfunction  in 
women (UNEP/WHO 2013, EU 2013).   Of particular concern are the estrogen-
mimicking EDs, such as polychlorinated biphenyls, that are persistent in the environment, 
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highly lipophilic, and readily bio-accumulate and magnify within the food chain (Roy et 
al. 1997, Roy et al. 1998). Polychlorinated biphenyls (PCBs) are a group of synthetic 
organic chemicals with half-lives ranging from a few months to a few decades depending 
on PCB chlorination, age, body fat, and breast feeding (Calafat et al. 2008, Woodruff et 
al. 2011, Silva et al. 2004).  PCBs have been shown to interfere with reproductive 
function and development in animals and humans by either increasing or blocking 
estrogen activity (Fielden et al. 2001, Ma and Sassoon 2006, McLachlan et al. 2006). 
Adverse reproductive health effects have been established in a number of animal studies 
and have linked PCB exposure to decreased sperm fertilizing ability in mice (Fielden et 
al. 2001), changes in the uterine myometrium and gland formation in mice (Ma and 
Sassoon 2006), and a significant dose-dependent relationship in the prevalence and 
severity of endometriosis in rhesus monkeys (Rier et al.2001).   
 Epidemiologic studies demonstrating the association between exposure to EDCs 
and endometriosis are limited and conflicting. Three case-control studies found 
significant associations between exposure to total PCBs and risk of endometriosis (Buck 
Louis et al. 2005, Porpora et al. 2009, Heiler et al.2005).  Buck Louis et al. (2005) found 
a significant increased risk of endometriosis for the sum of anti-estrogenic PCBs for 
women in the third tertile (OR=3.77, 95% CI 1.12-12.68), however, the risk remained 
elevated but not significant when adjusted for all listed covariates. Porpora et al. (2009) 
found the GM of total PCBs to be significantly higher in cases than controls (301.3 vs. 
203.0, p < 0.01) and the OR of endometriosis risk in the highest tertile of total PCBs 
compared with the lowest tertile, was 5.63 (95% CI 2.25-14.10).  Significant increased 
risk of endometriosis was also found for PCB congeners 118, 138, 153, and 170.   In a 
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case-control study conducted by Heiler et al. (2005) dioxin-like PCB concentrations were 
higher in women with deep endometriotic (DE) nodules compared to controls (12.4 vs. 
8.5, p = .026) but did not significantly differ for women with peritoneal endometriosis 
(PE) compared to controls (11.0 vs. 8.5) and for women with DE compared to women 
with PE (12.4 vs. 11.0).   
 In contrast, a number of case-control studies have failed to find significant 
associations between endometriosis and exposure to individual PCB congeners, total 
PCBs, or specific sub-groups (Niskar et al. 2009, Pauwels et al. 2001, Trabert et al. 2010, 
Tsukino et al. 2005). Niskar et al. (2009) conducted a case-control study with 60 
confirmed endometriosis cases staged as I (minimal), II (mild), III (moderate), and IV 
(severe) and 30 controls.  Mean lipid-adjusted PCB concentrations were not significantly 
different (179.98 vs. 217.33 vs. 194.76 vs. 193.37) between stage I-II cases, stage III 
cases, stage IV cases, and controls, respectively. In the largest case-control study, 
conducted by Trabert et al. (2010), total PCBs (n=20), estrogenic PCBs (n=6), and 
individual PCB congeners were measured in the serum from 251 cases and 538 controls, 
matched for age and reference year.  Adjusted total and estrogenic PCBs in the highest 
quartiles were not associated with an increased risk of endometriosis (Total:  OR=1.2, 
95% CI 0.6-2.3, Estrogenic: OR=0.9, 95% CI 0.5-1.4).  In two case-control studies 
measuring median TEQ values (pg TEQ/g lipid) Pauwels et al. (2001) found no 
association between endometriosis and the median TEQ values (pg TEQ/g lipid) in cases 
and controls (29 vs. 27) and Tsukino et al. (2005) found no difference in median TEQ 
values for endometriosis cases (stage II-IV) and controls (stage 0-I) (cPCBs: 3.40 vs. 
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3.59, PCBs: 4.61 vs. 5.14), respectively.  The OR of endometriosis risk in the highest 
quartile of total PCBs compared with the lowest quartile was 0.41 (95% CI 0.14-1.27). 
 Epidemiological studies pertaining to PCBs and uterine leiomyomas are limited. 
Trabert et al. (2014)  found PCB 99 (OR of 1.64, 95% CI: 1.08-2.49), PCB 138 (OR of 
1.64, 95% CI: 1.03-2.59), PCB 146  (OR of 1.54, 95% CI: 1.01-2.37), PCB 153 (OR of 
1.88, 95% CI: 1.12-3.13), PCB 196 (OR of 1.60, 95% CI: 1.02-2.51), and PCB 206 (OR 
of 1.52, 95% CI: 1.01-2.29) to be associated with fibroids but only in the absence of 
endometriosis.      
 In this study, we examined the relationship between 6 individual PCB congeners, 
the sum of dioxin-like PCBs, and the sum of non-dioxin-like PCBs with self-reported 
endometriosis and uterine leiomyomas in female subjects participating in the National 
Health and Nutrition Examination Survey (NHANES) between the years 1999-2004.  The 
objectives of this study were to: 1) describe the mean PCB levels in women (20-54 years 
of age) diagnosed with endometriosis or uterine leiomyomas compared to women not 
diagnosed with endometriosis or uterine leiomyomas; and 2) assess the association 
between higher body burdens of PCBs and increased risk of endometriosis or uterine 
leiomyomas.    
METHODS 
Study design and population. NHANES is an ongoing cross-sectional survey designed to 
be nationally representative of the non-institutionalized U.S. civilian population.  
Conducted annually since 1999 by the National Center for Health Statistics of the Centers 
for Disease Control and Prevention (CDC), NHANES uses a complex multi-stage 
sampling design where approximately 5,000 survey participants a year complete in-home 
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interviews and physical examinations in mobile examination units (CDC, 2012). 
Sociodemographic information and medical histories were collected during the in-home 
interview and biological samples and reproductive health information was collected in 
the mobile examination component (MEC). All participants provided written informed 
consent and all procedures were approved by the National Center for Health Statistics 
(NCHS) Institutional Review Board (CDC, 2012).  We merged data from the 1999-2000, 
2001-2002 and 2003-2004 survey cycles. We limited our analysis to women 20 to 54 
years of age who completed the reproductive questionnaire in a face-to-face interview at 
a mobile examination center.  
PCB measurements.  Blood serum concentrations of individual PCB congeners were 
measured in a representative, random one-third subsample of people 12 years of age and 
older in the 1999-2000, 2001-2002, and 2003-2004 survey cycles. PCB congeners were 
measured in serum by high-resolution gas chromatography/isotope-dilution high-
resolution mass spectrometry (HRGS/ID-HRMS).   NHANES provides both wet-weight 
and lipid adjusted values for each sample, corrected for sample weight and analyte 
recovery; we used lipid adjusted values in our analyses.  Detailed laboratory methods 
were consistent among survey cycles and are available online (CDC 2013b).   A detection 
limit variable is provided for all PCB congeners in the data set.  The variable LBD_LC 
has two values:  the value “0” indicates that the result was below the limit of detection 
and the value “1” indicates that the result was at or above the limit of detection.  Any 
participant with a serum PCB concentration below the limit of detection was assigned a 
serum level of the LOD divided by the square root of two.  Limits of detection vary by 
individual PCB congener and survey cycle and can be found in the CDC’s Fourth 
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National Report on Human Exposure to Environmental Chemicals (CDC 2103).  Lipid-
adjusted serum concentrations (ng/g) for 6 individual PCB congeners as well as the sum 
of the dioxin-like PCBs (74 + 118) and the sum of non-dioxin-like PCBs (99 + 138 +153 
+ 180) were used in this study.  PCB congeners 74, 99, 118, 138, 153, and 180 were 
selected because they were available in all three survey cycles and concentrations were 
above the limit of detection (LOD) in > 60% of the survey participants.   
Diagnosis of endometriosis and uterine leiomyomas.  We included female 1999-2004 
NHANES participants 20 to 54 years of age who completed the self-reported medical 
health questionnaire and provided a response for “Have you ever been told by a doctor or 
other health professional that you had endometriosis?” and “Have you ever been told by a 
doctor or other health professional that you had uterine fibroids?”.  Women who 
answered “yes” were subsequently asked “How old were you when you were first told 
you had endometriosis?” Questions pertaining to endometriosis and uterine leiomyoma 
diagnosis were restricted to women 20 to 54 years of age in the NHANES datasets.  PCB 
measurements were available in 80 women who reported an endometriosis diagnosis for 
PCB congeners 74, 99, 118, 138 and 153, and in 79 women for PCB 180.  PCB 
measurements were available in 1073 women who reported never being diagnosed with 
endometriosis for PCBs 74, 153 and 180, and in 1,074 women for PCBs 99, 118, and 
138.  PCB measurements were available in 148 women who reported a diagnosis of 
uterine leiomyomas for PCB congeners 74, 118, and 180, and in 149 women for PCBs 
99, 138, and 153.  PCB measurements were available in 1004 women who reported never 
being diagnosed with uterine leiomyomas for PCBs 153 and 180, in 1005 women for 
PCBs 74, 99 and 138, and in 1,006 women for PCB 118.   The sum of dioxin-like PCBs 
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was available in 80 endometriosis cases and 1,071 endometriosis non-cases and in 147 
uterine leiomyoma cases and 1004 uterine leiomyoma  noncases.  The sum of non-dioxin-
like PCBs was available in 79 endometriosis cases and 1,067 endometriosis noncases and 
in 148 uterine leiomyoma cases and in 998 uterine leiomyoma noncases.   
Statistical analysis.  All statistical analyses were performed using SAS system software 
(release 9.2; SAS Institute Inc. Cary, N.C.).  A six year subsample weight was calculated 
according to the National Center for Health Statistics guidelines to adjust for 
oversampling of minority groups in the merged 1999-2004 NHANES data cycles (CDC 
2013b). Nonmissing values for serum concentrations below the LOD were assigned a 
serum level of the LOD divided by the square root of two.  In our analysis, all lipid-
adjusted serum PCB concentrations were log transformed to satisfy normality 
assumptions.   Participants were categorized the following ways depending on data 
analysis: < LOD vs. ≥ LOD and tertiles:   < LOD to < 33rd percentile, ≥ 33rd percentile to 
66th percentile, and ≥ 66th percentile.  Significance was set at p < 0.05 for all analyses.   
 We used PROC SURVEYMEANS to account for the complex sampling design of 
NHANES and to obtain weighted means, 95% CIs, and standard errors of individual PCB 
congeners, the sum of dioxin-like PCBs, and the sum of non-dioxin-like PCBs. We used 
the Taylor Series (linearization) method to estimate standard errors.   A two-sided student 
t-test was calculated using PROC SURVEYREG to test whether the mean PCB levels 
between women who reported an endometriosis or uterine leiomyoma diagnosis and 
women who reported no endometriosis or uterine leiomyoma diagnosis were significantly 
different. Geometric mean (GM) PCB levels and geometric standard errors (GSE) were 
reported for endometriosis and uterine leiomyoma status, age at time of interview (years), 
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and race/ethnicity for all participants.  Serum levels of dioxin-like and non-dioxin-like 
PCBs and their 95% CIs were reported for endometriosis and uterine leiomyoma status 
and select confounding variables (age, race, BMI, parity, age at menarche, alcohol 
consumption and smoking status).  Age was divided into four groups (20-29 years, 30-39 
years, 40-49 years, and 50-54 years), race/ethnicity was divided into three groups (non-
Hispanic White, non-Hispanic Black and ‘Other’).  The category of ‘Other’ includes 
Mexican American, Other Hispanic and Other Race – Including Multi-Racial. To account 
for the different age structures among ethnicities in our study population, we presented 
age standardized GM PCB levels for race/ethnicity in individual PCB congeners and age 
standardized arithmetic mean dioxin-like and non-dioxin-like PCB levels for 
race/ethnicity.  We used the direct method for age standardization provided by the CDC 
(CDC 2014).   
   Using PROC SURVEYLOGISTIC, we derived unadjusted and adjusted ORs 
and their 95% CIs to evaluate the association between exposure to PCBs and 
endometriosis and uterine leiomyomas.  We conducted separate analyses for the sum of 
dioxin-like and non-dioxin-like PCBs and individual PCB congeners and endometriosis 
and uterine leiomyomas.  ORs were calculated using the following groups: < LOD vs. > 
LOD and tertiles (< LOD to 33rd percentile vs. 33rd percentile to 66th percentile vs. ≥ 66th 
percentile).     The reference group for each PCB congener is defined as those participants 
whose serum concentrations were < LOD or < LOD to 33rd percentile depending on the 
analysis.   
Covariates.  We considered a number of potential confounders based on previous 
literature and well-established risk factors for endometriosis. The following potential 
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confounders were either self-reported in the questionnaire interviews or taken as a 
laboratory measurement.  The demographic variables of age at interview (20-29, 30-39, 
40-49, and 50-54 years) and race (non-Hispanic White, non-Hispanic Black, Other) were 
obtained during the NHANES home interview (CDC 2012).  Reproductive variables 
including age at menarche (<12 years, 12-14 years, ≥15 years), parity (0, 1, ≥ 2), number 
of live births (0, 1, ≥ 2), oral contraceptive use (yes/no), having undergone a 
hysterectomy (yes/no), having undergone a oophorectomy (yes/no) as well as lifestyle 
variables including smoking (yes/no) and alcohol use (yes/no) were obtained from health 
questionnaires completed in the mobile examination center. Body mass index (< 25 
kg/m2, 25 to < 30 kg/m2, and ≥ 30 kg/m2) was obtained through the body measurement 
component in the mobile examination center (CDC 2012). For individual PCB congeners, 
the sum of dioxin-like PCBs and the sum of non-dioxin-like PCBs, ORs and 95% CIs are 
reported for three models: unadjusted; age and race/ethnicity adjusted; and age, 
race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, and 
alcohol adjusted.  
RESULTS 
Descriptive statistics. The study population included 1,154 female participants 20-
54years of age and older who completed the medical questionnaire and provided a 
response for “Have you ever been told by a doctor or other health professional that you 
had endometriosis?” and “Have you ever been told by a doctor or other health 
professional that you had uterine fibroids?” Women who answered “yes” were 
subsequently asked, “What was your age at diagnosis?” Among the 1,154 female 
participants who responded to those two questions and had available PCB data, 1,074 
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reported never being diagnosed with endometriosis, 80 reported being diagnosed with 
endometriosis, 1,005 reported never being diagnosed with uterine leiomyomas, and 149 
reported being diagnosed with uterine leiomyomas (Table 2.1). The majority of 
participants were of non-Hispanic white ethnicity (44.9%).  A diagnosis of endometriosis 
occurred in 4.59% of non-Hispanic white women, 1.13% of non-Hispanic black women, 
and 1.21% of women from ‘Other’ races.  A diagnosis of uterine leiomyomas occurred in 
5.11% of non-Hispanic white women, 4.59% of non-Hispanic black women, and 3.21% 
of women from ‘Other’ races (Table 2.1). The mean age at time of interview was 37.2 
years for the overall population, 41.0 and 44.3 years for women who an endometriosis or 
uterine leiomyoma diagnosis and 36.8 and 35.9 years for women who reported never 
being diagnosed with endometriosis or uterine leiomyoma, respectively.  The mean age at 
endometriosis diagnosis was 29.0 years and the mean age at uterine leiomyoma diagnosis 
was 38.8 years (Table 2.1).  The majority of endometriosis and uterine leiomyoma cases 
were reported from women in the 30-39 and 40-49 year old age groups.   BMI was 
normal (< 25 kg/m2) for 37.5%, overweight (25to < 30 kg/m2) for 26.3%, and obese (≥ 30 
kg/m2) for 36.2% of study participants.  Age of menarche was < 12 years of age for 
22.9%, 12-14 years for 65.5%, and ≥ 15 years for 11.6% of study participants.  The 
majority of study participants reported ≥ 2 live births (67.9%), responded yes to oral 
contraceptive use (72.7%) ,  responded no to having a hysterectomy (81.2%), responded 
no to having a oophorectomy (93.1%), responded no to a history of smoking (61.1%) and 
yes to alcohol consumption (61.7%) (Table 2.1).  
 
 
 
 
 
 Table 2.1.  Descriptive statistics for endometriosis and uterine leiomyomas in the study population, women 
20-54years of age, NHANES 1999-2004.   
                                          No          Uterine    No Uterine 
                    Overall      Endometriosis Endometriosis    Leiomyomas   Leiomyomas 
Variable                                  n(%)            n(%)        n (%)       n(%)        n(%) 
Total Population (n,%)         1154  (100%)   80 (6.93%)   1074 (93.1%)    149(12.9%)  1005 (87.1%)
Age at interview ( mean ± sd)     37.2 ± 0.40     41.0 ± .89    36.8 ± .43     44.3 ± .65   35.9 ± .42 
Age at diagnosis (mean ±sd)                29.0 ± .62             38.8 ± .79 
Race/Ethnicity           
 Non-Hispanic white       518 (44.9%)       53 (4.59%)  465 (40.3%)    59 (5.11%)   460 (39.8%) 
 Non-Hispanic black      221 (19.2%)    13 (1.13%)   208 (18.0%)    53(4.59%)   168 (14.6%) 
Other              415 (36.0%)    14 (1.21%)   401 (34.8%)    37 (3.21%)   378 (32.8%) 
Age at interview (years)         
 20-29              386 (33.5%)      12 (1.04%)   374 (32.4%)    10(0.87%)    376 (32.6%)
30-39             354 (30.7%)     25 (2.17%)   329 (28.5%)    32 (2.77%)   323 (27.9%) 
40-49             283 (24.5%)    30 (2.60%)   253 (21.9%)    67 (5.81%)   216 (18.7%) 
50-54             131 (11.4%)    13 (1.13%)     118 (10.2%)    40 (3.47%)   91 (7.89%) 
BMI (kg/m2)   
 Normal weight ( <25)       428 (37.5%)      24 (2.11%)   404 (35.4%)    43 (3.77%)   385 (33.8%) 
 Overweight (25 to <30)        300 (26.3%)        23 (2.02%)   277 (24.3%)     38 (3.33%)   263 (23.0%) 
 Obese (≥30)               412 (36.2%)       32 (2.81%)     380 (33.3%)    68 (5.96%)   344 (30.2%) 
Parity (no. of live births)  
 0                                      64 (5.94%)    9 (0.84%)        55 (5.11%)     10 (0.93%)   54 (5.01%) 
 1                                       282 (26.2%)    28(2.60%)     254 (23.6%)    25 (2.32%)   257 (23.9%) 
 ≥ 2                                 731 (67.9%)    41 (3.81%)     690(64.1%)     112 (10.4%)  619 (57.5%) 
Age at menarche (years)  
 < 12                                    258 (22.9%)    22 (1.95%)       236(20.9%)     45 (3.99%)   213 (18.9%) 
 12-14                                 740 (65.5%)    52 (4.61%)     688 (60.9%)    87 (7.71%)   653 (57.8%) 
 ≥  15                                      131 (11.6%)      5 (0.44%)     126 (11.2%)    14 (1.24%)   117 (10.4%) 
Oral contraceptive use     
 Yes                837 (72.7%)      72 (6.24%)     765 (66.4%)    125 (10.9%)  712 (61.8%) 
No                      315 (27.3%)    8 (0.69%)     307 (26.7%)    24 (2.08%)   291 (25.3%) 
Hysterectomy  
 Yes                 102 (18.9%)    29(5.36%)   73 (13.5%)     49 (9.06%)   53 (9.80%) 
 No                 439 (81.2%)    27 (4.99%)     412 (76.2%)    37 (6.84%)   402 (74.3%) 
Oophorectomy – at least one ovary removed.  
 Yes               79 (6.86%)        25 (2.17%)     54 (4.69%)     34 (2.95%)   34 (2.95%)  
 No               1072 (93.1%)      55 (4.78%)     1017 (88.4%)    113 (9.82%)  113 (9.82%) 
Alcohol Use  
 Yes                                712 (61.7%)       24 (2.08%)    418 (36.2%)    52 (4.51%)   390 (33.8%) 
No                  442 (38.3%)     56 (4.85%)     656 (56.9%)    97 (8.41%)   615 (53.3%) 
Ever Smoked  
 Yes                  449 (38.9%)     44 (3.82 %)   660 (57.2%)     88 (7.63%)   616 (53.4%) 
 No                  704 (61.1%)     36 (3.12%)      413 (35.8%)    61 (5.29%)   388 (33.7%) 
Estimated percent distribution  after applying NHANES sampling weights.
 
Table 2.2 presents GMs and GSEs of lipid adjusted PCBs by endometriosis and uterine 
leiomyoma diagnosis for all study participants. GM PCB levels were significantly higher 
for PCB congeners 138, 153, and 180 in women who reported a diagnosis of 
endometriosis compared to women who reported no diagnosis (Table 2.2). Overall GM 
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levels of individual blood PCBs ranged from 4.90 ng/g lipid to 21.3 ng/g lipid in women 
who reported never being diagnosed with endometriosis and from 5.31ng/g lipid to 27.1 
ng/g lipid in women who reported being diagnosed with endometriosis, with the lowest 
levels observed for PCB 99 and the highest levels observed for PCB 153 (Table 2.2; 
Figure 2.1).  GM PCB levels were significantly higher for all 6 PCB congeners in women 
who reported a diagnosis of uterine leiomyomas compared to women who reported no 
diagnosis (Table 2.2). Overall GM levels of individual blood PCBs ranged from 4.81 
ng/g lipid to 20.3 ng/g lipid in women who reported never being diagnosed with uterine 
leiomyomas and from 5.99 ng/g lipid to 33.1 ng/g lipid in women who reported no 
diagnosis, with the lowest levels observed for PCB 99 and the highest levels observed for 
PCB 153 (Table 2.2; Figure 2.2).   
 
 
Figure 2.1.  Lipid adjusted geometric mean PCB levels (ng/g) by endometriosis status 
among women 20-54 years of age, NHANES 1999-2004.   
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Figure 2.2.  Lipid adjusted geometric mean PCB levels (ng/g) by uterine leiomyoma 
status among women 20-54 years of age, NHANES 1999-2004.  
 
 Table 2.3 presents age standardized GMs and GSEs of lipid adjusted PCBs by 
race/ethnicity in participants with endometriosis data.  Non-Hispanic black women who 
reported being diagnosed with endometriosis had significantly higher GM PCB levels for 
PCB 138 and 180 compared to non-Hispanic White women (Table 2.3).  In women who 
reported never being diagnosed with endometriosis, non-Hispanic black women had 
significantly higher levels of  PCB congeners 99, 118, 138, 153, and 180 compared to 
non-Hispanic white women and significantly higher levels of all 6 PCB congeners 
compared  to women classified as ‘Other’ (Table 2.3).  Non-Hispanic white women not 
diagnosed with endometriosis had significantly higher levels of PCB 74, 118, 138, 153, 
and 180 compared to women classified as ‘Other’ (Table 2.3).   
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Table 2.3.  Age standardized geometric mean PCB levels (ng/g) for race by endometriosis diagnosis among women 
20-54 years of age, NHANES 1999-2004. 
                             Geometric mean2 (ng/g) (GSE, n)   
                  Non-Hispanic Black                             Non-Hispanic White            Other Races 
   No                                            No            No 
Analyte1          Endometriosis      Endometriosis         Endometriosis       Endometriosis        Endometriosis   Endometriosis 
PCB 074   6.89 (1.05, 207)e       6.42(1.14, 13)       6.17 (1.04, 464)f     5.87 (1.08, 53)     5.16 (1.04, 402)  6.42 (1.14, 14) 
PCB 099   6.82 (1.05, 207)c,e   5.53(1.07, 13)    4.90 (1.04, 466)f     4.66 (1.08, 53)   4.44 (1.04, 401)   5.16 (1.13, 14) 
PCB 118        8.67 (1.06, 208)d,f   6.96 (1.15, 13)        6.75 (1.04, 465)       6.75 (1.11, 53)   6.69 (1.06, 401)   8.17 (1.15, 14) 
PCB 138          22.0 (1.05, 208)c,e     19.9 (1.09, 13)d    15.6 (1.04, 465)f     14.9 (1.09, 53)    14.0 (1.04, 401)  20.3 (1.16, 14) 
PCB 153          29.1 (1.05, 208)d,e      27.7 (1.08, 13)       21.9 (1.04, 465)f     21.3(1.09, 53)    18.5 (1.04, 400)  27.7 (1.15, 14) 
PCB 180          16.8 (1.04, 208)d,e   16.6 (1.11, 13)d,     14.3 (1.04, 463) f  14.9 (1.11, 52)   11.8 (1.04, 402)      18.0 (1.14, 14) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
GM PCB levels significantly higher in women with endometriosis vs. women without endometriosis; 
 ap < 0.0001, bp < 0.05. 
GM PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white women;  
cp < 0.0001, dp < 0.05. 
GM PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to ‘Other’ women;
 ep < 0.0001, fp < 0.05.  
Table 2.4 presents age standardized GMs and GSEs of lipid adjusted PCBs by 
race/ethnicity in participants with uterine leiomyoma data.  Non-Hispanic black women 
who reported being diagnosed with uterine leiomyomas had significantly higher GM 
PCB levels for PCB 99, 118, 138, 153, and 180 compared to non-Hispanic White women 
and higher levels of PCB 99 compared to women classified as ‘Other’ (Table 2.4).   In 
women who reported never being diagnosed with uterine leiomyomas, non-Hispanic 
black women had significantly higher levels of  PCB congeners 99, 118, 138, 153, and 
180 compared to non-Hispanic white women and significantly higher levels of all 6 PCB 
congeners compared  to women classified as ‘Other’ (Table 2.4).  Non-Hispanic white 
women not diagnosed with uterine leiomyomas had significantly higher levels of PCB 
74, 99, 118, 138, 153, and 180 compared to women classified as ‘Other’ (Table 2.4).   
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Table 2.4.  Age standardized geometric mean PCB levels (ng/g) for race by uterine leiomyoma diagnosis 
among women 20-54 years of age, NHANES 1999-2004. 
                                 Geometric mean2 (ng/g) (GSE, n)   
        Non-Hispanic Black                              Non-Hispanic White            Other Races 
               No Uterine              Uterine                   No Uterine                Uterine           No Uterine         Uterine    
Analyte1              Leiomyomas         Leiomyomas            Leiomyomas           Leiomyomas         Leiomyomas       Leiomyomas 
PCB 074    6.69 (1.05, 168)e       6.96 (1.09, 52)       6.17 (1.04, 458)e       5.81 (1.09, 26)    5.00 (1.04, 379)  5.87 (1.05, 37)
PCB 099    6.69 (1.05, 167)c,e  6.89 (1.09, 53) c,d   4.90 (1.04, 460)f      4.10 (1.08, 25)   4.39 (1.04, 378)   4.66 (1.08, 37)
PCB 118        8.58 (1.06, 168)d,f   8.76 (1.08, 53)c        6.75 (1.04, 460)        5.99 (1.08, 26)   6.49 (1.05, 378)   7.77 (1.07, 37)
PCB 138          22.2 (1.05, 168)c,e   22.2 (1.09, 53)c    15.6 (1.04, 459)f        14.7 (1.09, 26)    13.9 (1.04, 378)  18.4 (1.13, 37)
PCB 153         29.1 (1.05, 168)c,e     30.3 (1.11, 53)c       21.5 (1.04, 459)f        20.9 (1.11, 26)    18.4 (1.04, 377)  23.6 (1.12, 37)
PCB 180         17.1 (1.05, 168 )d,e    17.1 (1.09, 53)c     14.4 (1.04, 457)f       12.8 (1.11, 26)   11.6 (1.04, 379)      15.0 (1.12, 37) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
GM PCB levels significantly higher in women with uterine leiomyomas vs. women without uterine 
leiomyomas; ap < 0.0001, bp < 0.05. 
GM PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white 
women; cp < 0.0001, dp < 0.05. 
GM PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to 
‘Other’ women; ep < 0.0001, fp < 0.05.  
 Table 2.5 shows the arithmetic means and 95% CIs of serum levels of dioxin-like 
PCBs for endometriosis and uterine leiomyoma status and selected variables in the study 
population.  Arithmetic means of dioxin-like PCBs were not significantly higher in 
women who reported being diagnosed with endometriosis (4.02 ng/g) compared to 
women who reported never being diagnosed with endometriosis (3.70 ng/g) but were 
significantly higher in women who reported being diagnosed with uterine leiomyomas 
(4.36 ng/g) compared to women who reported never being diagnosed with uterine 
leiomyomas (3.62 ng/g) (Table 2.5).   Mean dioxin-like PCBs increased with age, 
however there were no significant differences in the four age groups for endometriosis or 
uterine leiomyoma diagnosis with the exception of the 20-29 year old age group that had 
significantly higher dioxin-like PCB levels in the women not diagnosed with uterine 
leiomyomas compared to women diagnosed with uterine leiomyomas (Table 2.5).  Age 
standardized dioxin-like PCBs were not found to be significantly different among races 
for women diagnosed with endometriosis but were found to significantly different among 
races for women not diagnosed with endometriosis.  Non-Hispanic black women had 
 
  
138 
 
significantly higher dioxin-like PCBs compared to non-Hispanic white women and 
women classified as ‘Other’ (Table 2.5).  Dioxin-like PCBs were also found to be 
significantly higher in non-Hispanic black women with uterine leiomyomas compared to 
non-Hispanic white women with uterine leiomyomas and in non-Hispanic black  women 
without uterine leiomyomas compared to non-Hispanic white women and women  
classified as ‘Other’ (Table 2.5).  Dioxin-like PCBs were not found to be different among 
covariates for women with an endometriosis diagnosis but were found to be significantly 
higher in women with a uterine leiomyoma diagnosis compared to women without a 
uterine leiomyoma diagnosis for age at menarche, alcohol consumption and smoking 
status (Table 2.5).  
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Table 2.5. Arithmetic mean dioxin-like PCB levels in the study population, women 20 -54 years of age, 
NHANES 1999-2004.   
                                     No                        No  
                   Endometriosis   Endometriosis     Leiomyomas    Leiomyomas 
Variable                               Mean (SE,n)        Mean (SE,n)      Mean (SE,n)     Mean (SE,n) 
Dioxin-like PCBs          4.02 (0.19, 80)     3.70 (0.06, 1071)    4.36 (0.14, 147)a   3.62 (0.07, 1004)
Race/Ethnicity3          
 Non-Hispanic white       3.68 (0.17, 53)     3.74 (0.07, 463)e    3.54 (0.16, 58)b    3.73 (0.07, 458)e 
Non-Hispanic black      3.67 (0.20, 13)     4.08 (0.11, 207)c,e   4.11 (0.16, 52)b ,c   4.04 (0.11, 168)c,e
Other              3.96 (0.26, 14)       3.54 (0.08, 401)    3.82 (0.10, 37)a    3.47 (0.09, 378) 
Age at interview (years)         
 20-29              2.85 (0.13, 12)     2.87 (0.07, 375)    2.19 (0.10, 10)    2.89 (0.07, 377)a 
30-39             3.37 (0.24, 25)     2.54 (0.09, 327)    3.80 (0.23, 32)   3.49 (0.08, 320) 
40-49             4.27 (0.25, 30)     4.20 (0.08, 252)    4.42 (0.22, 66)   4.15 (0.09, 216) 
50-54             5.11 (0.62, 13)     4.77 (0.14, 117)    5.02 (0.22, 39)   4.70 (0.16, 91) 
BMI (kg/m2)   
 Normal weight ( <25)       4.18 (0.32, 24)     3.70 (0.08, 403)       4.38 (0.26, 42)    3.65 (0.08, 385) 
 Overweight (25 to <30)       3.99 (0.37, 23)     3.55 (0.12, 277)     4.13 (0.27, 38)    3.48 (0.12, 262) 
 Obese (≥30)                 3.88 (0.21, 32)       3.82 (0.09, 378)    4.51 (0.14, 67)    3.67 (0.10, 343) 
Parity (no. of live births)  
 0                                          4.47 (0.50, 9)              3.65 (0.20, 54)     4.60 (0.56, 9)b    3.62 (0.21, 54) 
 1                                          4.26 (0.37, 27)        3.66 (0.13, 224)    4.50 (0.43, 25)    3.64 (0.13, 258) 
 ≥ 2                                      3.81 (0.25, 34)           3.82 (0.08, 573)    4.34, (0.14, 111)   3.71 (0.07, 618) 
Age at menarche (years)  
 < 12                                    3.92 (0.18, 52)             3.68 (0.08, 688)    4.57 (0.31, 45)b    3.75 (0.13, 212) 
 12-14                                 4.05 (0.47, 22)            3.91 (0.14, 235)    4.30 (0.16, 86)b    3.61 (0.09, 654) 
 ≥  15                                        4.70 (0.41, 5)b         3.42 (0.09, 125)    4.11 (0.34, 14)b    3.38 (0.10, 116) 
Alcohol Use  
 No                                    3.90 (0.23, 24)     3.56 (0.09, 415)    4.11 (0.25, 51)b    3.51 (0.08, 388) 
Yes                   4.07 (0.22, 56)     3.77 (0.07, 656)    4.47 (0.16, 96)a    3.67 (0.08, 616) 
Ever Smoked  
 No                     3.88 (0.25, 44)          3.67 (0.08, 657)     4.35, (0.18, 87)b   3.58 (0.08, 614) 
 Yes                   4.17 (0.28, 36)     3.74 (0.08, 413)    4.37 (0.20, 60)b    3.68 (0.08, 389) 
1Means calculated after applying NHANES sampling weights.   
2Sum of Dioxin-like PCBs = (074 +118);  Lipid adjusted and log transformed PCBs (ng/g). 
3Age standardized. 
PCB levels significantly higher in women with endometriosis or uterine leiomyomas vs. women without 
endometriosis or uterine leiomyomas; ap < 0.0001, bp < 0.05. 
PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white women;  
 cp < 0.0001, dp < 0.05. 
PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to ‘Other’ 
women; ep < 0.0001, fp < 0.05. 
 
  Table 2.6 shows the arithmetic means and 95% CIs of serum levels of non-
dioxin-like PCBs for endometriosis and uterine leiomyoma status and selected variables 
in the study population.  Arithmetic means of non-dioxin-like PCBs were significantly 
higher in women who reported being diagnosed with endometriosis (10.9 ng/g) compared 
to women who reported no endometriosis diagnosis  (10.0 ng/g) and in women who 
 
  
140 
 
reported a uterine leiomyoma diagnosis (11.5 ng/g) compared women who reported no 
uterine leiomyoma diagnosis  (9.84 ng/g) (Table 2.6).  Mean non-dioxin-like PCBs 
increased with age, however there were only significant differences among women in the 
20-29 year old age group for both endometriosis diagnosis and uterine leiomyoma 
diagnosis (Table 2.6).  In women diagnosed with endometriosis, age standardized non-
dioxin-like PCBs were found to be significantly higher in non-Hispanic black women 
compared to non-Hispanic white women and in women not diagnosed with 
endometriosis, age-standardized non-dioxin-like PCBs were significantly higher in non-
Hispanic black women compared to non-Hispanic white women and women classified as 
‘Other’.  In women diagnosed with uterine leiomyomas, age standardized non-dioxin-like 
PCBs were found to be significantly higher in non-Hispanic black women compared to 
non-Hispanic white women  and women classified as ‘Other’ and in women not 
diagnosed with uterine leiomyomas, age-standardized non-dioxin-like PCBs were 
significantly higher in non-Hispanic black women compared to non-Hispanic white 
women and women classified as ‘Other’ (Table 2.5).  Non-dioxin-like PCBs were found 
to be significantly higher in women with a uterine leiomyoma diagnosis compared to 
women without a uterine leiomyoma diagnosis for BMI, parity, age at menarche, alcohol 
consumption and smoking status (Table 2.6).  
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Table 2.6. Arithmetic mean non-dioxin-like PCB levels in the study population, women  20 -54years of age, 
NHANES 1999-2004.   
                                   No                        No  
                   Endometriosis     Endometriosis       Leiomyomas    Leiomyomas 
Variable                               Mean (SE,n)         Mean (SE,n)        Mean (SE,n)     Mean (SE,n) 
Non-Dioxin-like PCBs       10.9 (0.34, 79)b      10.0 (0.12, 1067)    11.5 (0.19, 148)a   9.84 (0.13, 998) 
Race/Ethnicity3           
 Non-Hispanic white      10.0 (0.34, 52)     10.1 (0.15, 461)e     9.70 (0.34, 53)a    10.1 (0.15, 455)e 
Non-Hispanic black     10.8 (0.29, 13)c     11.2 (0.17, 207)d ,e    11.3 (0.33, 58)b,d   11.2 (0.19, 167)c,e
Other             10.9 (0.51, 14)       9.52 (0.14, 399)     10.3 (0.38, 37)a    9.48 (0.15, 376) 
Age at interview (years)        
 20-29             8.07 (0.44, 12)b     7.78 (0.014 372)     7.22 (0.55, 10)    7.81 (0.14 , 374)a
30-39            9.74 (0.46, 25)     9.77 (0.19, 327)     10.5 (0.37, 32)   9.69 (0.18, 320) 
40-49            11.4 (0.39, 30)     11.4 (0.14, 252)     11.4 (0.33, 67)   11.4 (0.16, 215) 
50-54            13.6 (1.18, 12)     12.3 (0.25, 116)     13.1 (0.41, 39)   12.1 (0.33, 89) 
BMI (kg/m2)   
 Normal weight ( <25)      11.8 (0.53, 24)     10.2 (0.16, 402)        12.5 (0.37, 43)a    10.1 (0.17, 383) 
 Overweight (25 to <30)      11.0 (0.67, 22)     9.72(0.21, 276)      10.9 (0.48, 37)b    9.63 (0.20, 261) 
 Obese (≥30)              9.94 (0.39, 32)       9.93 (0.20, 377)     11.4 (0.23, 68)a    9.60 (0.21, 341) 
Parity (no. of live births)  
 0                                       11.2 (1.04, 9)              9.97 (0.54, 55)      11.2 (0.56, 10)a    9.91 (0.56, 54) 
 1                                       11.1 (0.66, 28)        9.81 (0.28, 252)     12.2 (0.79, 25)b    9.72 (0.26, 255) 
 ≥ 2                                    10.8 (0.44, 40)           10.4 (0.13, 685)     11.5 (0.66, 111)   10.2 (0.14, 614) 
Age at menarche (years)  
 < 12                                  10.7 (0.38, 52)            9.96 (0.15, 682)     11.5 (0.57, 44)b    9.92 (0.29, 213) 
 12-14                               10.8 (0.86, 21)            10.2 (0.29, 236)     11.5 (0.26, 87)b    9.81 (0.17, 647) 
 ≥  15                                        12.7 (1.20, 5)b         10.1 (0.20, 125)     11.8 (0.69, 14)b    9.93 (0.20, 116) 
Alcohol Use  
 No                                  10.6 (0.23, 24)     9.77 (0.17, 417)      11.0 (0.40, 52)b    9.65 (0.17, 389) 
Yes                  11.0 (0.38, 55)b     10.1 (0.15, 650)     11.7 (0.23, 96)a    9.94 (0.16, 609) 
Ever Smoked  
 No                    10.2 (0.47, 43)        9.74 (0.16, 656)      11.2 (0.26, 87)a    9.54 (0.16, 612) 
 Yes                  11.6 (0.55, 36) b  10.4 (0.15, 410)     11.9 (0.32, 61)a    10.3 (0.16, 385) 
1Means calculated after applying NHANES sampling weights.   
2Sum of Dioxin-like PCBs = (099 +138 + 153 + 180);  Lipid adjusted and log transformed PCBs (ng/g). 
3Age Standardizd Mean. 
PCB levels significantly higher in women with endometriosis or uterine leiomyomas vs. women without 
endometriosis or uterine leiomyomas; ap < 0.0001, bp < 0.05. 
PCB levels significantly higher in non-Hispanic black women compared to non-Hispanic white women;  
 cp < 0.0001, dp < 0.05. 
PCB levels significantly higher in non-Hispanic black or non-Hispanic white women compared to ‘Other’ 
women; 
 ep < 0.0001, fp < 0.05. 
 
  GM and 95% CI’s of lipid-adjusted PCB levels are reported in table 2.7 for 
women with PCB levels < LOD and ≥ LOD.  Women with PCB concentrations ≥ LOD 
who reported being diagnosed with endometriosis had significantly higher GM levels of 
PCB 138 (22.0 ng/g vs 17.3 ng/g), PCB 153 (29.7 ng/g vs. 23.8 ng/g), and PCB 180 (24.0 
ng/g vs. 16.3 ng/g), compared to women who reported never being diagnosed with 
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endometriosis (Table 2.7). Women with PCB concentrations ≥ LOD who reported being 
diagnosed with uterine leiomyomas had significantly higher GM levels of all 6 PCB 
congeners 74 (9.39 ng/g vs.6.75 ng/g), PCB 99 (1.70 ng/g vs. 5.70 ng/g), PCB 118 (10.9 
ng/g vs. 8.08 ng/g), PCB 138 (25.3 ng/g vs. 16.4 ng/g),  PCB 153 (35.9 ng/g vs. 21.5 
ng/g), and PCB 180 (25.5 ng/g vs. 15.5 ng/g), compared to women who reported never 
being diagnosed with uterine leiomyomas (Table 2.7).   
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Table 2.7.  Geometric mean PCB levels (ng/g) by diagnosis of endometriosis or uterine leiomyomas 
among women 20 to 54 years of age, NHANES 1999-2004. 
      Geometric mean2(ng/g) (95% CI) 
                   No.        No.              No                     
 Analyte1            Noncases    Cases      Endometriosis              Endometriosis 
PCB 074 
 < LOD               396      23       4.01 (3.90-4.18)       3.74 (3.39-4.10)
  ≥ LOD              677      57         7.10 (6.49-7.69)       8.24 (6.69-10.2) 
PCB 099 
 < LOD              475      35       3.97 (3.86-4.10)         3.49 (3.25-3.78)b
 ≥ LOD                599      45       5.70 (5.16-6.30)       7.03 (5.26-9.39) 
PCB 118   
 < LOD              350      24       4.01 (3.90-4.18)       3.82 (3.42-4.26) 
 ≥ LOD              724      56       8.41 (7.77-9.12)       9.87 (7.92-12.4) 
PCB 138       
 < LOD              293      21       11.8 (10.9-12.7)        11.5 (9.21-14.4) 
 ≥ LOD              781      59       17.3 (16.0-18.7)       22.0 (18.2-26.3)b
PCB 153  
 < LOD              247        16         16.3 (15.2-17.6)       17.5 (16.4-18.5) 
 ≥ LOD              826      64       23.8 (21.1-25.0)       29.7 (23.8-36.6)b
PCB 180 
 < LOD              298        18       7.61 (7.17-8.17)          7.39 (5.93-9.21) 
 ≥ LOD              775      61       16.3 (15.0-17.6)       24.0 (19.5-56.8)b
                  No.          No.           No                        
Analyte1            Noncases     Cases     Uterine Leiomyomas    Uterine Leiomyomas
PCB 074 
 < LOD               396      23       4.01 (3.90-4.18)       3.67 (3.22-7.39)
  ≥ LOD              609    125         6.75 (6.17-7.39)       9.39 (8.08-10.8)b 
PCB 099 
 < LOD              472      38       3.97 (3.86-4.10)         3.60 (3.28-3.90)b
 ≥ LOD                533    111       5.70 (4.90-6.17)       7.10 (6.11-8.33)b
PCB 118   
 < LOD              355      19       4.06 (3.89-4.22)       3.49 (3.03-3.97  
 ≥ LOD              651    129       8.08 (7.39-8.85)       10.9 (9.39-12.7)b
PCB 138       
 < LOD              295      19       11.7 (10.7-12.8)        12.4 (11.0-13.9) 
 ≥ LOD              710    130       16.4 (15.2-17.8)       25.3 (22.4-28.8)a
PCB 153  
 < LOD              247        16         16.4 (15.2-17.8)       16.0 (13.7-18.5) 
 ≥ LOD              757    133       21.5 (19.7-23.6)       35.9 (31.8-40.4)a
PCB 180 
 < LOD              299        17       7.69 (7.17-8.17)          6.89 (5.10-9.21) 
 ≥ LOD              705    131       15.5 (14.3-16.8)       25.5 (22.9-28.5)a
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
GM PCB levels significantly higher in women diagnosed with endometriosis or uterine leiomyomas vs. 
women not diagnosed with endometriosis or uterine leiomyomas;ap < 0.0001, b < 0.05.   
 We further explored endometriosis and uterine leiomyoma diagnosis with 
exposure to PCBs in tertiles (Table 2.8 and 2.9)  For women with data on endometriosis, 
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only non-dioxin-like PCBs were found  to be significantly higher in women diagnosed 
with endometriosis compared to women not diagnosed with endometriosis (8.19 ng/g vs. 
7.60 ng/g) for subjects in the first tertile (Table 2.8).  For women with uterine 
leiomyomas, PCB 138 was significantly higher for women  in the first tertile (10.1 ng/g 
vs. 8.25 ng/g), PCB 153 was significantly higher for women in the first tertile (13.1 ng/g 
vs. 10.8 ng/g) and second tertile (30.3 ng/g vs. 26.8 ng/g), and non-dioxin-like PCBs 
were significantly higher for women in the first tertile (8.36 ng/g vs 7.58 ng/g) and 
second  tertile (11.2 ng/g vs. 10.8 ng/g) (Table 2.9).   
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Table 2.8.  Geometric Mean PCB levels (ng/g) by endometriosis status among women 20 to 54 years of age, 
NHANES 1999-2004. 
    Geometric mean2(ng/g) (95% CI) 
                    No.      No.                                     
PCB Percentiles1      Noncases   Cases       No Endometriosis         Endometrios is  
PCB 074 
 < 33rd              576     28        3.39 (3.25-3.49)       3.35 (3.03-3.71) 
 33rd to 66th            345     38          7.39 (7.03-7.69)       7.17 (6.62-7.77) 
 ≥ 66th               151     14        17.5 (16.4-18.5)       20.3 (15.2-27.1) 
 
PCB 099 
 < 33rd              494     36        2.83(2.69-2.94)        2.92 (1.10-3.16) 
  33rd to 66th            372     23        5.21 (5.10-5.31)       5.21 (4.85-5.58) 
 ≥ 66th               208     21        12.2 (11.4-13.1)       14.4 (10.9-18.9) 
 
PCB 118   
 < 33rd               544     33        3.71 (3.60-3.82)       3.74 (3.42-4.18) 
 33rd to 66th            348     29        8.05 (7.85-8.33)       7.92 (7.03-8.94) 
   ≥66th               180     18        22.4 (20.7-24.5)       22.4 (16.4-30.6) 
 
PCB 138       
 < 33rd              562     32        8.33 (7.85-8.76)       9.30 (7.92-11.0) 
  33rd to 66th            333     27        19.7 (18.9-19.9)         18.2 (16.6-19.7) 
 ≥ 66th               179     21         47.9 (44.7-51.4)         48.9 (37.7-63.4) 
 
PCB 153  
 < 33rd               576     30        10.8 (10.3-11.4)       12.7 (10.8-14.9) 
 33rd to 66th            326     29        27.7 (26.8-28.5)        26.8 (24.3-29.7) 
 ≥ 66th               171     21        66.7 (62.2-68.7)        68.0 (51.9-88.2) 
 
PCB 180 
 < 33rd               615     27        6.69 (6.30-7.03)       7.39 (6.23-8.67) 
   33rd to 66th            308     33        19.9 (19.5-20.5)       18.5 (16.6-20.9) 
 ≥ 66th               149     19        48.9 (45.2-53.0)       49.4 (40.4-59.7) 
 
Dioxin-like PCBs3            
 < 33rd              556     29        2.56 (2.48-2.63)        2.59 (2.38-2.80) 
   33rd to 66th            260     27        3.83 (3.76-3.89)       3.79 (3.59-3.99) 
 ≥ 66th               254     24        5.41 (5.31-5.52)       5.42 (4.89-5.96) 
 
Non-Dioxin-like PCBs4            
 < 33rd              575     30        7.60 (7.44-7.76)       8.19 (7.73-8.66)b 
   33rd to 66th            317     28        10.9 (10.8-11.0)       10.7 (10.4-11.1) 
 ≥ 66th               175     27        14.2 (14.0-14.5)       14.4 (13.4-15.4) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
3Arithmetic Mean Dioxin-like PCBs:  Sum of PCB 074 +118. 
4Arithmetic Mean Non-Dioxin-like-PCBs:  Sum of PCB 099 + 138 +153 +180. 
GM PCB levels significantly higher in women diagnosed with endometriosis vs. women not diagnosed with 
endometriosis; ap < 0.0001, b < 0.05.  
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Table 2.9.  Geometric Mean PCB levels (ng/g) by uterine leiomyoma status among women 20 to 54 years of 
age, NHANES 1999-2004. 
   Geometric mean2(ng/g) (95% CI) 
                  No.      No.                No                        
PCB Percentiles1      Noncases   Cases       Uterine Leiomyomas    Uterine Leiomyomas 
PCB 074 
 < 33rd              565     39        3.35 (3.25-3.49)       3.49 (3.19-3.82) 
 33rd to 66th            319     64          7.24 (7.03-7.54)       7.61 (7.03-8.25) 
 ≥ 66th               120     45        17.5 (16.4-18.5)       18.2 (16.6-20.1) 
 
PCB 099 
 < 33rd              489     41        2.80(2.69-2.94)        2.94 (2.69-3.22) 
  33rd to 66th            340     55        5.16 (5.10-5.26)       5.26 (5.05-5.53) 
 ≥ 66th               176     53        12.2 (11.4-12.9)       13.2 (11.5-15.0) 
 
PCB 118   
 < 33rd               543     34        3.74 (3.60-3.86)       3.53 (3.16-3.90) 
 33rd to 66th            313     64        8.00 (7.77-8.25)       8.33 (7.85-8.94) 
   ≥66th               148     50        22.2 (20.3-24.3)       23.1 (20.1-26.6) 
 
PCB 138       
 < 33rd              559     35        8.25 (7.77-8.67)       10.1 (9.03-11.4)b 
  33rd to 66th            298     62        19.1 (18.5-19.9)         20.1 (18.9-21.1) 
 ≥ 66th               148     52         48.4 (44.7-53.0)         46.5 (41.3-52.5) 
 
PCB 153  
 < 33rd               572     34        10.8 (10.3-11.2)       13.1 (11.1-15.3)b 
 33rd to 66th            291     64        26.8 (26.0-27.9)        30.3 (27.9-32.8)b 
 ≥ 66th               141     51        67.4 (62.1-73.0)        64.7 (57.4-73.0) 
 
PCB 180 
 < 33rd               607     35        6.69 (6.30-7.03)       6.96 (5.64-8.50) 
   33rd to 66th            270     71        19.3 (18.7-19.9)       21.5 (19.9-23.3)b 
 ≥ 66th               126     42        49.4 (45.2-55.1)       47.5 (43.4-51.9) 
 
Dioxin-like PCBs3            
 < 33rd              550     35        2.56 (2.49-2.64)        2.55 (2.37-2.74) 
   33rd to 66th            243     44        3.81 (3.75-3.86)       3.91 (3.77-4.04) 
 ≥ 66th               210     68        5.38 (5.25-5.52)       5.51 (5.27-5.74) 
 
Non-Dioxin-like PCBs4            
 < 33rd              569     36        7.58 (7.41-7.74)       8.36 (7.81-8.90)b 
   33rd to 66th            282     63          10.8 (10.6-10.9)       11.2 (11.1-11.4)b 
 ≥ 66th               147     49        14.2 (13.9-14.5)       14.3 (13.9-14.8) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2Geometric means calculated after applying NHANES sampling weights. 
3Arithmetic Mean Dioxin-like PCBs:  Sum of PCB 074 +118. 
4Arithmetic Mean Non-Dioxin-like-PCBs:  Sum of PCB 099 + 138 +153 +180. 
GM PCB levels significantly higher in women diagnosed with uterine leiomyomas vs. women not 
diagnosed with uterine leiomyomas; ap < 0.0001, b < 0.05.  
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 Estimated ORs and 95% confidence intervals for the risk of having breast cancer 
and the six individual PCB congeners are shown in table 2.10. We estimated 
endometriosis and uterine leiomyoma risk for subjects with PCB levels < LOD (reference 
group) and ≥ LOD. Results are presented for three logistic regression models: unadjusted; 
age and race/ethnicity adjusted; and age, race/ethnicity, BMI, parity, age at menarche, 
oral contraceptive use, smoking, and alcohol consumption adjusted. In unadjusted 
models, PCBs were significantly associated with endometriosis for PCB 74 (OR of 1.71, 
95% CI: 1.07-2.21).  PCBs were not significantly associated with endometriosis in any of 
the adjusted models (Table 2.10).  In unadjusted models, all six PCB congeners were 
significantly associated with uterine leiomyomas.  After adjusting final models for age, 
race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, and 
alcohol, PCB 74 and 118 remained significantly associated with uterine leiomyomas ORs 
of 1.91 (95% CI: 1.10-3.29) and 1.91 (95% CI: 1.13-3.22), respectively (Table 2.10).   
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Table 2.10. Estimated ORs (95% CIs) of endometriosis or uterine leiomyomas by concentrations of PCBs 
among women 20-54 years of age, NHANES 1999-2004.                                     
            No.    No.    Unadjusted OR        Adjusted OR2    Adjusted OR3,a 
Analyte1      Cases     Noncases    (95% CI)             (95% CI)      (95% CI) 
ENDOMETRIOSIS  
PCB 074       
< LOD        23    396       1.00           1.00          1.00 
≥ LOD       57      677         1.71 (1.07-2.71)b     1.15 (0.66-2.01)   1.18 (0.59-2.38) 
PCB 099  
< LOD        35    475     1.00             1.00          1.00 
 ≥ LOD       45    599     1.02 (0.58-1.80)     0.84 (0.44-1.60)   0.83 (0.40-1.73) 
PCB 118 
 < LOD         24    350       1.00           1.00          1.00 
 ≥ LOD       56    724      1.26 (0.72-2.20)    0.93 (0.49-1.77)   0.86 (0.40-1.85) 
PCB 138 
< LOD        21    293       1.00           1.00          1.00 
 ≥ LOD        59    781     1.24 (0.76-2.03)      0.97 (0.56-1.68)   1.02 (0.63-1.63) 
PCB 153 
< LOD        16    247       1.00           1.00          1.00 
 ≥ LOD       64    826     1.35 (0.76-2.39)      0.97 (0.97-1.72)   1.13 (0.68-1.87) 
PCB 180 
< LOD         18    298     1.00           1.00          1.00 
 ≥ LOD       61    775     1.49 (0.94-2.37)        0.97 (0.62-1.50)      1.07 (0.74-1.55) 
            No.    No.    Unadjusted OR        Adjusted OR2    Adjusted OR3,b 
Analyte1      Cases     Noncases      (95% CI)            (95% CI)      (95% CI) 
UTERINE LEIOMYOMAS 
PCB 074       
< LOD        23    396       1.00           1.00          1.00 
≥ LOD       125   609     3.63 (2.10-6.29)a     1.96 (1.15-3.35)b   1.91 (1.10-3.29)b 
PCB 099  
< LOD         38    472     1.00             1.00          1.00 
 ≥ LOD        111    533       2.25 (1.38-3.68)b     1.47 (0.87-2.48)   1.60 (0.95-2.72) 
PCB 118 
 < LOD         19    355     1.00           1.00          1.00 
 ≥ LOD         129   651     3.35 (1.87-6.03)a    2.00 (1.17-3.42)b   1.91 (1.13-3.22)b 
PCB 138 
< LOD        19    295     1.00           1.00          1.00 
 ≥ LOD        130   710     2.24 (1.22-4.12)b      1.31 (0.63-2.74)   1.63 (0.86-3.10) 
PCB 153 
< LOD        16    247     1.00           1.00          1.00 
 ≥ LOD        133   757     2.42 (1.55-3.78)a      1.32 (0.78-2.23)   1.45 (0.83-2.54) 
PCB 180 
< LOD        17    299     1.00           1.00          1.00 
 ≥ LOD       131   705     2.78 (1.64-4.74)b     1.28 (0.72-2.28)    1.38 (0.70-2.74) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age, race/ethnicity . 
3Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol 
use. 
aCases/noncases: 77/962 in PCB 074, 153, 180;  77/963 in PCB 138; 77/964 in PCB 099;  
77/965 in PCB 118. 
bCases/noncases: 143/896 in PCB 074; 144/897 in PCB 099;144/898 in PCB 118; 144/896 in PCB 138; 
144/895 in PCB 153, 180. 
Significance: ap < 0.0001, bp < 0.05. 
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 ORs and 95% confidence intervals for risk of endometriosis and uterine 
leiomyomas were further analyzed for subjects with PCB concentrations divided into 
tertiles (Tables 2.11and 2.12).  Subjects with PCB concentrations in the first tertile (< 
33rd percentile) were used as the reference group.  In the unadjusted models, risk of 
endometriosis was significantly associated with PCB 74 for subjects in the second tertile 
(OR of 2.32, 95% CI: 1.27-4.24) and PCB 180 for subjects in the second and third tertiles 
[ORs of 2.38 (95% CI: 1.38-4.09) and 3.44 (95% CI: 1.46-8.11)], respectively (Table 
2.11).  Endometriosis did not remain significantly associated with any PCBs in the 
adjusted models.  In the unadjusted models, risk of uterine leiomyomas were significantly 
associated with PCB 99 in the third tertile and  PCBs 74, 118, 138, and 180 for subjects 
in the second and third tertiles (Table 2.12).  After adjusting for age and race/ethnicity, 
PCB 180 remained significantly associated with uterine leiomyoma for subjects in the 
second tertile (OR of 1.64, 95% CI: 1.07-2.51). After adjusting for all variables in the 
final model, PCB 180 continued to remain significantly associated with uterine 
leiomyomas for subjects in the second tertile (OR of 1.87, 95% CI: 1.15-3.02) (Table 
2.12).   
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Table 2.11. Estimated ORs (95% CIs) of endometriosis by concentrations of PCBs among women 20-54 
years of age, NHANES 1999-2004. 
              No.       No.      Unadjusted OR         Adjusted OR2      Adjusted OR3,a 
Percentiles1      Cases   Noncases    (95% CI)             (95% CI)        (95% CI)  
PCB 074 
 < 33rd         28    576    1.00            1.00           1.0 0     
 33rd to 66th       38    345    2.32 (1.27-4.24)b       1.64 (0.85-3.18)    1.80 (0.90-3.57)
 ≥ 66th          14    151    1.75 (0.73-4.23)     1.04 (0.45-2.38)    1.00 (0.46-2.16)
 
PCB 099 
 < 33rd          36    494    1.00            1.00           1.00 
  33rd to 66th        23    372    0.72 (0.36-1.44)     0.64 (0.31-1.32)    0.74 (0.36-1.50)
 ≥ 66th           21    208    1.12 (0.66-1.89)     0.79 (0.44-1.40)    0.83 (0.42-1.63)
 
PCB 118   
 < 33rd           33    544    1.00            1.00           1.00       
 33rd to 66th        29    348    1.22 (0.63-2.37)     0.94 (0.46-1.95)    0.96 (0.44-2.09)
   ≥66th           18    180    1.75 (0.82-3.74)     1.19 (0.55-2.59)    1.09 (0.47-2.51)
 
PCB 138       
 < 33rd          32    562    1.00            1.00           1.00       
  33rd to 66th        27    333    1.39 (0.65-2.98)     0.98 (0.43-2.25)    1.13 (0.49-2.58)
 ≥ 66th             21    179    1.97 (0.95-4.11)     1.25 (0.58-2.70)    1.33 (0.56-3.16)
 
PCB 153  
 < 33rd           30    576    1.00            1.00           1.00       
 33rd to 66th         29    326    1.52 (0.90-2.57)     1.04 (0.55-1.98)    1.25 (0.63-2.45)
 ≥ 66th           21    172    2.02 (0.91-4.47)     1.18 (0.50-2.78)    1.43 (0.54-3.83)
 
PCB 180 
 < 33rd           27    615    1.00            1.00           1.00       
   33rd to 66th        33    308    2.38 (1.38-4.09)b     1.59 (0.83-3.04)    1.69 (0.78-3.65)
 ≥ 66th           19    149    3.44 (1.46-8.11)b     2.20 (0.82-5.96)    2.70 (0.93-7.81)
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age, race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol. 
a Cases/Noncases:  79/1034 in PCB 074; 79/1037 in PCB 099, 79/1035 in PCB 118 and 153;  
79/1036 in PCB 138; 78/1034 in PCB 180.   
Significance: ap < 0.0001, bp < 0.05. 
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Table 2.12. Estimated ORs (95% CIs) of uterine leiomyomas by concentrations of PCBs among women 20-
54 years of age, NHANES 1999-2004. 
              No.      No.        Unadjusted OR         Adjusted OR2       Adjusted OR3,a 
Percentiles1     Cases   Noncases      (95% CI)             (95% CI)       (95% CI)  
PCB 074 
 < 33rd         39    565    1.00            1.00            1.0 0     
 33rd to 66th       64    319    2.24 (1.36-3.70)b       1.29 (0.72-2.34)     1.30 (0.72-2.35) 
 ≥ 66th          45    120    4.39 (2.42-7.97)a     1.68 (0.84-3.34)     1.56 (0.81-3.02) 
 
PCB 099 
 < 33rd           41    489    1.00            1.00            1.00 
  33rd to 66th        55    340    1.32 (0.75-2.30)     1.04 (0.56-1.91)     1.06 (0.58-1.95) 
 ≥ 66th           53    176    2.25 (1.32-3.86)b     1.00 (0.57-1.76)     1.04 (0.61-1.78) 
 
PCB 118   
 < 33rd           34    543    1.00            1.00            1.00       
 33rd to 66th        64    313    1.54 (1.43-4.53)b     1.61 (0.88-2.95)     1.62 (0.90-2.91) 
   ≥66th           50    148    4.11 (2.34-7.08)a     1.66 (0.91-3.05)     1.57 (0.88-2.79) 
 
PCB 138       
 < 33rd          35    559    1.00            1.00            1.00       
  33rd to 66th        62    298    2.16 (1.23-3.77)b     1.14 (0.60-2.16)     1.28 (0.67-2.46) 
 ≥ 66th             52    148    4.12 (2.42-7.03)a     1.39 (0.75-2.59)     1.61 (0.89-2.88) 
 
PCB 153  
 < 33rd           34    572    1.00            1.00            1.00       
 33rd to 66th         64    291    2.69 (1.64-4.42)     1.41 (0.79-2.52)     1.61 (0.89-2.89) 
 ≥ 66th           51    141    4.65 (2.61-8.29)     1.54 (0.77-3.09)     1.71 (0.86-3.39) 
 
PCB 180 
 < 33rd           35    607    1.00            1.00            1.00       
   33rd to 66th        71    270    3.80 (2.56-5.64)a     1.64 (1.07-2.51)b     1.87 (1.15-3.02)b
 ≥ 66th           42    126    5.47 (3.38-8.86)a     1.60 (0.87-2.97)     1.70 (0.84-3.45) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age, race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol. 
a Cases/Noncases:  145/968 in PCB 074; 146/968 in PCB 118 and 153; 146/969 in PCB 118,  
146/970 in PCB 099; 145/967 in PCB 180.   
Significance: ap < 0.0001, bp < 0.05. 
 
 Estimated ORs and 95% CIs of endometriosis and uterine leiomyomas by dioxin-
like and non-dioxin-like PCBs are shown in table 2.13.  In the unadjusted models, non-
dioxin-like PCBs were significantly associated with endometriosis (OR of 1.11, 95% CI: 
1.02-1.21).  Dioxin and non-dioxin-like PCBs did not remain significantly associated 
with endometriosis in the adjusted models (Table 2.13).  In all of the unadjusted models, 
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dioxin-like and non-dioxin-like PCBs were significantly associated with uterine 
leiomyomas, however, none of the models remained significant after adjusting for age, 
race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking status, and 
alcohol consumption (Table 2.13).   
Table 2.13.  Estimated ORs (95% CIs) of endometriosis and uterine leiomyomas by concentration of lipid 
adjusted dioxin-like and non-dioxin-like PCBs in women 20 to 54 years of age, NHANES 1999-2004.  
                                                            
                      Cases/      Unadjusted OR   Adjusted OR1       Adjusted OR2  
                 Noncases            (95% CI)         (95% CI)                   (95% CI)   
Endometriosis 
Dioxin-like PCBs4         80/1071    1.18 (0.96-1.41)   1.03 (0.84-1.27)      0.97 (0.76-1.23)+ 
 
Dioxin-like PCBs4,7 
 < 33rd               29/566    1.00          1.00           1.00 
 33rd to 66th              27/260    1.75 (0.82-3.73)   1.35 (0.62-3.04)      1.48 (0.62-3.51) 
 ≥ 66th                   24/254    1.89 (0.88-4.07)   1.20 (0.54-2.68)      1.04 (0.46-2.38) 
 
Non- Dioxin-like PCBs5     79/1067   1.11 (1.02-1.21)b     1.04 (0.93-1.16)      1.04 (0.91-1.18)* 
 
Non-Dioxin-like PCBs4,7 
 < 33rd                  30/575   1.00          1.00             1.00 
 33rd to 66th                28/317   1.37 (0.77-2.44)   0.92 (0.47-1.77)      1.08 (0.50-2.34) 
 ≥ 66th                     27/175   2.01 (0.98-4.14)   1.22 (0.53-2.79)    1.23 (0.46-3.30) 
Uterine Leiomyomas 
Dioxin-like PCBs4          80/1071   1.47 (1.27-1.71)a   1.12 (0.94-1.33)        1.11 (0.94-1.30)++
 
Dioxin-like PCBs4,7 
 < 33rd                35/550   1.00          1.00              1.00 
 33rd to 66th               71/270   1.99 (1.14-3.49)b   1.22 (0.65-2.28)        1.24 (0.65-2.39) 
 ≥ 66th                    42/126   3.81 (2.22-6.54)a   1.59 (0.84-3.02)      1.56 (0.87-2.80) 
 
Non- Dioxin-like PCBs5     79/1067  1.23 (1.15-1.31)a   1.05 (0.96-1.14)      1.06 (0.97-1.15)**
 
Non-Dioxin-like PCBs4,7 
 < 33rd                 36/569   1.00          1.00             1.00 
 33rd to 66th               63/282   2.45 (1.55-3.85)b   1.20 (0.70-2.05)      1.39 (0.78-2.45) 
 ≥ 66th                    49/147   3.62 (2.05-6.39)a   1.08 (0.70-2.05)        1.23 (0.63-2.38) 
1Adjusted for age and race/ethnicity. 
2Adjusted for age, race/ethnicity, BMI, parity, age at menarche, oral contraceptive use, smoking, alcohol. 
4Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (074 + 118). 
+Cases/noncases:  77/962;  ++Cases/noncases:  143/896. 
5Non-Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (099+138+153+180). 
*Cases/noncases:  76/957; **Cases/noncases: 143/890. 
Significance: ap < 0.0001, bp < 0.05.  
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DISCUSSION 
 Evidence supporting the role of PCBs in endometriosis and uterine leiomyoma is 
conflicting and inconclusive.   Experimental animal studies  have linked PCB exposure to 
prolonged estrus and decreased sexual receptivity in rats, decreased sperm fertilizing 
ability in mice (Fielden et al. 2001), decreased conception in mice, changes in the uterine 
myometrium and gland formation in mice (Ma and Sassoon 2006), prolonged 
menstruation, decreased birth weights, and decreased conception rates in rhesus monkeys 
(ASTDR 2000), and a significant dose-dependent relationship in the prevalence and 
severity of endometriosis in rhesus monkeys (Rier et al. 2001). Although these animal 
studies have shown the have potential endocrine disrupting activities of PCBs, the data on 
their endocrine disrupting effects in humans is inconsistent (Buck Louis et al. 2005, 
Porpora et al. 2009, Heiler et al. 2005, Trabert et al. 2010, Pauwels et al. 2001).    In this 
cross-sectional study of U.S. women, we evaluated the concentrations of 6 PCB 
congeners, dioxin-like PCBs, and non-dioxin-like PCBs and explored the association 
between PCB exposure and diagnosis of endometriosis and uterine leiomyomas.   
 Analysis of dioxin-like PCBs and non-dioxin-like PCBs by endometriosis and 
uterine leiomyoma status and age and race/ethnicity was done to assess PCB 
concentrations in subpopulations.  Dioxin-like and non-dioxin-like PCBs showed an 
increasing trend with age. These results are supported by previously reported associations 
of PCB body burdens and age in women (Axelrad et al. 2009, Thompson et al. 2013).  
While this may be a result of lower levels of PCBs in the environment today, it may also 
be due to the persistent nature of PCBs and increased accumulations in the human body 
over time. Although not significant, women diagnosed with uterine leiomyomas had the 
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highest dioxin-like PCB levels in the 30-39, 40-49 and 50-54 year old age groups.   Non-
Hispanic black women had significantly higher mean PCB levels compared to non-
Hispanic white women and women classified as ‘Other’.  This finding is consistent with 
higher PCB and DDE levels that have been previously reported among African-American 
women compared with non-Hispanic white women by Millikan et al. (2013) and Zheng et 
al. (1999), respectively.  While these results do not provide any evidence of causal 
associations, it is noteworthy that women diagnosed with uterine leiomyomas have higher 
levels of dioxin-like and non-dioxin-like PCBs and all six PCB congeners compared to 
women who reported never being diagnosed with uterine leiomyomas.   
 Our results show that women diagnosed with endometriosis have slightly higher 
body burdens of PCB congeners 138, 153, and 180 compared to women never diagnosed 
with endometriosis. Our findings of the association between endometriosis and  higher 
body burdens of PCB congeners 138, 153, 180, and the sum of non-dioxin-like PCBs are 
consistent with a two previously reported case-control studies  by Porpora et al. (2006 
and 2009).  Porpora et al. (2006) reported higher levels of total PCBs in endometriosis 
cases vs. controls   (410 ng/g vs.250 ng/g), as well as an increased risk in involving both 
dioxin-like (105, 118, 156, 167) and non-dioxin-like (101, 138, 153, 170, 180) congeners, 
after adjusting for age and smoking.  Porpora et al. (2009) found the GM of total PCBs to 
be significantly higher in cases than controls (301.3 vs. 203.0, p < 0.01). In contrast, 
Niskar et al. (2009) did not find mean lipid-adjusted PCB concentrations to be 
significantly different (179.98 vs. 217.33 vs. 194.76 vs. 193.37) between stage I-II cases, 
stage III cases, stage IV cases, and controls, respectively.  Pauwels et al. (2001) found no 
association between endometriosis and the median TEQ values (pg TEQ/g lipid) in cases 
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and controls (29 vs. 27) and Tsukino et al.(2005) found no difference in median TEQ 
values for endometriosis cases (stage II-IV) and controls (stage 0-I) (cPCBs: 3.40 vs. 
3.59, PCBs: 4.61 vs. 5.14), respectively.   
 Risk of endometriosis was only present for PCB 74 and non-dioxin-like PCBs in 
unadjusted logistic regression models and did not remain in any of the adjusted models.  
These findings are consistent with Trabert et al. (2005), who reported no association 
between adjusted total and estrogenic PCBs in the highest quartiles and an increased risk 
of endometriosis (Total PCBs:  OR=1.2, 95% CI: 0.6-2.3, Estrogenic PCBs: OR=0.9, 
95% CI: 0.5-1.4) after adjusting for age, lipids, income, alcohol consumption, and DDE 
exposure.  Our findings do not agree with Buck Louis et al. (2005) who reported a 
significant increased risk of endometriosis for the sum of anti-estrogenic PCBs for 
women in the third tertile (OR=3.77, 95% CI: 1.12-12.68), however, the risk remained 
elevated but not significant when adjusted for all listed covariates and Porpora et al. 
(2009) who reported the OR of endometriosis risk in the highest tertile of total PCBs 
compared with the lowest tertile to be 5.63 (95% CI: 2.25-14.10). 
 We observed   significantly higher body burdens of PCBs in women diagnosed 
with uterine leiomyomas and an increased risk of uterine leiomyomas in association with 
PCB 180 after adjusting for age, race/ethnicity, BMI, parity, age at menarche, oral 
contraceptive use, smoking status, and alcohol consumption.  Epidemiological studies 
demonstrating the association between PCBs and uterine leiomyomas are lacking.  Our 
findings are difficult to compare due to differences in the study population and methods.   
Findings from Lambertino et al. (2011) reported that uterine leiomyomas were 
significantly associated with exposure to dioxin-like- PCBs in women who never 
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breastfed (OR=8.6, 95% CI: 2.0-36.6) but not in women who breastfed (OR=0.80, 95% 
CI: .023-2.8).   Qin et al. (2009) et al. found significantly higher concentrations of PCB 
123 (17.8 ng/g vs.11.7 ng/g, p<0.01), 126 (21.0 ng/g vs. 10.4 ng/g, p<0.01), and 180 
(13.9 ng/g vs. 6.99 ng/g, p<0.05) in the subcutaneous fat of patients compared to 
controls.  While these results are consistent with our findings for PCB 180, they are 
difficult to compare because they assessed PCB concentrations in adipose tissue as 
opposed to serum blood.    
 There are a number of limitations to our study, the most important of which is its 
cross-sectional design with self-reported data.  Self-reported data increases the risk of 
misclassification bias of cases and controls.  It is possible that false reports or 
undiagnosed endometriosis or uterine leiomyoma cases may have occurred.   
Furthermore, observed associations could be potentially confounded by lack of 
information on geographical location of primary residence and family history of some of 
the variables.  Strengths of this cross-sectional study design include the large sample 
survey size, availability of biological measurements of environmental contaminants, and 
oversampling of minority populations that make it highly representative and 
generalizable to the U.S. population.   
CONCLUSION 
 Based on our analysis of serum blood lipid PCB levels in the 1999-2004 
NHANES data cycles, biological levels of PCBs may contribute to reproductive 
dysfunction among U.S. women.  Given the proven contribution of unopposed estrogens 
to the risk for endometriosis or endometrial neoplasia, it is biologically plausible that an 
altered endogenous estrogen levels presumably from exposure to estrogen mimicking 
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EDCs may contribute to the risk of these diseases. In conclusion, we have identified 
preliminary evidence suggesting that exposure to PCBs may be associated with uterine 
leiomyomas.  Thus, further research with an epidemiologic approach is warranted to 
investigate reproductive health outcomes in relation to PCB exposure among women in 
the general population.   
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CHAPTER VI 
MANUSCRIPT 3 
ENDOCRINE DISRUPTING COMPOUNDS AND REPRODUCTIVE CANCERS 
AMONG U.S. WOMEN: NHANES 1999-2010 
ABSTRACT 
Background.  A number of chemicals are suspected to act as endocrine disruptors (EDs) 
by mimicking natural or synthetic estrogen resulting in an increased risk of hormonal 
cancer in women.  Polychlorinated biphenyls (PCBs), phthalates and bisphenol A (BPA) 
have been recognized as endocrine disrupters due to their ability to interfere with 
reproductive function and development in animals and humans by either increasing 
estrogen activity or blocking estrogens from acting.   
Objectives: The purpose of this study was to explore the cross-sectional relationship 
between exposure to PCBs, phthalates, and BPA and reproductive cancers (breast, 
cervical, ovarian, and uterine) among U.S. women.   
Methods:  We analyzed data from female participants (20 years of age and older) who 
provided blood  and urine samples for the Centers for Disease Control and Prevention’s 
National Health and Nutrition Examination Survey (NHANES) between 1999 and 2010. 
Exposure was based on lipid adjusted serum levels of 6 individual PCB congeners (74, 
99, 118, 138, 153, and 180), the sum of dioxin-like PCBs (074 + 118), the sum of non-
dioxin-like PCBs (099 + 138 + 153+187), 8 urinary phthalate metabolites (MNP, MEP, 
MEHP, MBzP, MCPP, MEHHP, MEOHP, and MIB), the sum of DEHP metabolites 
(MHP + MHH + MOH), the sum of  total phthalates, and urinary BPA  in conjunction 
with data obtained from the medical and reproductive health questionnaires.  We 
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calculated geometric means to compare EDCs concentrations in women who self-
reported a breast, cervical, ovarian, or uterine cancer diagnosis vs. women who self-
reported never being diagnosed with cancer. We used logistic regression models to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association 
between exposure to EDCs and reproductive cancers.  We evaluated age, race/ethnicity, 
body mass index (BMI; kg/m2), and age at menarche as potential confounding variables 
in our final models.   
Results: Separate analyses showed weighted geometric mean levels of individual PCB 
congeners to be significantly higher among women with breast cancer, ovarian cancer, 
and uterine cancer when compared to the rest of the study population.  Mono-(2-ethyl-5-
hydroxyhexyl) phthalate (MEHHP) was found to be significantly higher among women 
with ovarian cancer compared to women never diagnosed with cancer and BPA was 
significantly higher in women never diagnosed with cancer compared to women 
diagnosed with breast cancer. After adjusting for age, race, BMI, and age at menarche we 
found PCB 138 to be significantly associated with breast cancer, cervical cancer, and 
uterine cancer [odds ratios of 2.52.; 95% confidence interval (CI): 1.06-5.99;  3.05, 95% 
CI: 1.21-7.69; and 5.83,  95% CI: 1.63-20.9], respectively,  and PCB 74 and 118 to be 
significantly associated with ovarian cancer [odds ratios of 6.47, 95% CI: 1.23-3.41 and 
6.68, 95% CI: 1.39-32.3), respectively.  We also found the sum of non-dioxin-like PCBs 
to be significantly associated with ovarian cancer (OR of 1.12, 95% CI: 1.03-1.23) and 
the sum of dioxin-like PCBs to be significantly associated with ovarian cancer (OR of 
2.02, 95% CI: 1.06-3.85).  We found null associations between urinary phthalates and 
BPA and reproductive cancers.  
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Conclusions: Our results suggest a link between environmental exposures to PCBs and 
an increased risk of reproductive cancers (breast, cervix, ovarian and uterine) among U.S. 
women.  
Keywords:  NHANES, PCBs, phthalates, BPA, EDC, reproductive cancers. 
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MANUSCRIPT 3 
ENDOCRINE DISRUPTING COMPOUNDS AND REPRODUCTIVE CANCERS 
AMONG U.S. WOMEN: NHANES 1999-2010 
INTRODUCTION 
 Human populations are continually exposed to a wide variety of environmental 
estrogen-like chemicals.  A recent report by the United Nations Environment Programme 
(UNEP) and WHO  highlighted  the increasing rates of endocrine-related  cancers over 
the past 40-50 years in conjunction with approximately 800 chemicals that are suspected 
to act as endocrine disruptors (EDs) (UNEP/WHO 2013, EU 2013).  Many of these 
chemicals are used in a variety of consumer products; therefore exposure to EDCs among 
the general population is widespread. Human exposure to EDCs may result from 
inhalation through the air, absorption through the skin, and most commonly through the 
ingestion of contaminated food and water (Balabanic et al. 2001). In the last decade, 
exposure to multiple EDCs such as polychlorinated biphenyls (PCBs), phthalates, and 
bisphenol A (BPA) have been detected in  90% of blood and urine samples collected 
(Calafat et a. 2008, Woodruff et al. 2011, Silva et al. 2004)  
Although a number of experimental animal studies have shown many chemicals 
have potential endocrine disrupting activities, the data on their endocrine disrupting 
effects in humans is limited.  The role of EDC’s in the etiology of some of the human 
cancers and reproductive health hazards has been implicated, although the linkage 
between these two processes is highly controversial (Burantrevedh and Roy 2001). PCBs 
have been shown to interfere with reproductive function and development in animals and 
humans by either increasing or blocking estrogen activity (Fielden et al. 2001, Ma and 
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Sassoon 2006, McLachlan et al. 2006, Roy et al. 1997, Roy et al. 1998).  Animal studies 
have linked PCB exposure to decreased sperm fertilizing ability in mice (Fielden et al. 
2001), changes in the uterine myometrium and gland formation in mice (Ma and Sassoon 
2006), and a significant dose-dependent relationship in the prevalence and severity of 
endometriosis in rhesus monkeys (Rier et al. 2001).  Among various phthalates, di (2-
ethylhexyl) phthalate (DEHP), di-butyl phthalate (DBP) and butylbenzyl phthalate (BBP) 
have been studied for their endocrine disrupting effects. Phthalates have been shown to 
produce anti-androgenic effects by suppressing testosterone and estrogen production.  
Reproductive abnormalities reported in rodent females include increased uterine and 
ovarian weights and malformations at very high phthalate levels, delayed onset of 
puberty and modified morphology of the mammary gland (Moral et al. 2008).  We have 
shown that bisphenol A (BPA) is oxidized to bisphenol-o-quinone by cytochrome P450 
activation system. Administration of a single dose or multiple doses of 200 mg/kg of 
BPA to CD1 male rats produces in vivo DNA adducts matching the profile of dGMP-bis-
phenol-o-quinone. Covalent modifications in DNA by in vivo exposure of BPA are 
suspected to be a factor in the induction of endocrine toxicity (Atkinson and Roy 1995). 
In rodent females, BPA exposure has shown to cause alterations in the mammary gland 
development, changes in gene expression of the mammary gland, cystic ovaries, 
endometrial hyperplasia, adenomyosis,  leiomyomas, atypical hyperplasia, stromal 
polyps, ductal hyperplasias and carcinoma, a decline in fertility and fecundity, decreased 
wet weight of the vagina, decreased volume of the endometrial lamina propria, and an 
increased expression of estrogen receptor- (ER) and progesterone receptors  (Moral et 
al. 2008, Atkinson et al. 1995, Colerangle and Roy 1997, Munoz-de-Toro et al. 2005,  
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Newbold et al. 2007, Murray et al. 2007, Signorile et al. 2010, Cabaton et al. 2011).  In 
summary, exposure to EDCs - PCBs, BPA, or phthalates during early development of the 
breast, endometrium, and prostate can alter their development, possibly contributing to 
the susceptibility to complex chronic diseases through effects on stem cells.  Through 
research on hormone contraception, postmenopausal hormonal therapies and estrogen-
receptor (ER)-based endocrine therapies, we know estrogens are a major risk factor of 
both breast cancer and endometriosis (Evans 2008, Lin et al. 2009, Bertelsen et al. 2007). 
Given the proven contribution of unopposed estrogens to the risk for hormonal cancer, 
renewed health concerns have aroused about estrogen mimicking EDCs found in food, 
personal care products or as environmental contaminants. PCBs, BPA, and phthalates are 
the most extensively studied EDCs, and therefore, our objective of this study was to use 
the National Health and Nutrition Examination Survey (NHANES) data to assess the 
association of reproductive cancers (breast, cervix, ovarian, and uterine) with exposure to 
these three selected classes of EDCs: PCBs, BPA, and phthalates, commonly found in the 
environment today.   
METHODS 
Study design and population. NHANES is an ongoing cross-sectional survey designed to 
be nationally representative of the non-institutionalized U.S. civilian population.  
Conducted annually since 1999 by the National Center for Health Statistics of the Centers 
for Disease Control and Prevention (CDC), NHANES uses a complex multi-stage 
sampling design where approximately 5,000 survey participants a year complete in-home 
interviews and physical examinations in mobile examination units (CDC, 2012). 
Sociodemographic information and medical histories were collected during the in-home 
 
  
168 
 
interview and biological samples and reproductive health information was collected in 
the mobile examination component (MEC). All participants provided written informed 
consent and all procedures were approved by the National Center for Health Statistics 
(NCHS) Institutional Review Board (CDC, 2012).  We merged data from the 2003-2004, 
2005-2006, 2007-2008, and 2009-2010 survey years to analyze phthalate metabolites and 
from the 2005-2006, 2007-2008, and 2009-2010 survey years to analyze bisphenol A.  
During the 2003-2004 survey years, NHANES sampled urinary phenols and phthalates 
from two separate one-third subsets, therefore we did not include the 2003-2004 survey 
years in our analysis of bisphenol A.  We conducted a separate analysis of PCBs with 
data merged from the 1999-2000, 2001-2002, and 2003-2004 survey years.  We were not 
able to analyze PCBs from the 2005-2006 and 2007-2008 survey years because the 
datasets were withdrawn due to a quality control issue (CDC 2014).  In each survey year, 
subsets are a representative one-third sample of NHANES participants.  We limited our 
analysis to women 20 to 85 years of age who completed the reproductive and medical 
condition questionnaires in a face-to-face interview at a mobile examination center.  
Measurement of PCBs.  Blood serum concentrations of individual PCB congeners were 
measured in a representative, random one-third subsample of people 12 years of age and 
older in the 1999-2000, 2001-2002, and 2003-2004 survey cycles. PCB congeners were 
measured in serum by high-resolution gas chromatography/isotope-dilution high-
resolution mass spectrometry (HRGS/ID-HRMS).   NHANES provides both wet-weight 
and lipid adjusted values for each sample, corrected for sample weight and analyte 
recovery; we used lipid adjusted values in our analyses.  Detailed laboratory methods 
were consistent among survey cycles and are available online (CDC, 2013b).   Lipid-
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adjusted serum concentrations (ng/g) for 6 individual PCB congeners as well as the sum 
of the dioxin-like PCBs (74 + 118) and the sum of non-dioxin-like PCBs (118 + 138 
+153 + 170) were used in this study.  PCB congeners 74, 99, 118, 138, 153, and 180 were 
selected because they were available in all three survey cycles and concentrations were 
above the LOD in > 60% of the survey participants.   
Measurement of urinary phthalates and phenols. Bisphenol A and phthalate metabolites 
were quantified in urine by the use of solid phase extraction (SPE) coupled to reverse 
phase high performance liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS).  Laboratory methods and quality control were consistent across survey years 
and documentation in available online (CDC, 2012).  We examined  8 phthalate 
metabolites measured in the 4 consecutive NHANES cycles:  mono-n-butyl phthalate 
(MBP), mono-ethyl phthalate (MEP), mono-(2-ethyl)-hexyl phthalate (MEHP), mono-
benzyl phthalate (MBzP), mono-(3-carboxypropyl) phthalate (MCPP), mono-(2-ethyl-5-
hydroxyhexyl) phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP), and 
mono-isobutyl phthalate (MIB).  We summed MEHP, MEHHP, and MEOHP to represent 
the sum of di (2-ethylhexyl) phthalate (DEHP) and we summed all 8 phthalate 
metabolites (MBP + MEP + MEHP + MBzP + MCPP + MEHHP + MEOHP + MIB) to 
represent total phthalate exposure.  Bisphenol A (BPA) was the only phenol included in 
this study.  To correct for urine dilution, we divided all phthalate metabolites and BPA 
concentrations by urinary creatinine concentration and used the resulting creatinine 
corrected concentrations (mg/g) for all of our analyses. Urine samples with creatinine 
levels > 300 mg/dL or < 30 mg/dL were excluded because they were too dilute or too 
concentrated for accurate analysis (Sata et al. 1995).   
 
  
170 
 
Limit of detection.  A detection limit variable is provided for each PCB congener, 
phthalate metabolite and BPA in the data sets.  The variable LBD_LC has two values:  
the value “0” indicates that the result was below the limit of detection and the value “1” 
indicates that the result was at or above the limit of detection.  Any participant with a 
serum PCB concentration below the limit of detection was assigned a serum level of the 
LOD divided by the square root of two.  Limits of detection vary by metabolite and 
survey cycle and can be found in the CDC’s Fourth National Report on Human Exposure 
to Environmental Chemicals (CDC, 2013b).   
Data analysis.  We included female NHANES participants 20 to 85 years of age who 
completed the physical exam, reproductive questionnaire, and medical health 
questionnaire and provided a response for “Have you ever been told by a doctor or other 
health professional that you had cancer or a malignancy of any kind?” Women who 
answered “yes” were subsequently asked “What kind of cancer was it?”  and “What was 
your age at diagnosis?” 
PCB data analysis.  8,315 women 20 to 85 years of age provided a response in the 1999-
2004 survey cycles to for “Have you ever been told by a doctor or other health 
professional that you had cancer or a malignancy of any kind?”  After deleting 
observations that were missing PCB data our PCB study population consisted of 2,072 
participants:  43 reported a breast cancer diagnosis, 27 reported a cervical cancer 
diagnosis, 11 reported an ovarian cancer diagnosis, 26 reported a uterine cancer diagnosis 
and women who reported never being diagnosed with cancer ranged from 1955 to 1962 
participants depending on the PCB congener being evaluated.  
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Phthalate data analysis.   Our phthalate study population consisted of women 20 to 85 
years of age who provided a response in the 2003-2010 survey years to “Have you ever 
been told by a doctor or other health professional that you had cancer or a malignancy of 
any kind?”  After deleting creatinine observations that were < 30 mg/dL and > 300 
mg/dL our study populations consisted of 3,003 participants of whom 97 reported a 
breast cancer diagnosis, 28 reported a cervical cancer diagnosis, 20 reported an ovarian 
cancer diagnosis, 27 reported a uterine cancer diagnosis, and 2,731reported never being 
diagnosed with cancer.   
BPA data analysis.   Our BPA study population consisted of women 20 to 85 years of 
age provided a response in the 2005-2010 survey cycles to for “Have you ever been told 
by a doctor or other health professional that you had cancer or a malignancy of any 
kind?”  After deleting creatinine observations that were < 30 mg/dL and > 300 mg/dL our 
study populations consisted of 2,202 participants of whom 78 reported a breast cancer 
diagnosis, 16 reported a cervical cancer diagnosis, 16 reported an ovarian cancer 
diagnosis, 22 reported a uterine cancer diagnosis, and 2,070 reported never being 
diagnosed with cancer.   
Statistical analysis.  All statistical analyses were performed using SAS system software 
(release 9.2; SAS Institute Inc. Cary, N.C.).  Appropriate subsample weights were 
calculated according to the National Center for Health Statistics guidelines to adjust for 
oversampling of minority groups (CDC, 2013b). Nonmissing values for serum 
concentrations below the LOD were assigned a serum level of the LOD divided by the 
square root of two.  In our PCB analysis, all lipid-adjusted serum PCB concentrations 
were log transformed to satisfy normality assumptions.   In our phthalate and BPA 
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analyses, all urinary compounds and metabolites were log transformed and creatinine 
corrected.  Due to a small number of cervical, ovarian and uterine cancer cases, we 
conducted logistic regression analyses using the following two groups: < LOD to 50th 
percentile (reference) vs. ≥ 50th percentile.  We also conducted separate analyses on 
females with serum PCB, phthalate, and BPA levels > LOD where cancer cases were 
compared with non-cancer cases.   Significance was set at p < 0.05.   
We used PROC SURVEYMEANS to account for the complex sampling design of 
NHANES and to obtain weighted means, 95% confidence intervals, and standard errors 
of individual PCB congeners, the sum of dioxin-like PCBs, the sum of non-dioxin-like 
PCBs, individual phthalate metabolites, the sum of DEHP (MHH+MOH+MHP), and 
BPA. We used the Taylor Series (linearization) method to estimate standard errors.   A 
two-sided student t-test was calculated using PROC SURVEYREG to test whether the 
mean EDC (PCB, phthalate, or BPA) levels between women who reported a breast, 
cervical, ovarian, or uterine cancer diagnosis and women who reported no cancer 
diagnosis were significantly different.    Age was divided into three groups (20-59 years, 
60-74 years, and ≥ 75 years) that were selected based on the age distribution of 
reproductive cancer cases and noncases in our data set. Race/ethnicity was divided into 
two groups (non-Hispanic White and ‘Other’) due to a very small number of reproductive 
cancer cases from races/ethnicities other than non-Hispanic White.  The category of 
‘Other’ includes Mexican American, Non-Hispanic Black, Other Hispanic and Other 
Race – Including Multi-Racial. We also calculated GMs for reproductive cancer cases 
and noncases in women with PCB, phthalate, and BPA levels above the LOD.  
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Using PROC SURVEYLOGISTIC, we derived unadjusted and adjusted ORs and 
their 95% CIs to evaluate the association between exposure to EDCs and breast cancer, 
cervical cancer, ovarian cancer, or uterine cancer.   We conducted separate analyses for 
the sum of dioxin-like and non-dioxin-like PCBs and individual PCB congeners and 
reproductive cancers. Due to a small number of cervical, ovarian, and uterine cancer 
cases, ORs and 95% CIs were calculated using the following group: < LOD to 50th 
percentile vs. ≥ 50th percentile.    The reference group for each PCB congener is defined 
as those participants whose serum concentrations were < LOD to 50th percentile.   
Covariates.  We considered a number of potential confounders based on previous 
literature and well-established risk factors for reproductive cancers. The following 
potential confounders were either self-reported in the questionnaire interviews or taken as 
a laboratory measurement.  The demographic variables of age at interview (20-59 years, 
60-74 years, and ≥ 75 years), race (white vs. other) were obtained during the NHANES 
home interview (CDC 2012).  Reproductive variables including age at menarche (<12 
years, 12-14 years, ≥15 years),  parity (0, 1, ≥ 2), oral contraceptive use (yes/no) and 
lactation (yes/no) as well as lifestyle variables including smoking (yes/no) and alcohol 
use (yes/no) were obtained from health questionnaires completed in the mobile 
examination center. Body mass index (< 25 kg/m2, 25 to < 30 kg/m2, and ≥ 30 kg/m2) 
was obtained through the body measurement component in the mobile examination 
center (CDC 2013b). For all EDCs, ORs and 95% CIs are reported for three models: 
unadjusted; age and race/ethnicity adjusted; and age, race/ethnicity, BMI, and age at 
menarche adjusted. Parity, oral contraceptive use and lactation were not included in the 
models because of the extent of missing data.  Smoking history and alcohol consumption 
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were not significant predictors of breast cancer risk and therefore were also not presented 
in the final models.   
RESULTS 
PCB descriptive statistics. The study population included 2,008 female participants 20 
years of age and older with available PCB data and who completed the medical 
conditions questionnaire and provided a response for “Have you ever been told by a 
doctor or other health professional that you had cancer or a malignancy of any kind?” 
Women who answered “yes” were subsequently asked, “What kind of cancer was it?” 
and “What was your age at diagnosis?” Among the women who responded to the 
questions stated above and had available PCB data, 1,965 (91.5%) reported never being 
diagnosed with cancer, 43 (2.14%) reported being diagnosed with breast cancer, 27 
(1.36%) reported being diagnosed with cervical cancer, 11 (0.56%) reported being 
diagnosed with ovarian cancer, and 26 (1.31%) reported being diagnosed with uterine 
cancer (Table 3.1). Participants were fairly evenly distributed over the two races: 48.6% 
were of non-Hispanic white ethnicity and 51.4% were classified as ‘Other’, however the 
majority of breast cancer cases were in non-Hispanic white women (81.5%).   The 
majority of participants were 20-59 years of age at the time of interview (65.9%) (Table 
3.1).  The mean age at time of interview was 45.6 years for women who reported never 
being diagnosed with cancer, 65.7 years, 47.5 years, 52.0 years, and 52.4 years for 
women who reported being diagnosed with breast cancer, cervical cancer, ovarian cancer, 
and uterine cancer, respectively.  The mean age at diagnosis was 54.9 years, 30.6 years, 
41.9 years, and 53.2 years for women diagnosed with breast cancer, cervical cancer, 
ovarian cancer, and uterine cancer, respectively (Table 3.1).  BMI was normal (< 25 
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kg/m2) for 35.5%, overweight (25to < 30 kg/m2) for 28.6%, and obese (≥ 30 kg/m2) for 
39.0% of study participants.  The majority of study participants reported and an age of 
menarche of 12-14 years (64%), ≥ 2 live births (71.4%), responded yes to breastfeeding 
(57.6%), responded yes to oral contraceptive use (58.8%),  responded no to a history of 
smoking (57.8%), and yes to alcohol consumption (54.5%) (Table 3.1).  
Table 3.1.  Descriptive statistics for cancer diagnosis and selected covariates among women ≥ 20 years of 
age with serum PCB measurements, NHANES 1999-2004.   
                                    Breast     Cervical     Ovarian       Uterine  
                                                     No Cancer      Cancer     Cancer    Cancer        Cancer 
Variable                                      n(%)         n(%)                n(%)               n(%)                 n(%) 
Total Population (n,%)           1965 (91.5%)    43 (2.14%)   27 (1.36%)   11 (0.56%)   26 (1.31%)
Age at interview (years; mean ± se)     45.6 ± .42     65.7 ± 2.12   47.5 ± 2.61   52.0 ± 3.75   52.4 ± 5.17
Age at diagnosis (years; mean ± se)             54.9 ± 3.91   30.6± 1.14   41.9 ± .1.97  53.2 ± 1.52
Race/Ethnicity 1     
 Non-Hispanic white          942 (44.0%)    35 (1.74%)   19 (0.95%)   6 (0.30%)   17 (0.85%)
Other                 1023 (47.6%)    8 (0.40%)   8 (0.40%)   5 (0.25%)   9 (0.45%) 
Age  (years) 
 20-59                  1369(63.7%)     7 (0.35 %)   18(0.90%)   7 (0.35%)   11 (0.55%)
 60-74                 384 (17.8%)     26 (1.29%)   6 (0.30%)   3 (0.15%)   11 (0.55%)
 ≥ 75                  212 (9.87%)    10 (0.50%)   3 (0.15%)   1 (0.05%)   4 (0.20%) 
Age at menarche (years)  
 < 12 years              344 (17.9%)    6 (0.33%)   10 (0.56%)   2 (0.11%)   7 (0.39) 
 12-14 years              1161 (60.4%)    30 (1.67%)   14 (0.79%)   6 (0.34%)   14 (0.78%)
 ≥ 15 years               254 (13.2%)    4 (0.22%)   0 (0.00%)   2 (0.11%)   4 (0.22%) 
Parity (no. of live births)  
 0                                                    82 (4.89%)     0 (0.00%)   3 (0.19%)   1 (0.07%)   1 (0.06%) 
 1                                                    319 (19.0%)    5 (0.32%)   4 (0.26%)   2 (0.13%)   5 (0.32%) 
 > 2                                               1121 (66.9%)    29 (1.86)%   16(1.04%)   6 (0.39%)   18 (1.16%)
BMI (kg/m2)   
 Normal weight (18.5 to <25)       715 (33.3%)    13 (0.65%)   16 (0.80%)   4 (0.20%)   12 (0.60%)
 Overweight (25 to <30)           580(27.0%)     18 (0.90%)   2 (0.10%)   4 (0.20%)   8 (0.40%) 
 Obese (≥30)                  670 (31.2%)    12 (0.60%)   9 (0.45%)   3 (0.15%)   6 (0.30%) 
Breastfed   
 Yes                    835 (54.1%)    19 (1.33%)   12 (0.85%)   5 (0.36%)   13 (0.92%)
 No                                                559 (36.2%)    15 (1.05%)   8 (0.57%)   3 (0.21%)   10 (0.71%)
Oral Contraceptive Use    
 Yes                    1101(55.9%)    22 (0.91%)   18 (0.98%)   6 (0.33%)   12 (0.66%)
 No                                              701 (35.5%)    30 (1.25%)   6 (0.33%)   4 (0.22%)   14 (0.76%)
Ever Smoked   
 Yes                                               775(36.1 %)    21 (1.14%)   13 (0.65%)   7 (0.35%)   16 (0.80%)
No                     1189 (55.4%)    19 (1.03%)   14 (0.70%)   4 (0.20%)   10 (0.50%)
Alcohol Use   
 Yes                     1019 (51.5%)    23 (1.15%)   10 (0.55%)   7 (0.38%)   17 (0.93%)
 No                     790 (39.9%)    20 (1.00%)   15 (0.85%)   3 (0.16%)   9 (0.49%) 
Estimated percent distribution after applying NHANES sampling weights.   
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Phthalate and BPA descriptive statistics. The study population included 3,003 female 
participants 20 years of age and older with available phthalate and/or BPA data and who 
completed the medical conditions questionnaire and provided a response for “Have you 
ever been told by a doctor or other health professional that you had cancer or a 
malignancy of any kind?” Women who answered “yes” were subsequently asked, “What 
kind of cancer was it?” and “What was your age at diagnosis?” Among the 3,003 
participants, 2,731 (90.4%) reported never being diagnosed with cancer, 97 (2.22%) 
reported being diagnosed with breast cancer, 28 (0.65%) reported being diagnosed with 
cervical cancer, 20 (0.47%) reported being diagnosed with ovarian cancer, and 27 
(0.63%) reported being diagnosed with uterine cancer (Table 3.2). Of the women who 
reported a reproductive cancer or no cancer, 43.5% of the participants were of non-
Hispanic white ethnicity and 52.6% were classified as ‘Other’.  The majority of 
participants were 20-59 years of age at the time of interview (67.7%) (Table 3.2).  The 
mean age at time of interview was 45.3 years for women who reported never being 
diagnosed with cancer, 65.1 years, 48.1 years, 56.1 years, and 58.3 years for women who 
reported being diagnosed with breast cancer, cervical cancer, ovarian cancer, and uterine 
cancer, respectively.  The mean age at diagnosis was 56.0 years, 30.5 years, 46.3 years, 
and 52.3 years for women diagnosed with breast cancer, cervical cancer, ovarian cancer, 
and uterine cancer, respectively (Table 3.2).  BMI was normal (< 25 kg/m2) for 28.3%, 
overweight (25to < 30 kg/m2) for 28.6%, and obese (≥ 30 kg/m2) for 39.3% of study 
participants.  The majority of study participants reported and an age of menarche of 12-
14 years (62.1%), ≥ 2 live births (74.0%), responded yes to breastfeeding (54.9%), and 
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responded yes to oral contraceptive use (63.4%) ,  responded no to a history of smoking 
(58.4%), and yes to alcohol consumption (57.1%) (Table 3.2).  
Table 3.2.  Descriptive statistics for cancer diagnosis and selected covariates among women ≥ 20 years of 
age with urinary phthalate and bisphenol A measurements, NHANES 2003-2010.    
                                     Breast     Cervical     Ovarian       Uterine 
                                                  No Cancer       Cancer      Cancer      Cancer         Cancer 
Variable                                    n(%)          n(%)                n(%)                 n(%)                  n(%) 
Total Population (n,%)           2731 (90.4%)    97 (2.22%)   28 (0.65%)   20 (0.47%)   27 (0.63%)
Age at interview (years; mean ± se)     45.3 ± .40     65.1 ± 2.40   48.1 ± 2.71   56.1 ± 5.09   58.3 ± 3.10
Age at diagnosis (years; mean ± se)             56.0 ± 2.27   30.5 ± 0.76   46.3 ± 1.42   52.3 ± 2.04
Race/Ethnicity           
 Non-Hispanic white          1202 (39.6%)    63 (2.23%)   18 (0.65%)   9 (0.33%)   20 (0.73%)
Other                 1529 (50.4%)    34 (1.20%)   10 (0.36%)   11 (0.40%)   7 (0.25%) 
Age  (years) 
 20-59                  1971(65.0%)    22 (0.78%)   24 (0.87%)   9 (0.33%)   8 (0.29%) 
 60-74                 504(16.6%)     38 (1.34%)   3 (0.11%)   6 (0.22%)   11 (0.40%)
 ≥ 75                  256 (8.44%)    37 (1.31%)   1 (0.04%)   5 (0.18%)   8 (0.29%) 
Age at menarche (years)  
 < 12 years              517 (19.0%)    18 (0.71%)   5 (0.20%)   4 (0.16%)   5(0.20%) 
 12-14 years              1574 (58.0%)    57 (2.26%)   18 (0.73%)   10 (0.41%)   17 (0.69%)
 ≥ 15 years               343 (12.6%)    16 (0.63%)   3 (0.12%)   3 (0.12%)   5 (0.20%) 
Parity (no. of live births)  
 0                                                     54 (2.42%)    2 (0.10%)   1 (0.05%)   0 (0.00%)   0 (0.00%) 
 1                                                     400 (17.9%)    13 (0.63%)   4 (0.20%)   4 (0.20%)   1 (0.21%) 
 > 2                                                1531(68.5%)    63 (3.05%)   21 (1.04%)   11 (0.55%)   4 (0.82%) 
BMI (kg/m2)  
 Normal weight (18.5 to <25)         800 (26.6%)    32 (1.14%)   7 (0.26%)   3 (0.11%)   6(0.22%) 
 Overweight (25 to <30)            803 (26.7%)     26 (0.93%)   7 (0.26%)   12 (0.44%)   6 (0.22%) 
 Obese (≥30)                  1102 (36.7%)    38 (1.36%)   14 (0.51%)   5 (0.18%)   15 (0.55%)
Breastfed  
 Yes                    1117 (51.1%)    42 (2.09%)   15 (0.77%)   7 (0.36%)   11 (0.56%)
 No                                                 816 (37.4%)    35 (1.74%)   10 (0.51%)   8 (0.41%)   15 (0.77%)
Oral Contraceptive Use    
 Yes                    1650 (60.0%)    42 (1.64%)   21(0.84%)   7 (0.28%)   15 (0.60%)
 No                                               827 (30.%)    49 (1.91%)   5 (0.20%)   10 (0.40%)   12 (0.48%)
Ever Smoked   
 Yes                                               1060 (35.0%)    39 (1.38%)   21 (0.76%)   6 (0.22%)   13 (0.47%)
No                     1669 (55.1%)    58 (2.05%)   7 (0.25%)   14 (0.51%)   14 (0.51%)
Alcohol Use   
 Yes                     1480 (53.6%)    50 (1.95%)   19 (0.76%)   6 (0.24%)   14 (0.56%)
 No                     998 (36.1%)    41 (1.60%)   7 (0.28%)   11 (0.44%)   13 (0.52%)
Estimated percent distribution after applying NHANES sampling weights.    
 Table 3.3 presents GMs and GSEs of EDCs by reproductive cancer status. GM 
PCB levels were significantly higher for all 6 PCB congeners in women diagnosed with 
breast cancer, PCB 74, 99, 118, 138, and 153 were significantly higher  in women 
diagnosed with uterine cancer and PCB 138, 153, and 180 were significantly higher in 
women diagnosed with uterine cancer compared to women never diagnosed with cancer.  
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None of the PCB congeners were significantly higher in women diagnosed with cervical 
cancer (Table 3.3, Figure 3.1).  MEHHP was significantly higher in women diagnosed 
with ovarian cancer and MEP was significantly higher in women diagnosed with uterine 
cancer compared to women never diagnosed with cancer (Table 3.3, Figure 3.2).  MBzP 
was found to be significantly higher in women without cancer compared to women with 
breast cancer. Women diagnosed with a reproductive cancer did not have significantly 
higher levels of BPA compared to women never diagnosed with cancer. In contrast, 
women never diagnosed with cancer had significantly higher levels of BPA than women 
diagnosed with breast cancer (Table 3.3).  
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Table 3.3.  Geometric Mean serum PCB, urinary phthalate and urinary BPA levelsby cancer diagnosis for 
women ≥ 20 years of age.  
      Geometric mean1(ng/g) (GSE,n)  
              No           Breast           Cervical             Ovarian          Uterine 
                                      Cancer            Cancer            Cancer       Cancer          Cancer  
PCB Metabolites2 
PCB 074           8.08 (1.03, 1960)   15.6 (1.14, 43)a   9.58 (1.21, 27)    30.0 (1.32, 11)b       10.8 (1.21, 26) 
PCB 099      5.99 (1.03, 1958)   9.39 (1.12, 43)b    6.82 (1.16, 26)    51.9 (1.32, 11)b     7.24 (1.21, 25) 
PCB 118           9.49 (1.03, 1960)   17.5 (1.16, 43)b   12.2 (1.25, 27)        38.9 (1.38, 11)b      11.1 (1.32, 26) 
PCB 138           20.9 (1.03, 1961)   39.6 (1.11, 43)a     25.3 (1.20, 27)         22.3 (1.36, 11)b      30.9 (1.14, 26)b 
PCB 153           28.8 (1.02, 1962)   56.2 (1.11, 43)a     33.8 (1.20, 27)        12.2 (1.42, 11)b     40.9 (1.15, 26)b 
PCB 180           19.5 (1.02, 1955)   44.3 (1.10, 43)a     23.8 (1.17, 27)    16.6 (1.28, 11)     30.3 (1.20, 26)b 
Phthalate Metabolites3 
MBP                        1.93 (1.01, 2723)   1.90 (1.04, 97)   1.92 (1.04, 28)   1.93 (1.04, 20)          2.03 (1.07, 27) 
MEP                         2.83 (1.01, 2723)  2.66 (1.05, 97)   2.86 (1.04, 28)   2.64 (1.05, 20)    3.10 (1.16, 27)b
MEHP                      1.19 (1.01, 2723)  1.14 (1.05, 97)   1.20 (1.05, 28)   1.36 (1.05, 20)           1.07 (1.07, 27) 
MBzP                       1.54 (1.01, 2723)d  1.45 (1.04, 97)   1.51 (1.05, 28)   1.68 (1.07, 20)    1.46 (1.08, 27) 
MCCP                      1.21 (1.01, 2723)  1.19 (1.03, 97)   1.18 (1.05, 28)   1.26 (1.09, 20)    1.20 (1.04, 27) 
MEHHP                   1.90 (1.01, 2723)  1.92 (1.03, 97)   1.88 (1.05, 28)   2.32 (1.25, 20)b    1.93 (1.08, 27) 
MEOHP                   1.72 (1.01, 2723)  1.73 (1.04, 97)   1.77 (1.05, 28)   2.03 (1.28, 20)    1.72 (1.08, 27) 
MIB                          1.46 (1.01, 2723)  1.39 (1.05, 97)   1.39 (1.04, 28)   1.46 (1.06, 20)    1.46 (1.09, 27) 
DEHP4                      3.86 (1.03, 2723)  3.78 (1.13, 97)   3.34 (1.17, 28)   6.55 (2.08, 20)    3.53 (1.23, 27) 
Total Phthalates5       58.0 (1.04, 2723)  46.5 (1.15, 97)   54.6 (1.31, 28)   102 (1.54, 20)    56.8 (1.22, 27) 
Bisphenol A6 
BPA                          1.16 (1.01, 2070)c     1.06 (1.03, 78)   1.17 (1.08, 16)   1.23 (1.08, 16)    1.09 (1.06, 22) 
1Geometric means calculated after applying NHANES sampling weights.  
2Lipid adjusted and log transformed polychlorinated biphenyls (ng/g); NHANES 1999-2004.  
3Log transformed and creatinine corrected urinary phthalate metabolites (ng/mg); NHANES 2003-2010.   
4DEHP = Sum of MEHP, MEHHP and MEOHP. 
5Total Phthalates = Sum of MBP, MEP, MEHP, MBzP, MCCP, MEHHP, MEOHP and MIB.   
6Log transformed and creatinine corrected urinary BPA measurements (ng/g); NHANES 2005-1010.  
PCB or phthalate levels significantly higher in women with cancer vs. women without cancer; 
 ap < 0.0001, bp < 0.05. 
BPA significantly higher in women without cancer vs. women with breast cancer, cp < 0.05. 
MBzP is significantly higher in women without cancer vs. women diagnosed with breast cancer, dp<0.05. 
  
 
 
  
180 
 
 
 Figure 3.1.  Geometric Mean PCB levels (ng/g) by cancer diagnosis among women ≥ 20 
years of age, NHANES 1999-2004. 
 
 
Figure 3.2.  Geometric mean urinary phthalate levels (ng/mg) by cancer diagnosis among 
women ≥ 20 years of age, NHANES 2003-2010.   
 
GM EDC levels were also examined by cancer status in women with individual 
PCB concentrations above the LOD (Table 3.4).  All 6 PCB congeners remained 
significantly higher in women diagnosed with breast cancer, PCB 74, 99, 118, 138, and 
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153 were significantly  higher in women diagnosed with ovarian cancer, and PCB 138 
was significantly higher in women diagnosed with uterine cancer compared to women 
never diagnosed with cancer. For women with phthalate concentrations above the LOD, 
GM levels did not differ between women diagnosed with a reproductive cancer and 
women never diagnosed with cancer (Table 3.4). When observations below the LOD 
were removed BPA became significantly higher in women diagnosed with cervical 
cancer compared to women never diagnosed with cancer (Table 3.4).  
Table 3.4.  Geometric Mean PCB, urinary phthalate and urinary BPA levels by cancer diagnosis among 
women ≥ 20 years of age with concentrations above the LOD.   
        Geometric mean1 (GSE,n)  
             No            Breast         Cervical          Ovarian          Uterine 
                                    Cancer          Cancer         Cancer        Cancer          Cancer  
PCB Metabolites2 
PCB 074           9.87 (1.03, 1484)   16.0 (1.07, 43)b   10.7 (1.25, 24)    21.8 (1.19, 9)a        10.9 (1.21, 23)  
PCB 099      7.24 (1.02, 1334)   9.87 (1.08, 43)b    7.61 (1.21, 21)    20.1 (1.21, 8)b     8.50 (1.22, 19) 
PCB 118           11.7 (1.03, 1534)   17.5 (1.16, 43)b   14.4 (1.29, 24)        30.9 (1.25, 9)a      12.9 (1.25, 23) 
PCB 138           23.6 (1.03, 1594)   39.6 (1.11, 43)a     28.2 (1.22, 24)         47.5 (1.38, 9)b      31.5 (1.14, 25)b
PCB 153           31.8 (1.03, 1651)   56.2 (1.11, 43)a     37.7 (1.21, 25)        63.4 (1.35,9)b       41.3 (1.15, 25) 
PCB 180           23.3 (1.03, 1600)   44.3 (1.10, 43)a     25.0 (1.17, 25)    37.7 (1.36, 9)      30.9 (1.21, 24) 
Phthalate Metabolites3 
MBP                        1.93 (1.01, 2718)   1.93 (1.03, 97)   1.92 (1.04, 27)   1.93 (1.04, 20)         2.03 (1.08, 27) 
MEP                        2.83 (1.01, 2722)   2.66 (1.04, 97)   2.86 (1.06, 28)   2.64 (1.05, 20)     3.10 (1.06, 27) 
MEHP                     1.34 (1.01, 1913)   1.28 (1.04, 64)   1.45 (1.06, 18)   1.55 (1.27, 16)         1.16 (1.04, 19) 
MBzP                      1.55 (1.01, 2704)   1.46 (1.03, 96)   1.51 (1.05, 28)   1.68 (1.07, 20)     1.46 (1.05, 27) 
MCCP                     1.22 (1.01, 2677)   1.22 (1.03, 95)   1.19 (1.05, 28)   1.26 (1.09, 20)     1.20 (1.05, 27) 
MEHHP                  1.90 (1.01, 2719)   1.92 (1.03, 97)   1.88 (1.06, 28)   2.32 (1.25, 20)     1.93 (1.04, 27) 
MEOHP                  1.72 (1.01, 2714)   1.73 (1.03, 97)   1.77 (1.05, 28)   2.03 (1.28, 20)     1.72 (1.03, 27) 
MIB                        1.48 (1.01, 2695)   1.42 (1.03, 95)   1.43 (1.04, 27)   1.46 (1.06, 20)     1.46 (1.06, 27) 
Bisphenol A4 
BPA                        1.18 (1.01, 1959)   1.11 (1.03, 71)   1.27 (1.05, 14)a   1.30 (1.08, 15)    1.16 (1.05, 20) 
1Geometric means calculated after applying NHANES sampling weights.  
2Lipid adjusted and log transformed polychlorinated biphenyls (ng/g); NHANES 1999-2004.   
3Log transformed and creatinine corrected phthalate metabolites (ng/mg); NHANES 2003-2010.   
4Log transformed and creatinine corrected urinary BPA measurements (ng/g); NHANES 2005-1010.  
PCB, BPA, or phthalate levels significantly higher in women with cancer vs. women without cancer; 
 ap < 0.0001, bp < 0.05  
Estimated ORs and 95% confidence intervals for the risk of having breast, 
cervical, ovarian, or uterine cancers cancer and the six individual PCB congeners are 
shown in tables 3.5-3.8. Due to the lack of breast cancer cases in women with low blood 
PCB levels and in women with blood PCB levels below the LOD, the following two 
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groups were used to estimate breast cancer risk:  < LOD to 50th percentile (reference 
group) and ≥ 50th percentile. Results are presented for three logistic regression models: 
unadjusted; age and race/ethnicity adjusted; and age, race/ethnicity, BMI, and age at 
menarche adjusted. In unadjusted models, PCBs were significantly associated with breast 
cancer risk for subjects in the second group (≥ 50th percentile) when compared to the 
reference group (< LOD to 50th percentile) for PCB congeners 74, 99, 118, 138, 153, and 
180 (Table 3.5). After adjusting for age and race/ethnicity, PCB138 was the only 
congener found to be significantly associated with breast cancer [OR of 3.16; 95% CI: 
1.14-8.76] (Table 3.5)After adjusting for age, race/ethnicity, BMI, lactation, and age at 
menarche, PCB138 remained significantly associated with breast cancer (OR of 2.88, 
95% CI) (Table 3.5).   
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Table 3.5. Estimated ORs (95% CIs) of breast cancer by concentration of PCBs, among women ≥ 20 years 
of age, NHANES 1999-2004. 
                                                                   
             No.    No.    Unadjusted OR         Adjusted OR2     Adjusted OR3 
Analyte1       Cases    Noncases     (95% CI)              (95% CI)       (95% CI) 
PCB 074       
< LOD to 50%      4    1047     1.00           1.00          1.00 
≥ 50%          39   912     5.82 (2.56-13.1)a     1.62 (0.48-5.38)   1.95 (0.31-12.4)
PCB 099  
< LOD to 50%      12   1172     1.00             1.00          1.00 
 ≥ 50%          31   787     3.09 (1.60-5.98)b     1.40 (0.66-2.94)   1.52 (0.62-3.74)
PCB 118 
 < LOD to 50%      6    999     1.00           1.00          1.00 
 ≥ 50%          37   960     4.34 (1.95-9.70)b    1.38 (0.40-4.78)   1.54 (0.29-8.35)
PCB 138 
< LOD to 50%      4    1068     1.00           1.00          1.00 
 ≥ 50%           39   891     7.35 (3.10-17.5)a      3.14 (1.14-8.62)b   2.52 (1.06-5.99)b
PCB 153 
< LOD to 50%      4    1078     1.00           1.00          1.00 
 ≥ 50%           39   882     9.20 (2.30-36.8)b      3.94 (0.58-26.6)   3.15 (0.53-18.6)
PCB 180 
< LOD to 50%      4    1148     1.00           1.00          1.00 
 ≥ 50%          39   806     10.6 (3.03-37.1)b      4.33 (0.79-23.6)    3.45 (0.76-15.6)
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age and  race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  40/1754 in 074; 40/1753 in099; 
40/1755 in 118; 40/1756 in 138 and 153; 40/1749  in 180.   
Significance ap < 0.0001, bp < 0.05.  
Estimated ORs and 95% confidence intervals for the risk of having cervical and the six 
individual PCB congeners are shown in table 3.6. In unadjusted models, PCBs were 
significantly associated with cervical cancer risk for subjects in the second group (≥ 50th 
percentile) when compared to the reference group (< LOD to 50th percentile) for PCB 
congeners 138 and 153 (Table 3.6). After adjusting for age and race/ethnicity, PCB138 
was the only congener found to be significantly associated with cervical cancer (OR of 
3.12; 95% CI: 1.32-8.74) (Table 3.6).   After adjusting for age, race/ethnicity, BMI, 
lactation, and age at menarche, PCB138 remained significantly associated with cervical 
cancer (OR of 3.05, 95% CI: 1.21-7.69) (Table 3.6).   
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Table 3.6. Estimated ORs (95% CIs) of cervical cancer by concentration of PCBs, among women ≥ 20 
years of age, NHANES 1999-2004. 
                                                                     
              No.     No.    Unadjusted OR         Adjusted OR2     Adjusted OR3 
Analyte1         Cases      Noncases   (95% CI)              (95% CI)       (95% CI) 
PCB 074       
< LOD to 50%      12    1048     1.00           1.00          1.00 
≥ 50%          15    912     1.26 (0.55-2.87)     1.01 (0.37-2.77)   0.87 (0.28-2.70) 
PCB 099  
< LOD to 50%      13    1172     1.00             1.00          1.00 
 ≥ 50%          13    787     1.52 (0.81-2.83)     1.53 (0.81-2.88)   1.40 (0.72-2.74) 
PCB 118 
 < LOD to 50%      11    1000     1.00           1.00          1.00 
 ≥ 50%          16    960      1.47 (0.57-3.77)    1.39 (0.48-3.96)   1.28 (0.40-4.04) 
PCB 138 
< LOD to 50%      9     1070     1.00            1.00          1.00 
 ≥ 50%           18    891     2.96 (1.45-6.06)b      3.12 (1.32-87.40)b  3.05 (1.21-7.69)b 
PCB 153 
< LOD to 50%        11    1080      1.00          1.00          1.00 
 ≥ 50%           16    882      2.17 (1.04-4.53)b     2.18 (0.86-5.53)   2.46 (0.90-6.67) 
PCB 180 
< LOD to 50%      14    1149      1.00          1.00          1.00 
 ≥ 50%          13    806      1.75 (0.95-3.23)      1.61 (074-3.50)    1.58 (0.70-3.56) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age and race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  24/1754 in 074; 23/1753 in 099; 
24/1755 in 118; 24/1756 in 138 and 153; 24/1749 in 180.   
Significance ap < 0.0001, bp < 0.05. 
  
Estimated ORs and 95% confidence intervals for the risk of having ovarian cancer and 
the six individual PCB congeners are shown in table 3.7. In unadjusted models, PCBs 
were significantly associated with ovarian cancer risk for subjects in the second group (≥ 
50th percentile) when compared to the reference group (< LOD to 50th percentile) for 
PCB congeners 74 and 118 (Table 3.7). After adjusting for age, race/ethnicity, BMI, 
lactation, and age at menarche, PCB 74 and 118 remained significantly associated with 
ovarian cancer [ORs of 6.47 (95% CI: 1.23-34.1) and 6.68 (95% CI: 1.39-32.3)] (Table 
3.7).   
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Table 3.7. Estimated ORs (95% CIs) of ovarian cancer by concentration of PCBs among women ≥ 20 
years of age, NHANES 1999-2004, 
                                                                    
              No.      No.    Unadjusted OR        Adjusted OR2    Adjusted OR3 
Analyte1        Cases    Noncases   (95% CI)             (95% CI)      (95% CI) 
PCB 074       
< LOD to 50%       2   1048      1.00           1.00          1.00 
≥ 50%           9   912      5.88 (1.67-207)b     7.31 (1.62-32.9)b   6.47 (1.23-34.1)b
PCB 099  
< LOD to 50%       3   1171      1.00             1.00          1.00 
 ≥ 50%            8   787      3.67 (0.65-20.9)     4.15 (0.55-31.3)   3.69 (0.43-31.7) 
PCB 118 
 < LOD to 50%       2    1000      1.00           1.00          1.00 
 ≥ 50%           9   960      5.81 (1.66-20.4)b    7.17 (1.64-31.3)b   6.68 (1.39-32.3)b
PCB 138 
< LOD to 50%       4   1070      1.00           1.00          1.00 
 ≥ 50%              7   891      1.22 (0.24-6.28)      1.23 (0.15-9.81)      0.97 (0.12-7.63) 
PCB 153 
< LOD to 50%         3   1080      1.00           1.00          1.00 
 ≥ 50%            8   882      2.12 (0.49-9.13)      2.36 (0.46-12.0)   2.05 (0.50-8.41) 
PCB 180 
< LOD to 50%       3   1149      1.00           1.00          1.00 
 ≥ 50%           8   806      2.49 (0.58-10.7)      2.88 (0.53-15.6)    2.55 (0.66-9.85) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age and race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  10/1754in 074; 10/1753 in 099;
 10/1755  in 118; 10/1756 in 138 and 153; 10/1749 in 180.   
Significance ap < 0.0001, bp < 0.05.  
Estimated ORs and 95% confidence intervals for the risk of having uterine cancer 
and the six individual PCB congeners are shown in table 3.8. In unadjusted models, PCBs 
were significantly associated with uterine cancer risk for subjects in the second group (≥ 
50th percentile) when compared to the reference group (< LOD to 50th percentile) for 
PCB congeners 138 and 153 (Table 3.8). After adjusting for age, race/ethnicity, BMI, 
lactation, and age at menarche, PCB 138 remained significantly associated with ovarian 
cancer [OR of 5.83 (95% CI: 1.63-20.9)] (Table 3.8).   
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Table 3.8. Estimated ORs (95% CIs) of uterine cancer by concentration of PCBs among women ≥ 20 years 
of age, NHANES 1999-2004. 
                                                                    
              No.    No.   Unadjusted OR        Adjusted OR2    Adjusted OR3 
Analyte1        Cases    Noncases   (95% CI)              (95% CI)       (95% CI) 
PCB 074       
< LOD to 50%       8    1048    1.00           1.00          1.00 
≥ 50%           18   912    2.13 (0.63-7.15)     1.41 (0.36-5.55)   1.55 (0.34-7.06) 
PCB 099  
< LOD to 50%       13   1171    1.00             1.00          1.00 
 ≥ 50%           12   787    1.55 (0.46-5.27)     1.19 (0.28-4.97)   1.43 (0.34-6.06) 
PCB 118 
 < LOD to 50%       10   1000    1.00           1.00          1.00 
 ≥ 50%           16   960    1.60 (0.55-4.63)    1.07 (0.24-4.76)   1.52 (0.39-5.92)
PCB 138 
< LOD to 50%       7    1070    1.00           1.00          1.00 
 ≥ 50%            19   891    4.84 (1.68-13.9)b      4.29 (1.21-15.2)b    5.83 (1.63-20.9)b
PCB 153 
< LOD to 50%        8   1080    1.00           1.00          1.00 
 ≥ 50%              18   882    3.71 (1.39-9.89)b      3.14 (0.89-11.0)   4.07 (1.19-14.0) 
PCB 180 
< LOD to 50%       8    1149    1.00           1.00          1.00 
 ≥ 50%           18   806    2.64 (0.79-8.87)      2.00 (0.60-6.61)    1.70 (0.53-5.45) 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g). 
2 Adjusted for age and race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  24/1754 in 074; 24/1753in 099; 
25/1755 in 118; 25/1756 in 138 and 153; 25/1749 in 180.   
Significance ap < 0.0001, bp < 0.05. 
  
Estimated ORs and 95% confidence intervals for the risk of having a reproductive 
cancer and dioxin-like and non-dioxin-like PCBs are shown in table 3.9.  In the 
unadjusted models, dioxin-like and non-dioxin-like PCBs were significantly associated 
with breast cancer, ovarian cancer and uterine cancer.  In the age and race/ethnicity 
adjusted models, dioxin-like PCBs were significantly associated with breast cancer (OR 
of 1.50, 95% CI: 1.27-1.77) and ovarian cancer (OR of 1.95, 95% CI: 1.25-3.05) and 
non-dioxin-like PCBs were significantly associated with breast cancer (OR of 1.14, 95% 
CI: 1.00-1.29), cervical cancer (OR of 1.29, 95% CI: 1.18-1.40), ovarian cancer (OR of 
1.32, 95% CI: 1.02-1.69), and uterine cancer (OR of 1.11, 95% CI: 1.01-1.22).   After 
adjusting for age, race/ethnicity, BMI, and age at menarche dioxin-like PCBs remained 
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significantly associated with ovarian cancer risk (OR of 2.02, 95% CI: 1.06-3.85) and 
non-dioxin-like PCBs remained significantly associated with uterine cancer risk (OR of 
1.12, 95% CI: 1.03-1.23) (Table 3.9).  We further analyzed reproductive cancer risk of 
dioxin-like and non-dioxin-like PCBs using the following two groups:  < LOD to 50th 
percentile (reference group) and ≥ 50th percentile.  In subjects with PCB levels ≥ 50th 
percentile, breast cancer, ovarian cancer, and uterine cancer were associated with dioxin-
like and non-dioxin-like PCBs in the unadjusted models.  Non-dioxin-like PCBs were 
significantly associated with cervical cancer risk and ovarian cancer risk in the age and 
race/ethnicity adjusted models [ORs of 2.59, (95% CI: 1.04-6.42) and 6.62, )95% CI: 
1.50-29.2)], respectively.  Dioxin-like PCBs were associated with the risk of ovarian 
cancer in the age and race/ethnicity adjusted models [OR of 6.32 (95% CI: 1.44-27.7)].  
In the final adjusted models (age, race/ethnicity, BMI, age at menarche) the risk of 
ovarian cancer remained significant for dioxin-like PCBs [OR of 5.71 (95% CI: 1.12-
29.2)] and non-dioxin-like PCBs [OR of 5.99 (95% CI: 1.20-29.9)] and the risk of uterine 
cancer remained significant for non-dioxin-like PCBs [OR of 4.85 (95% CI: 1.32-17.8)] 
(Table 3.9).   
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Table 3.9.  Estimated ORs (95% CIs) of a reproductive cancer by concentrations of dioxin-like and non-
dioxin-like PCBs among women ≥ 20 years of age, NHANES 1999-2004.  
                                                            
                            Unadjusted OR    Adjusted OR1      Adjusted OR2a,b  
                Cases/Noncases      (95% CI)       (95% CI)                 (95% CI)   
Breast Cancer  
Dioxin-like PCBs3          43/1953    1.50 (1.27-1.78)a   1.50 (1.27-1.77)a   1.08 (0.80-1.45)   
Dioxin-like PCBs_503,5 
 < LOD to 50%             4/985    1.00          1.00          1.00        
 ≥ 50%                  39/968    5.23 (2.25-12.2)a   1.55 (0.49-4.90)   1.90 (0.33-10.8) 
Non- Dioxin-like PCBs4     43/1941    1.28 (1.18-1.38)a   1.14 (1.00-1.29)b   1.12 (0.98-1.28)   
Non-Dioxin-like PCBs_504,5 
 < LOD to 50%               2/997    1.00          1.00          1.00        
 ≥ 50%                   41/944    12.7 (2.58-62.2)b   5.40 (0.87-33.5)   4.27 (0.68-26.8) 
Cervical Cancer  
Dioxin-like PCBs3          27/1954    1.15(0.91-1.45)    1.13 (0.82-1.56)   1.10 (0.78-1.55)   
Dioxin-like PCBs_503,5 
 < LOD to 50%            1 2/985    1.00          1.00          1.00        
 ≥ 50%                  15/968    1.13 (0.50-2.58)   1.04 (0.90-1.20)   0.80 (0.27-2.38) 
Non- Dioxin-like PCBs4     26/1941    1.05 (0.94-1.16)   1.29 (1.18-1.40)a   1.02 (0.87-1.19)   
Non-Dioxin-like PCBs_504,5 
 < LOD to 50%             9/997    1.00          1.00          1.00        
 ≥ 50%                   17/944    2.38 (1.14-4.94)b   2.59 (1.04-6.42)b   2.51 (0.94-6.68) 
Ovarian Cancer  
Dioxin-like PCBs3          11/1954    1.61 (1.19-2.17)a   1.95 (1.25-3.05)b   2.02 (1.06-3.85)b  
Dioxin-like PCBs_503,5 
 < LOD to 50%             2/985    1.00          1.00          1.00        
 ≥ 50%                  9/968    5.26 (1.51-18.4)b   6.32 (1.44-27.7)b   5.71 (1.12-29.2)b 
Non- Dioxin-like PCBs3     11/1941    1.24 (1.01-1.53)b   1.32 (1.02-1.69)b   1.30 (0.98-1.72)   
Non-Dioxin-like PCBs_504,5 
 < LOD to 50%             2/997    1.00          1.00          1.00        
 ≥ 50%                   9/994    5.51 (1.56-19.5)b   6.62 (1.50-29.2)b   5.99 (1.20-29.9)b  
Uterine Cancer  
Dioxin-like PCBs3            26/1954      1.16 (0.88-1.52)   1.02 (0.76-1.37)   1.10 (0.83-1.46)   
Dioxin-like PCBs_503,5 
 < LOD to 50%            10/985      1.00          1.00          1.00        
 ≥ 50%                   16/968     1.14 (1.04-1.25)b   0.87 (0.18-4.21)   1.24 (0.29-5.28) 
Non- Dioxin-like PCBs4      25/1941     1.28 (1.18-1.38)b   1.11 (1.01-1.22)b   1.12 (1.03-1.23)b  
Non-Dioxin-like PCBs_504,= 
 < LOD to 50%              7/997    1.00          1.00          1.00        
 ≥ 50%                  18/944    4.14 (1.44-11.3)b   3.53 (0.96-13.1)   4.85 (1.32-17.8)b 
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1Adjusted for age and race/ethnicity. 
2Adjusted for age, race/ethnicity, BMI, age at menarche. 
aCases/Noncases in dioxin-like PCBs :  40/1749 for breast cancer, 24/1749 for cervical cancer, 10/1749 for 
ovarian cancer, 25/1749 for uterine cancer. 
bCases/Noncases in non-dioxin-like PCBs:  40/1737 for breast cancer, 23/1737 for cervical cancer, 10/1737 
for ovarian cancer, 24/1737 for uterine cancer.  
3Dioxin-like PCBs: Sum of lipid adjusted and log transformed PCB Congeners (074 + 118). 
4Non-Dioxin-like PCBs: Sum of lipid adjusted & log transformed PCB Congeners (099 + 138 + 153 + 180).
5 Serum PCB Levels < 50th percentile vs ≥ 50th percentile.  
Significance ap < 0.0001, bp < 0.05.  
 
 Estimated ORs and 95% CIs for the risk of having breast, cervical, ovarian, or 
uterine cancer and the eight phthalate metabolites, the sum of DEHP, and total phthalates 
are shown in tables 3.10-3.13. We analyzed the phthalate levels the in the following 
group:  < LOD to 50th percentile (reference group) and ≥ 50th percentile. Results are 
presented for two logistic regression models: age and race adjusted; and age, 
race/ethnicity, BMI, and age at menarche adjusted. Results were not presented for 
unadjusted models because the derived ORs and 95% CIs did not differ from the models 
presented.  A significant association between breast cancer or cervical cancer and 
phthalates was not found in any of the models (Table 3.10 and 3.11).   
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Table 3.10. Estimated ORs (95% CIs) of breast cancer by concentration of creatinine corrected urinary 
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.   
                                                                    
                   No.          No.         Adjusted OR2          Adjusted OR3   
Metabolite1            Cases         Noncases        (95% CI)              (95% CI)   
MBP       
< LOD to 50%           41       1045         1.00           1.00         
≥ 50%               56       1678         0.89 (0.49-1.64)     0.85 (0.47-1.55)  
MEP   
< LOD to 50%           47       1106       1.00             1.00         
 ≥ 50%               50       21616      0.66 (0.38-1.15)     0.63 (0.36-1.10)  
MEHP 
 < LOD to 50%           57       1339       1.00           1.00        
 ≥ 50%               40       1376       0.94 (0.50-1.76)    0.92 (0.48-1.74) 
MBzP 
< LOD to 50%           52       1205       1.00           1.00         
 ≥ 50%                45       1517       0.75 (0.44-1.29)      0.72 (0.42-1.23)  
MCCP 
< LOD to 50%           51       1396       1.00           1.00         
 ≥ 50%                46       1326       0.86 (0.51-1.43)      0.83 (0.49-1.40)  
MEHHP 
< LOD to 50%           40       1280       1.00           1.00         
 ≥ 50%               57       1443       1.23 (0.74-2.03)      1.15 (0.71-1.86)  
MEOHP      
< LOD to 50%           39       1267           1.00           1.00         
≥ 50%               58       1456       1.27 (0.75-2.17)     1.19 (0.71-1.99)  
MIB  
< LOD to 50%           57       1260       1.00             1.00         
 ≥ 50%               40       1457       0.69 (0.42-1.14)     0.71 (0.42-1.18)  
DEHP 
 < LOD to 50%           50       1301       1.00           1.00        
 ≥ 50%               47       1422       0.91 (0.50-1.64)    0.85 (0.46-1.55) 
Total   
< LOD to 50%           55       1423       1.00           1.00         
 ≥ 50%                42       1300       0.84 (0.48-1.48)      0.81 (0.40-1.63)  
1 Log transformed and creatinine adjusted urinary phthalates (ng/mg). 
2Adusted for age and race/ethnicity . 
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  91/2410 in MBP, MEHHP, 
MEOHP, MIB, DEHP; 91/2409 in MEP, MCCP, MBzP; 91/2403 in MEHP. 
Significance ap < 0.001, bp < 0.05. 
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Table 3.11. Estimated ORs (95% CIs) of cervical cancer by concentration of creatinine corrected urinary 
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.   
                                                                     
                    No.          No.       Adjusted OR2         Adjusted OR3    
Metabolite1             Cases         Noncases       (95% CI)           (95% CI)     
MBP       
< LOD to 50%            10       1045        1.00           1.00         
≥ 50%                18       1678      0.70 (0.25-1.97)     0.64 (0.22-1.85)  
MEP   
< LOD to 50%            14       1106      1.00             1.00         
 ≥ 50%                14       1616      0.91 (0.39-2.14)     0.80 (0.33-1.97)  
MEHP 
 < LOD to 50%            12       1339      1.00           1.00         
 ≥ 50%                16       1376      0.95 (0.46-1.96)    0.91 (0.44-1.88)  
MBzP 
< LOD to 50%            10       1205      1.00           1.00         
 ≥ 50%                 18       1517      1.07(0.51-2.22)       1.04 (0.49-2.21)  
MCCP 
< LOD to 50%            16       1396      1.00           1.00         
 ≥ 50%                 12       1326      0.73 (0.38-1.38)      0.77 (0.41-1.47)  
MEHHP 
< LOD to 50%            10       1280      1.00           1.00         
 ≥ 50%                18       1443      1.10 (0.39-3.11)      1.00 (0.36-2.77)  
MEOHP       
< LOD to 50%            11       1267        1.00           1.00         
≥ 50%                17       1456      0.77 (0.31-1.87)     0.68 (0.28-1.65)  
MIB  
< LOD to 50%            14       1260      1.00             1.00         
 ≥ 50%                14       1457      0.81 (0.35-1.87)     0.85 (0.35-2.03)  
DEHP 
 < LOD to 50%            12       1301      1.00           1.00         
 ≥ 50%                16       1422      0.79 (0.33-1.92)    0.73 (0.30-1.76)  
Total   
< LOD to 50%            12       1423      1.00           1.00         
 ≥ 50%                 16       1300      0.98 (0.44-2.17)      0.81 (0.38-1.74)  
1 Log transformed and creatinine adjusted urinary phthalates (ng/mg). 
2Adjusted for age and race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  26/2410 in MBP, MEHHP, 
MEOHP, MIB, DEHP; 26/2409 in MEP, MBzP, MCCP; 26/2403 in MEHP. 
Significance ap < 0.0001, bp < 0.05. 
 
Estimated ORs and 95% CIs for the risk of ovarian cancer and uterine cancer by 
concentration of the eight phthalate metabolites, the sum of DEHP, and total phthalates 
are shown in table 3.12 and 3.13. In the age and race adjusted model, MEHHP showed a 
weak association with ovarian cancer [OR of 3.63 (95%CI: 1.00-13.2), p=.0497], 
however this association did remain significant after adjusting for age, race/ethnicity, 
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BMI, and age at menarche (Table 3.12).  None of the phthalates were significantly 
associated with the risk of uterine cancer (Table 3.13).   
Table 3.12. Estimated ORs (95% CIs) of ovarian cancer by concentration of creatinine corrected urinary 
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.   
                                                                     
                    No.          No.         Adjusted OR2          Adjusted OR3   
Metabolite1             Cases         Noncases        (95% CI)               (95% CI)    
MBP       
< LOD to 50%            6       1045         1.00            1.00        
≥ 50%                14      1678       1.96 (0.61-6.31)      1.48 (0.42-5.19) 
MEP   
< LOD to 50%            11      1106       1.00              1.00        
 ≥ 50%                9       1616       0.43 (0.17-1.12)      0.38 (0.11-1.30) 
MEHP 
 < LOD to 50%            7       1339       1.00            1.00        
 ≥ 50%                13      1376       2.56 (0.92-7.10)     1.91 (0.61-5.94) 
MBzP 
< LOD to 50%            10      1205       1.00            1.00        
 ≥ 50%                 10      1517       1.65 (0.56-4.83)       1.59 (0.50-5.11) 
MCCP 
< LOD to 50%            12      1396       1.00            1.00        
 ≥ 50%                 8       1326       1.13 (0.35-3.60)       1.24 (0.36-4.25) 
MEHHP 
< LOD to 50%            4       1280       1.00            1.00        
 ≥ 50%                16      1443       3.63 (1.00-13.2)b       2.73 (0.67-11.1) 
MEOHP       
< LOD to 50%            4       1267          1.00            1.00        
≥ 50%                16      1456        3.58(0.98-13.1)      2.67 (0.678-10.6) 
MIB  
< LOD to 50%            11      1260       1.00              1.00        
 ≥ 50%                9       1457       0.57 (0.16-1.99)      0.61 (0.13-2.83) 
DEHP 
 < LOD to 50%            6       1301       1.00            1.00        
 ≥ 50%                14      1422       2.88 (0.95-8.76)     2.29 (0.64-8.23) 
Total   
< LOD to 50%            9       1423       1.00            1.00        
 ≥ 50%                 11      1300       1.21 (0.46-3.17)       1.38 (0.46-4.17) 
1 Log transformed and creatinine adjusted urinary phthalates (ng/mg). 
2Adjusted for age and race/ethnicity. 
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  17/2410 in MBP, MEHHP, 
MEOHP, MIB, DEHP; 17/2409 in MEP, MBzP, MCCP; 17/2403 in MEHP.   
Significance ap < 0.0001, bp < 0.05.   
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Table 3.13. Estimated ORs (95% CIs) of uterine cancer by concentration of creatinine corrected urinary 
phthalate metabolite among women ≥ 20 years of age, NHANES 2003-2010.   
                                                                     
                    No.          No.          Adjusted OR2           Adjusted OR3 
Metabolite1             Cases         Noncases         (95% CI)               (95% CI)  
MBP       
< LOD to 50%            10       1045         1.00           1.00        
≥ 50%                17       1678       1.17 (0.36-3.78)     1.11 (0.33-3.68) 
MEP   
< LOD to 50%            12       1106       1.00             1.00        
 ≥ 50%                15       1616       1.02 (0.47-2.20)     0.99 (0.46-2.12) 
MEHP 
 < LOD to 50%            21       1339       1.00           1.00        
 ≥ 50%                6        1376       0.34 (0.11-1.03)    0.34 (0.11-1.09) 
MBzP 
< LOD to 50%            16       1205       1.00           1.00        
 ≥ 50%                 11       1517       0.59 (0.23-1.48)      0.55 (0.21-1.43) 
MCCP 
< LOD to 50%            14       1396       1.00           1.00        
 ≥ 50%                 13       1326       0.88 (0.32-2.45)      0.85 (0.31-2.32) 
MEHHP 
< LOD to 50%            10       1280       1.00           1.00        
 ≥ 50%                17       1443       1.55 (0.65-3.70)      1.43 (0.61-3.34) 
MEOHP       
< LOD to 50%            11       1267         1.00           1.00        
≥ 50%                16       1450        1.02 (0.46-2.23)     0.95 (0.45-2.02) 
MIB  
< LOD to 50%            12       1260       1.00             1.00        
 ≥ 50%                15       2337       1.20 (0.45-3.17)     1.21 (0.45-3.20) 
DEHP 
 < LOD to 50%            15       1301       1.00           1.00        
 ≥ 50%                12       1422       0.92 (0.40-2.12)    0.87 (0.39-1.93) 
Total   
< LOD to 50%            13       1423       1.00           1.00        
 ≥ 50%                 14       1300       0.98(0.34-2.84)       0.92 (0.30-2.79) 
1 Log transformed and creatinine adjusted urinary phthalates (ng/mg). 
2 Adjusted for age and race/ethnicity  
3Adjusted for age, race/ethnicity, BMI, age at menarche; Cases/Noncases:  27/2410 in MBP, MEHHP, 
MEOHP, MIB, DEHP; 27/2409 in MEP, MBzP, MCCP; 27/2403 in MEHP   
Significance ap < 0.0001, bp < 0.05.  
 Estimated ORs and 95% confidence intervals for the risk of having breast, 
cervical, ovarian, or uterine cancers cancer by concentration of BPA are shown in table 
3.14. The following two groups were used to estimate reproductive cancer risk:  < LOD 
to 50th percentile (reference group) and ≥ 50th percentile. Results are presented for three 
logistic regression models: unadjusted; age and race/ethnicity adjusted; and age, 
race/ethnicity, BMI, and age at menarche adjusted.  None of the models showed a 
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significant association between BPA and breast cancer, cervical cancer, ovarian cancer, 
or uterine cancer (Table 3.14).   
Table 3.14. Estimated ORs (95% CIs) of a reproductive cancer by concentration of creatinine adjusted 
urinary BPA among women ≥ 20 years of age, NHANES 2005-2010.   
                                                                     
              No.      No.     Unadjusted OR        Adjusted OR1    Adjusted OR2 
             Cases     Noncases     (95% CI)             (95% CI)       (95% CI) 
Breast Cancer        
< LOD to 50%      44    985      1.00           1.00          1.00 
≥ 50%          34    1082      0.67 (0.40-1.14)     0.76 (0.45-1.30)   0.73 (0.42-1.23)
Cervical Cancer  
< LOD to 50%      6     985      1.00             1.00          1.00 
 ≥ 50%          9     1082       1.34 (0.37-4.81)     1.39 (0.39-4.91)   1.33 (0.42-4.18)
Ovarian Cancer 
 < LOD to 50%      6     985      1.00           1.00          1.00 
 ≥ 50%          10    1082      1.57 (0.43-5.76)    1.64 (0.43-6.25)   1.41 (0.30-6.70)
Uterine Cancer  
< LOD to 50%      13    985      1.00           1.00          1.00 
 ≥ 50%           9     1082      0.58 (0.27-1.28)      0.65 (0.30-1.41)      0.57 (0.25-1.29)
Log –transformed and creatinine adjusted BPA measurements (ng/mg); NHANES 2005-2010.   
1 Adjusted for age and race/ethnicity. 
2Adjusted for age, race/ethnicity, BMI, age at menarche; Noncases=1821. 
Significance ap < 0.0001, bp < 0.05. 
 
DISCUSSION 
In this cross-sectional study of women 20-85 years of age, we separately 
evaluated 6 individual PCB congeners, the sum of dioxin-like PCBs, the sum of non-
dioxin-like PCBs, eight phthalate metabolites, the sum of DEHP, the sum of total 
phthalates, and BPA  in association with reproductive cancers (breast, cervical, ovarian, 
and uterine) in women.  In women with detectable PCB levels, higher exposures were 
found in women diagnosed with breast cancer, ovarian cancer, and cervical cancer 
compared to women never diagnosed with cancer.  Epidemiological studies on the 
association of PCBs with cervical cancer, ovarian cancer, and uterine cancer are lacking 
but our findings are consistent with breast cancer studies that have reported higher PCB 
levels in breast cancer cases compared to controls (Charlier et al. 2004 and Recio-Vega et 
al. 2001) Charlier et al. 2004found total PCBs and PCB 153 to be significantly higher in 
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cases compared to controls [7.08 ppb vs. 5.10 ppb (p=0.012)] and [1.63 ppb vs. 0.63 ppb 
(p <0.0001)] respectively, and Recio-Vega et al. (2001 ) found total PCBs to be 
significantly higher in cases vs. controls (5.26 ppb vs. 3.33 ppb) as well as an increased 
risk of breast cancer among 8 PCB congeners.  While these results do not provide any 
evidence of causal associations, it is noteworthy that women diagnosed with breast 
cancer, ovarian cancer, and uterine cancer  have higher body burdens of  PCBs compared 
to women  never diagnosed with cancer.   
Significant higher MEHHP levels were found in women diagnosed with ovarian 
cancer and significantly higher MEP levels were found in women diagnosed with uterine 
cancer compared between to women never diagnosed with cancer. However, when 
comparing phthalate levels only among women with concentrations above the LOD, GM 
levels of phthalate metabolites did not differ in the study population.  In women with 
detectable levels of BPA, higher exposure was found in women with cervical cancer 
only.  Epidemiological studies on the association with phthalates and BPA with breast, 
cervical, ovarian, and uterine cancers are lacking or limited.  Our findings are not 
consistent with findings by Lopez-Carillo et al. 2010, who reported significantly higher 
concentrations of MEP in breast cancer cases compared to controls when comparing the 
highest vs. lowest tertile of exposure (169.58 vs 106.78 ug/g creatinine) and significant 
negative associations  for MBzP (OR=0.46, 95% CI 0.27-0.79) and  MCPP (OR=0.44, 
95% CI 0.24-0.80). Yang et al. (2008) measured median blood BPA levels in 70 cases 
and 80 controls and reported higher median BPA levels in cases compared to controls 
(0.61 vs. 0.03 ug/L), however, the differences were not found to be statistically 
significant (p = 0.42).   
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Risk of a reproductive cancer (breast, cervix, ovarian, or uterine) was not found to 
be significantly associated with BPA in unadjusted or adjusted logistic regression models.  
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) was weakly associated (p=0.0497) 
with ovarian cancer risk in the model adjusted for age and race but did not remain 
significantly associated when the additional variables of BMI and age at menarche were 
added.  PCBs showed the most significant associations with all reproductive cancers.  
After adjusting for all confounding variables, women with ovarian cancer had significant 
associations with PCB 74 and 118, and therefore the dioxin-like PCBs.  PCB 138 had the 
strongest associations and was found to significantly increase the risk of breast, cervical, 
and uterine cancers. Epidemiological data is lacking on the associations between PCBs 
and cervical, ovarian, and uterine cancers, however significant associations have been 
found between individual PCB congeners and breast cancer risk (Charlier et al. 2004, 
Cohn et al. 2012, Demers et al. 2002).  Dioxin-like PCBs were significantly associated 
with ovarian cancer and non-dioxin-like PCBs were significantly associated with ovarian 
and uterine cancers, after adjusting for age, race, BMI, and age at menarche. In contrast 
to our findings , Gammon et al. (2002) failed to find any association between PCB 
exposure and breast cancer risk when comparing the highest quintile of serum Peak-4 
(nos. 118, 153, 138, and 180) PCB levels to the lowest quintile (OR=0.83, 95% CI 0.54-
1.29).   
There are a number of limitations to our study, the most important of which is its 
cross-sectional design with self-reported data that does not allow for causal inferences to 
be made.  Self-reported data increases the risk of misclassification bias of cases and 
controls with the possibility of undiagnosed or incorrectly reported cancer cases.  In the 
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PCB data analysis, we had relatively small sample sizes for cervical cancer (n=27), 
ovarian cancer (n=11), and uterine cancer (n=26), resulting in decreased statistical power.    
Breast cancer cases were larger in the phthalate and BPA data analysis (n=97 and 78, 
respectively), however cervical, ovarian, and uterine cancer cases were still limited. 
Missing data on reproductive confounding variables such as parity and lactation also 
limits the findings of our study. Furthermore, observed associations could be potentially 
confounded by lack of information on family history of hormonal cancers.  Strengths of 
this cross-sectional study design include the large sample survey size, availability of 
biological measurements of environmental contaminants, and oversampling of minority 
populations that make it highly representative and generalizable to the U.S. population.  
In addition, this study has the ability to analyze the combined effect of EDCs within a 
class or across classes.  Since chemicals may have an additive, synergistic, or 
antagonistic effect when combined, it is important to investigate associations for 
combined chemical exposures in addition to single chemical exposures.  
CONCLUSION 
Based on our analysis of urinary phthalates and BPA from the 2003-2010 and 
2003-2008 NHANES data cycles, biological levels of phthalates and BPA did not 
contribute to the risk of reproductive cancers in women.  In contrast, our analysis of 
serum blood lipid PCB levels in the 1999-2004 NHANES data cycles, showed a 
significantly increased risk of breast, ovarian, and uterine cancers in women with higher 
body burdens of PCBs.   Due to their lipophilic nature, exposures to environmental PCBs 
appear to continue to pose significant threats on the reproductive health of women.   
Given the proven contribution of unopposed estrogens to the risk for hormonal cancers, it 
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is biologically plausible that altered endogenous estrogen levels presumably from 
exposure to estrogen mimicking EDCs may contribute to the risk of disease. Exposure to 
EDCs, such as PCBs, during early development of the breast and endometrium can alter 
its development, and possibly contribute to the susceptibility to diseases through effects 
on stem cells. Although we did not find significant associations between phthalates, BPA, 
and reproductive cancers, our research is based on the use of cross-sectional self-reported 
data thus further research is needed. Our findings, coupled with the lack of available 
epidemiological evidence concerning EDCs and cervical, ovarian, and uterine cancers 
warrants the need for future prospective studies.   
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CHAPTER VII  
 
OVERALL CONCLUSIONS 
  
The primary objective of the findings in this dissertation was to assess exposure to 
EDCs (PCBs, BPA, and phthalates) and determine whether exposure to these agents is a 
contributing factor in reproductive dysfunction in the U.S. general population.  In 
particular, the associations between PCBs and endometriosis and leiomyomas and the 
associations between PCBs, phthalates, and BPA and reproductive cancers (breast, 
cervical, ovarian, and uterine) were examined using the CDC’s NHANES database.   
A number of chemicals are suspected to act as endocrine disruptors (EDs) by 
mimicking natural or synthetic estrogen resulting in an increased risk of hormonal cancer 
in women.  Polychlorinated biphenyls (PCBs), phthalates and bisphenol A (BPA) have 
been recognized as endocrine disrupters due to their ability to interfere with reproductive 
function and development in animals and humans by either increasing estrogen activity or 
blocking estrogens from acting.  Epidemiologic studies on the role of EDCs and 
reproductive toxicity are inconsistent and lacking, particularly in regards to the role of 
EDCs in the development of cervical, breast, and uterine cancers.  Thus, our specific aims 
were identified to address gaps in the literature and provide recommendations for future 
studies.   
 To support or refute the proposed role of EDCs, secondary statistical analysis 
was conducted using data from the CDCs 1999-2010 NHANES.  NHANES, conducted 
annually since 1999 by the Centers for Disease Control and Prevention (CDC), is an 
ongoing cross-sectional survey designed to be nationally representative of the non-
institutionalized, U.S. civilian population.  Once eligibility is determined participants 
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complete a confidential and voluntary home interview followed by a standardized 
physical examination in a specially equipped mobile evaluation clinic (MEC).  The MEC 
examination consists of a physical examination, dental examination, detailed face-to-face 
personal interview, and collection of biological specimens. Each survey includes a 
nationally representative sample of approximately 5,000 participants.  
The first specific aim addressed in manuscript 1 examined the cross-sectional 
relationship between exposure to PCBs and breast cancer among U.S. women.  We 
analyzed data from female participants (20-85 years of age) with available PCB data 
using the 1999 to 2004 data cycles.  Exposure was based on lipid adjusted serum levels of 
6 individual PCB congeners (PCB 074, 099, 118, 138, 153, and 180), the sum of dioxin-
like PCBs (074 + 118), and the sum of non-dioxin-like PCBs (099 + 138 + 153+187) in 
conjunction with self-reported data obtained from the medical and reproductive health 
questionnaires.  We calculated geometric means to compare PCB concentrations in 
women with a breast cancer diagnosis vs. women without a cancer diagnosis. Geometric 
means of the 6 PCB congeners were found to be significantly higher among women with 
breast cancer when compared to the rest of the study population. We used logistic 
regression models to estimate odds ratios (ORs) and 95% confidence intervals (CI) for 
the association between PCB measurements and breast cancer.  After adjusting for age, 
race, BMI, lactation, and age at menarche we found that PCB 138 was significantly 
associated with breast cancer [odds ratios of 2.88; 95% CI: 1.14-7.30;  2.93, 95% CI: 
1.04-8.26; and 3.43,  95% CI: 1.12-10.4] in women with higher body burdens of 
individual PCB congeners. After adjusting for age and race, we also found the sum of 
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non-dioxin-like PCBs to be significantly associated with breast cancer [OR of 1.14; 95% 
CI: 1.00-1.29].   
The second specific aim, addressed in manuscript 2 examined the relationship 
between exposure to PCBs endometriosis and uterine leiomyomas among U.S. women, 
20-54 years of age.    Endometriosis and uterine leiomyomas have been identified as 
estrogen dependent diseases that occur during the reproductive years, however previous 
research on the role of EDCs in the development of endometriosis and uterine 
leiomyomas is conflicting.  Due to the role of estrogen in the development of 
endometriosis and uterine leiomyomas we hypothesized that women with higher body 
burdens of PCBs would have an increased risk of disease.   We calculated GMs to 
compare PCB concentrations in women who self-reported an endometriosis or uterine 
leiomyoma diagnosis vs. women who self-reported never being diagnosed with 
endometriosis or uterine leiomyomas. We used logistic regression models to estimate 
ORs and 95% CIs of endometriosis and uterine leiomyomas by concentration of lipid-
adjusted serum PCBs.  GM levels of PCB congeners 138, 153, and 180 were found to be 
significantly higher among women diagnosed with endometriosis, GM levels of PCB 
congeners 74, 99, 118, 138, 153, and 180 were found to be significantly higher among  
women diagnosed with uterine leiomyomas, dioxin-like PCBs were found to be 
significantly higher in women diagnosed with uterine leiomyomas and non-dioxin-like 
PCBs were found to be significantly higher in women diagnosed with endometriosis and 
uterine leiomyomas compared to the rest of the study population.  We found PCB 74 and 
118 to be significantly associated with uterine leiomyomas [OR of 1.91: 95% CI: 1.10-
3.29 and 1.91, 95% CI: 1.13-3.22] and non-dioxin-like PCBs to be significantly 
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associated with endometriosis [OR of 95% CI: 1.00-1.29] in women with higher body 
burdens of PCBs.     
The third specific aim, addressed in manuscript 3, explored the cross-sectional 
relationship between exposure to PCBs, phthalates, and BPA and reproductive cancers 
(breast, cervical, ovarian, and uterine) among U.S. women.   We evaluated the risk of 
breast cancer, cervical cancer, ovarian cancer, and uterine cancer with exposure to 6 
individual PCB congeners (74, 99, 118, 138, 153, and 180), the sum of dioxin-like PCBs 
(074 and 118), the sum of non-dioxin-like PCBs (099 + 138 + 153+187), 8 urinary 
phthalate metabolites (MNP, MEP, MEHP, MBzP, MCPP, MEHHP, MEOHP, and 
MIB), the sum of DEHP metabolites (MHP + MHH + MOH), the sum of  total 
phthalates, and urinary BPA. We calculated geometric means to compare EDCs 
concentrations in women who self-reported a breast, cervical, ovarian, or uterine cancer 
diagnosis vs. women who self-reported never being diagnosed with cancer and used 
logistic regression models to estimate ORs and 95% CIs for the association between 
exposure to EDCs and reproductive cancers.    
Separate analyses showed geometric mean levels of individual PCB congeners to 
be significantly higher among women with breast cancer, ovarian cancer, and uterine 
cancer when compared to the rest of the study population.  Mono-(2-ethyl-5-
hydroxyhexyl) phthalate (MEHHP) was found to be significantly higher among women 
with ovarian cancer and monoethyl phthalate (MEP) was found to be significantly higher 
among women with uterine cancer compared to women never diagnosed with cancer, 
however BPA was significantly higher in women never diagnosed with cancer compared 
to women diagnosed with breast cancer. When evaluating GM levels in only women with 
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phthalate and BPA concentrations above the LOD, phthalate levels did not differ among 
the study population, however women diagnosed with cervical cancer had significantly 
higher levels of BPA compared to women never diagnosed with cancer. We found PCB 
138 to be significantly associated with breast cancer, cervical cancer, and uterine cancer 
[ORs of 2.52.; 95% CI: 1.06-5.99;  3.05, 95% CI: 1.21-7.69; and 5.83,  95% CI: 1.63-
20.9], respectively,  and PCB 74 and 118 to be significantly associated with ovarian 
cancer [ORs of 6.47, 95% CI: 1.23-3.41 and 6.68, 95% CI: 1.39-32.3), respectively, in 
the final adjusted models.   We also found the sum of non-dioxin-like PCBs to be 
significantly associated with uterine cancer (OR of 1.12, 95% CI: 1.03-1.23) and the sum 
of dioxin-like PCBs to be significantly associated with ovarian cancer (OR of 2.02, 95% 
CI: 1.06-3.85).  We found a very weak association between MEHHP and ovarian cancer 
(OR of 3.63, 95% CI: 1.00-13.2, p=.0497) but did not find significant associations 
between any other phthalate metabolites or BPA and reproductive cancers.  
In sum, the major findings from the research in this dissertation indicate that 
exposure to PCBs may increase the risk of endometriosis, uterine leiomyomas, and 
cancers of the breast, cervix, ovaries, and uterus.  Our findings are consistent with the 
proven contributions of unopposed estrogens to the risk for reproductive toxicity.  
Exposure to estrogenic environmental chemicals, particularly PCBs, during early 
development of the breast and endometrium can alter their development, and possibly 
contribute to the susceptibility to diseases through effects on stem cells.  
Limitations 
There are a number of limitations to our study, the most important of which is its 
cross-sectional design with self-reported data that does not allow for causal inferences to 
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be made.  Self-reported data increases the risk of recall bias and misclassification bias of 
cases ad controls with the possibility of undiagnosed or incorrectly reported cancer, 
endometriosis, or uterine leiomyoma cases, thereby impacting the observed associations 
in the study. We also had relatively small sample sizes for cervical cancer (n=27), ovarian 
cancer (n=11), and uterine cancer (n=26), resulting in decreased statistical power within 
analyses.    Missing data on reproductive confounding variables such as parity and 
lactation also limits the findings of our study. We were not able to assess the potential of 
additional reproductive health variables in our analysis due the extent of non-response. 
Furthermore, observed associations could be potentially confounded by lack of 
information on family history of endometriosis, uterine leiomyomas, and reproductive 
cancers.   
Future Studies  
Although our findings must be interpreted with caution, they indicate that EDCs 
still deserve consideration for their impact on the female reproductive system.  
Epidemiological studies on EDCs are often lacking or inconsistent, especially in regards 
to their in the development of cervical, ovarian, and uterine cancers.  Because a single 
exposure to an internal or external environmental factor alone cannot explain the 
development of a complex chronic disease, such as cancer, future studies exploring the 
combined effect of EDCs and their influence in the development of chronic diseases in an 
individual are warranted.  Widespread human exposure to EDC’s and the increasing 
concern for their potential to induce reproductive toxicity, especially in susceptible 
populations with sensitive gene polymorphisms, warrants a clear need for more research.   
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